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1 Introduction 
 
Normal cellular homeostasis depends on a balanced regulated interaction between cells and 
their immediate environment. In response to these interactions, cell surface receptors are 
activated and induce intracellular signals leading to the maintenance of normal 
physiological functions and cellular integrity. During tumourigenesis this tissue 
homeostasis is perturbed and subpopulations of cells acquire the ability to grow, detach 
from the surrounding tissue, migrate through the extracellular matrix and to invade host 
tissue eventually leading to metastatic dissemination. These cellular responses are the 
result of genetic and epigenetic alterations resulting in dysregulation of various genes 
during tumour initiation, progression and metastasis. One of the hallmarks of cancer 
progression is the capacity of cells to invade through tissue boundaries. Proteolytic 
enzymes that degrade the surrounding extracellular matrix play a fundamental role in 
cancer progression by facilitating cell migration and providing access for tumour cells to 
the vascular or lymphatic systems (chapters 1.1 and 1.2). 
A major line of current oncologic research addresses the molecular changes accumulated 
in tumour cells to selectively target proteins for the design of novel therapeutics. However, 
recent findings emphasise the importance of molecular networks and pathways 
downstream of potential targets, as these proteins are involved in a plethora of cellular 
functions involved in both, physiological and pathophysiological processes. A better 
understanding of the mechanistic and molecular level of potential target-proteins is 
therefore crucial to selectively inhibit specific functions without affecting the roles of the 
respective proteins in normal physiological processes.  
 
1.1 The role of proteinases in carcinogenesis  
 
Proteinases play a key role in physiological as well as pathophysiological conditions. Their 
involvement in biological processes exceeds the initial characterisation of proteinases as 
non-specific degrading enzymes that are involved in protein catabolism. There is an 
emerging body of data implicating proteinase activity in a plethora of biological processes 
including the shedding of cell surface proteins, receptors and adhesion proteins, activation 
or inactivation of proteases, other enzymes, cytokines, chemokines, hormones and growth 
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factors as well as determining the subcellular localisation of proteins, and thus modulating 
key cellular responses 1. 
Analysis of the human genome revealed currently 662 proteinases annotated in the 
peptidase database (http://merops.sanger.ac.uk), which are distributed into 5 classes: 
Metalloproteinases, Serine proteinases, Cysteine proteinases, Threonine proteinases, 
Aspartic proteinases and proteinases of an unknown class. These proteinases function both 
intracellularly and extracellularly and are recognised as being important for all stages of 
tumour progression. Their functional spectrum includes regulation of cell proliferation, 
adhesion, migration, differentiation, angiogenesis, senescence, autophagy and apoptosis. 
The role of the intracellular caspases, deubiquitylases (DUBs) and autophagins is generally 
associated with the removal of damaged or unwanted proteins, whereas the extracellular 
proteinases are actively involved in tumourigenesis. They are frequently overexpressed in 
human tumours and are implicated in facilitating cell motility by degrading the 
extracellular matrix, processing of cell receptors, thus attenuating cell adhesion and 
inducing intracellular signal transduction pathways 2,3. In addition to the members of 
serine, cysteine and aspartic proteinases, the extracellular metalloproteinases (MPs) play 
an essential role during cell migration and were shown to be most abundantly expressed in 
malignant cells clustered at the leading edge of migrating cells (chapter 1.2) 4,5.  
 
1.2 Matrix Metalloproteinases 
 
The family of Matrix Metalloproteinases (MMPs) belongs to the metzincin family of zinc-
dependent endopeptidases. They are considered to be key proteinases involved in the 
remodelling and turnover of the extracellular matrix (ECM) and play therefore an essential 
role in physiological and pathophysiological processes including embryonic development, 
tissue morphogenesis, inflammation and wound healing as well as tumour growth, 
tumourigenic angiogenesis and metastasis 6-8. Their specific but often overlapping 
substrates comprise a wide range of cell surface proteins, growth factors, growth factor 
binding proteins, other proteinases, cytokines, chemokines and cell adhesion molecules 6,9-
11. Under normal physiological conditions, the activity of MMPs is tightly regulated on the 
level of transcription, activation of the zymogen, inhibition by endogenous inhibitors, 
internalisation and ectodomain shedding. A loss of activity control may lead to the 
development of various diseases including cancer, atherosclerosis, arthritis and fibrosis 12. 
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Accordingly, the expression of these proteinases was shown to be increased in malignant 
tissue and MMPs are especially enriched in areas at the tumour-stroma interface 13. Their 
presence often correlates with poor prognosis 14-18. Several findings have emphasised that 
MMPs contribute not only to the initiation of tumour-formation but also to tumour growth, 
angiogenesis and metastasis, making MMPs a particular promising target in oncologic 
research.  
 
1.2.1 Structure and function of MMPs 
 
The MMP family is highly conserved across different species and includes 24 members in 
humans. MMPs share a conserved domain structure comprising of a propeptide, a zinc-
dependent catalytic domain, a flexible linker/hinge region and a hemopexin-like domain 
(HPX) (except MMP-7, -23, and -26) followed either by a linker- and transmembrane 
domain as well as an intracellular domain or by a glycosylphosphatidylinositol (GPI) -
anchor (Figure 1.1). The cysteine switch motif (PRCGXPD) within the propeptide, that 
maintains the latent zymogen form (pro-MMP) as well as the zinc-binding motif 
(HEXGHXXGXXH) assign proteinases to the MMP family. Only MMP-23 is lacking the 
cysteine switch motif but exhibits strong homology of its catalytic sequence to MMP-1. 
The members of the MMP family are divided into two subgroups: the soluble MMPs and 
the Membrane-type MMPs (MT-MMPs) (Figure 1.1).  
The MT-MMP subgroup comprises of 6 members, of which 4 are type-I transmembrane 
proteinases (MT1- (MMP-14)-, MT2- (MMP-15), MT3- (MMP-16) and MT5-MMP 
(MMP-24)), whereas MT4- (MMP-17) and MT6-MMP (MMP-25) are anchored to the 
plasma membrane via a GPI-anchor (Figure 1.1). Based on their substrate specificity and 
sequence homology the subgroup of soluble MMPs can be subdivided further in: 
Collagenases (MMP-1, MMP-8, MMP-13, MMP-18 (Xenopus)), Gelatinases (MMP-2, 
MMP-9), Stromelysins (MMP-3, MMP-10), Matrilysins (MMP-7, MMP-26) and other 
MMPs (MMP-11, MMP-12, MMP-19, MMP-20, MMP-21, MMP-22, MMP-23, MMP-27, 
MMP-28) 19. The domain-structure of the MMP family is summarised in Figure 1.1 based 
on their sequence homology.  
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Figure 1.1: The Matrix Metalloproteinase family 
Schematic representation of the domain-structure of MMPs, comprising of a signal peptide (directs the MMP 
to the secretory pathway or to membrane insertions), a prodomain (confers latency of the zymogen), catalytic 
domain (with indicated active zinc ion), a hemopexin-like domain (determines in addition to catalytic domain 
the substrate specificity) and a hinge/linker region. The MT-MMP subgroup contains an additional 
transmembrane and intracellular domain (membrane-associated MMPs) or a GPI anchor (GPI-linked 
MMPs). MMP-2 and MMP-9 exhibit fibronectin-like type II repeats, which facilitate collagen substrate 
binding. MMP-7 and MMP-26 lack the hemopexin domain. Adapted from 20. 
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MMPs are synthesised as inactive zymogens that are activated by cleavage of the 
prodomain at a conserved amino acid stretch (RXK/RR) by furin, plasmin or related 
proprotein convertases. The activation of MMPs may occur either intracellularly or 
extracellularly 21,22. As an exception, pro-MMP-2 is not activated by one of the previously 
described proteinases but its activation takes place on the cell surface mediated by MT1-
MMP and TIMP-2 (chapter 1.3.4.3).  
MMPs are multi-functional enzymes, which main function is the degradation and re-
organisation of the extracellular matrix (ECM) by cleaving various ECM components 
(collagens, laminin, fibronectin, vitronectin, aggrecan, enactin, versican, perlecan, 
tenascin, elastin and many others). Processing of these components plays a pivotal role in 
liberating various growth factors and cytokines that are sequestered within the ECM 
milieu. In addition to the cleavage of ECM components, MMPs have also been shown to 
process a variety of proteins via their “sheddase” function, including the shedding of 
bioactive molecules from the cell surface as well as processing transmembrane proteins 
and cell surface receptors. Surface anchoring of the membrane-bound MMPs has been 
recognised to be important for the cells to modify their pericellular environment and 
provides an essential mechanism for the spatial regulation of substrate processing.  
 
1.3 Membrane type-1 Matrix Metalloproteinase (MT1-MMP) 
 
Membrane type 1-Matrix Metalloproteinase (MT1-MMP) was first described in 1994 by 
Sato et al. as a specific activator of MMP-2 activity 23 and is the best characterised MMP 
to date. MT1-MMP has been implicated in various physiological and pathophysiological 
processes including wound healing, bone development, angiogenesis, inflammation, 
rheumatoid arthritis, atherosclerosis, cancer invasion and metastasis 24. MT1-MMP is 
highly expressed in different cancers and its expression was shown to promote migration, 
invasion and metastasis of cancer cells in vitro and in vivo 25. Indeed, overexpression of 
MT1-MMP in cells in vivo enhances the growth and size of tumours, and the cells acquire 
a more invasive and malignant phenotype 26-28. Subcutaneous inoculation of normally 
benign MDCK (Madin-Darby canine kidney) cells that are induced to express MT1-MMP 
was demonstrated to be sufficient to initiate tumour formation in vivo 29. Expression of 
MT1-MMP as well as MMP-2 correlates with a poor prognosis in patients with advanced 
neuroblastoma, small cell lung cancer, tongue squamous cell carcinoma, head and neck 
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carcinoma, bladder cancer and ovarian cancer 30-34. Interestingly, MT1-MMP expression is 
not only detected in various malignant cells but also in the adjacent stromal cells of various 
human tumours 24.  
 
1.3.1 Structure of MT1-MMP 
 
MT1-MMP shares the conserved domain structure with the other MMP family members, 
including a pre/propeptide (M1 – R111), the zinc-dependent catalytic domain (Y112 – G285), 
a flexible hinge region (E286 – I318), the hemopexin domain (C319 – C508) and a stalk region 
(P509 – S538). In addition MT1-MMP is attached to the plasma membrane with a 
transmembrane domain (A539 – F562) and a short intracellular tail (R563 – V582) 23,25,35 
(Figure 1.1). Following synthesis, MT1-MMP is matured in the trans-Golgi complex and is 
transported to the plasma membrane via a Rab8- 36, VAMP7- 37 and by a microtubule-
dependent process 38-40. It has been shown that the enzyme is post-translationally modified 
by o-glycosylation at T291, T299, T300, and/or S301 within the hinge region. In the absence of 
glycosylation, pro-MMP-2 activation was ablated, although the mutants retained the ability 
to degrade collagen I and to undergo autocatalytic processing 41. 
 
1.3.2 Substrates of MT1-MMP 
 
Initial studies on MT1-MMP revealed its ability to process various components of the 
extracellular matrix including collagens I, II, and III, fibronectin, gelatin, laminins 1 and 5, 
vitronectin, fibrin, aggrecan, lumican and proteoglycan 42-46. More recently new MT1-
MMP functions have emerged including the processing of growth factors, cell surface 
proteins, receptors, cytokines and chemokines, including the activation of latent 
transforming growth factor ß (TGF-ß) 47,48, tumour necrosis factor ? (TNF-?) 42 as well as 
processing of CD44 (chapter 1.4.1) 49, tissue transglutaminase 2, low-density lipoprotein 
receptor related protein (LRP) 50, Syndecan-1 51 and the ?v integrin subunit 2,23,49,51-53. 
Additionally, angiogenesis was shown to be enhanced by the MT1-MMP mediated release 
of sequestered VEGF165 from extracellular CTGF (connective tissue growth 
factor)/VEGF165 and HARP (heparin affin regulatory peptide)/VEGF165 complexes 
54. 
Cellular proteolytic responses initiated by MT1-MMP function are further increased by 
MT1-MMP mediated activation of pro-MMP-2 23 and pro-MMP-13 52. These functions 
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indicate that MT1-MMP surface expression induces a wide proteolytic repertoire, 
facilitating (i) cell migration, (ii) invasion through the extracellular matrix, (iii) 
angiogenesis and (iv) proliferation 55.  
MT1-MMP induced functions are summarised in Figure 1.2. 
 
 
Figure 1.2: Summary of MT1-MMP functions 
Schematic representation of MT1-MMP functions. Cellular invasion and cell migration is enhanced through 
(i) the activation of the proteolytic cascade by activating pro-MMP-2 and pro-MMP-13, (ii) the cleavage of 
Collagen, the basement membrane component Laminin-5 and further ECM components as well as (iii) the 
processing of Syndecan-1, CD44, LRP, TGF-?, tissue transglutaminase, ?v integrin and TNF-?. MT1-MMP 
was also found to induce the ERK intracellular signalling pathway and to modulate gene transcription of 
VEGF-A (dependent on Src activity), Smad1 and DKK-3, inducing proliferation, angiogenesis and invasion. 
 
1.3.3 Functions of MT1-MMP 
 
Due to the variety of substrates that are processed by MT1-MMP (Figure 1.2), the enzyme 
is involved in a plethora of cellular functions involved in physiological and 
pathophysiological processes as listed below. 
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1.3.3.1 MT1-MMP regulates cell motility 
 
Overexpression of MT1-MMP has been shown to enhance cellular invasiveness in in vitro 
invasion assays using Matrigel 23 and in in vivo lung metastasis assays 56, whereas MT1-
MMP gene silencing was sufficient to decrease Matrigel invasion of cancer cells 57. MT1-
MMP mediated increase in cell motility was shown to be at least partly driven by CD44 
sheddding 49. CD44 is a ubiquitously expressed hyaluronan receptor that mediates 
interaction with the cytoskeleton through its intracellular domain 58. Although the exact 
mechanism of the MT1-MMP - CD44 mediated cell motility is not exactly known, MT1-
MMP may play a role in either modulating adhesion properties of lamellipodia through 
CD44 shedding or by modulating CD44 dependent signalling after release of the CD44 
intracellular domain (chapter 1.4.1) 59. A similar increase of cell motility was observed 
following MT1-MMP mediated syndecan-1 shedding 51. Although the molecular 
mechanism underlying the MT1-MMP and syndecan-1 induced cell migration has not been 
identified yet, syndecan-1 is known to associate with and stabilise ?v?3 integrin 60, raising 
the possibility that MT1-MMP induced syndecan-1 shedding affects integrin signalling 
pathways. Additionally, the extracellular signal-regulated protein kinase (ERK) pathway 
has been shown to be activated by MT1-MMP expression, a process being implicated in 
cell migration 61,62 (chapter 1.3.6, Figure 1.2). However, it is not clear whether ERK is 
directly activated by MT1-MMP or if its activation is a cellular response occurring down-
stream of transmembrane protein shedding. Adhesion of cells to the ECM seems to be 
important for this process since activation of the ERK signalling pathway was observed in 
cells growing on type I collagen but was ablated in cells growing in suspension or on poly-
L-lysine-coated culture vessels 61,62. Cancer cell invasion through the basement membrane 
is an important step in metastasis. Type IV collagen as well as laminin 5 are key 
components of the basement membrane and were shown to be degraded either by MT1-
MMP directly or by MMP-2 activity 45,55. MT1-MMP mediated cleavage of laminin 5 
leads to the release of EGF like domains, which further stimulate cell motility through an 
EGFR induced signalling pathway 63. 
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1.3.3.2 MT1-MMP dependent collagen degradation 
 
One of the most prominent roles of MT1-MMP is its ability to cleave collagen. Collagen is 
a key component of the extracellular matrix and consists of 3 ?-chains forming triple 
helical structures, which are assembled into fibrils. These structures are resistant to most 
proteinases except MT1-MMP and the soluble collagenases MMP-1, MMP-2, MMP-8 and 
MMP-13 19. The importance of MT1-MMP induced collagen degradation is emphasised by 
the observations that in mice, MT1-MMP deficiency led to craniofacial dysmorphism, 
arthritis, osteopenia, dwarfism, fibrosis in periskeletal soft tissues, a reduced 
vascularisation and premature death 64,65. These knockout mice die around 7-12 weeks of 
age 64,65, indicating that MT1-MMP expression is required during embryonic and postnatal 
development and for survival. Interestingly, engineered soluble MT1-MMP lacking the 
transmembrane domain, failed to induce cell migration through collagen or fibrin gels 
despite its proteolytic activity 66. These findings emphasise that proteolytic activity per se 
is not sufficient for ECM invasion and that the proper localisation of active MT1-MMP at 
the cell surface is required. The importance of the MT1-MMP cell surface localisation was 
also confirmed by using an MT1-MMP mutant in which the transmembrane domain was 
replaced with the MT6-MMP GPI anchor. This membrane-bound chimera retained the 
ability to invade 3D collagen gels and to proliferate within these matrices 67,68. 
Interestingly, replacement of the catalytic domain with that of MMP-1 conferred cells with 
a collagen invading potential indicating that proteolytic activity correlates with the 
localisation of the protease at the cell membrane and a potential requirement of the other 
non-proteolytic MT1-MMP domains in cellular functions 67.  
 
1.3.3.3 MT1-MMP functions during angiogenesis 
 
During angiogenesis new blood vessels are established from pre-existing vessels. In this 
process endothelial cells have to detach from adjacent cells, invade into stromal tissue and 
establish new tubular structures. Angiogenesis plays an important role in wound healing 
and has been implicated in pathophysiological processes including tumour growth and 
rheumatoid progression 69. MMP expression was demonstrated to be increased in 
endothelial cells (ECs) during migration as well as in blood vessels in vivo, and was shown 
to be modulated by angiogenic factors 44,70. Interestingly, angiogenesis takes place in mice 
lacking MMP-2, MMP-9, their cell surface receptors (CD44 and ?3-integrin) or 
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plasminogen whereas aortic vessel explants from MT1-MMP-/- mice failed to induce 
endothelial cell invasion and neovessel formation 71. Sounni et al. showed that MT1-MMP 
overexpression in human melanoma cells, which express pro-MMP-2 endogenously 
enhances invasion in vitro as well as growth, size and vascularity of tumours in vivo 27. 
MT1-MMP overexpression in MCF-7 breast cancer cells, which are MT1-MMP and pro-
MMP-2 deficient, promoted in vitro blood vessel sprouting in the rat aortic ring assay and 
induced highly vascularised tumours when injected into mice 72, most likely by inducing 
transcription of the pro-angiogenic vascular endothelial growth factor (VEGF) 73. 
Furthermore MT1-MMP affects angiogenesis by degradation of the extracellular matrix, 
thus either unmasking angiogenic sites and/or releasing pro- and antiangiogenic factors, 
which were sequestered within the ECM.  
 
1.3.4 Regulation of MT1-MMP function 
 
The functions of MT1-MMP previously described and its role in cancer cell proliferation, 
metastasis and tumour angiogenesis emphasise that regulation of MT1-MMP activity is 
critical for the maintenance of normal cellular function. Regulatory mechanisms apply at 
the level of transcription, activation of the zymogen, endocytosis, interaction with ECM 
components, endogenous inhibitors and by subcellular localisation, as briefly described in 
the following sections.  
 
1.3.4.1 Regulation by gene transcription 
 
MT1-MMP is constitutively expressed in vitro in fibroblasts, endothelial cells, malignant 
epithelial cells and smooth muscle cells. Its expression may be up-regulated in phases of 
inflammation and remodelling in response to mechanical stress, cytokines, growth factors 
and chemical agents 74. MT1-MMP mRNA levels were shown to be increased in 3D 
collagen I matrices by hepatocyte growth factor (HGF) treatment 75 and by granulocyte-
macrophage colony stimulating factor (GM-CSF) stimulation of endothelial cells via a 
MEK-dependent pathway 76, whereas its expression is moderately enhanced following 
treatment with TGF-? or the chemical agents phorbol 12-myristate 13-acetate (PMA) and 
concanavalin A, which are known to enhance MT1-MMP ectodomain shedding (chapter 
1.3.4.4) 77-79. Treatment of glioma cells with epidermal growth factor (EGF) was further 
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found to increase MT1-MMP transcription 80, whereas stimulation of cells with TNF-? led 
to controversial results. TNF-? dependent MT1-MMP transcription was only observed in 
fibroblasts cultured within a 3D collagen I matrix, but not in 2D, indicating the regulation 
of MT1-MMP expression by cytoskeleton-ECM interactions 81. These results were in 
agreement with studies demonstrating enhanced MT1-MMP mRNA levels in fibroblasts 
embedded in a 3D collagen matrix following mechanical stretching and treatment of cells 
with the cytoskeleton disrupting agent Cytochalasin D 82-84. Promoter analyses revealed 
that in contrast to most soluble MMPs the MT1-MMP gene lacks the conserved TATA 
sequence as well as the AP-1 binding site 5’-upstream of the coding region 85. Further 
information about the regulatory elements within the promoter region is incomplete but 
transcription factor binding sites for the transcription factors Sp1 and Egr-1 have been 
identified 85,86. 
 
1.3.4.2 Regulation by zymogen activation 
 
MT1-MMP is synthesised as a ?64 kDa latent zymogen that requires the removal of the 
NH2-terminal propeptide in order to be catalytically active. The conserved furin 
recognition site (RRKR111) in the prodomain is cleaved either intracellularly by the 
proprotein convertase furin during the MT1-MMP trafficking between the endoplasmic 
reticulum to the plasma membrane, or extracellularly by plasmin 21,87-90. The active ?57 
kDa MT1-MMP starting at Y112 is subsequently inserted into the plasma membrane with 
the catalytic domain facing the extracellular milieu (Figure 1.2).  
 
1.3.4.3 Regulation by endogenous inhibitors 
 
Inhibition of active MT1-MMP at the cell surface is a crucial step in regulating its activity. 
Tissue inhibitors of Metalloproteinases (TIMPs) belong to a family of endogenous 
proteinase inhibitors which are able to bind and inhibit MMPs in tight non-covalent 
complexes of 1:1 stoichiometry 91. MT1-MMP is inhibited by TIMP-2, -3, and -4 but not 
by TIMP-1 92,93. MT1-MMP catalytic activity was further inhibited by RECK (reversion-
inducing-cysteine rich protein with Kazal motifs) 94, which also inhibits MMP-2 and 
MMP-9, as well as by TFPI-2 (tissue factor pathway inhibitor 2) and ?2-Macroglobulin55. 
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Various other proteins including chondroitin/heperan sulphate proteoglycans as well as 
testican 1 and 3 have been reported to block MT1-MMP activity, although the mechanism 
underlying this inhibition remains to be investigated 55. Amongst the endogenous 
inhibitors, TIMP-2 plays an ambivalent role in regulating MMP activity. Although being a 
potent inhibitor of MT1-MMP function it is also involved in the MT1-MMP mediated pro-
MMP-2 activation. Thereby, pro-MMP-2 forms a complex with TIMP-2 through their C-
terminal domains, enabling the N-terminal inhibitory domain of TIMP-2 in the complex to 
bind to MT1-MMP at the cell surface. This pro-MMP-2 – TIMP-2 – MT1-MMP ternary 
complex is presented to an adjacent active MT1-MMP that is not inhibited by TIMP-2 
function, which subsequently activates pro-MMP-2 21,95,96. Dimerisation or multimerisation 
of MT1-MMP on the cell surface through its hemopexin domains facilitates pro-MMP-2 
activation 97.  
 
1.3.4.4 Processing of MT1-MMP 
 
MT1-MMP has been shown to undergo autocatalytic and non-autocatalytic processing, 
thus regulating the amount of active MT1-MMP present at the cell surface. Autocatalytic 
degradation of the ~57 kDa active membrane-bound MT1-MMP results in a membrane-
tethered ~44 kDa form 98-100. During this process a ~18 kDa fragment corresponding to the 
catalytic domain is released, whereas the remaining inactive enzyme remains attached to 
the plasma membrane (G285 – V582) 101. Surprisingly, the presence of the ~44 kDa MT1-
MMP form correlates with an enhanced level of pro-MMP-2 activation 98,99. Exposure of 
cells to concanavalin A or phorbol esters, chemical agents that are known to increase MT1-
MMP-dependent pro-MMP-2 activation, was shown to enhance MT1-MMP processing to 
its ~44 kDa form 98,100,102-104. Although autocatalytic cleavage terminates MT1-MMP 
catalytic activity, the ~44 kDa fragment has been shown to exhibit a regulating function of 
enzymatic activity. It competes with full-length MT1-MMP for collagen binding, thus 
reducing the collagenolytic activity and cellular invasion through collagen-rich matrices 105 
as well as influencing the formation of the MT1-MMP – pro-MMP-2 – TIMP-2 ternary 
complex. Sequencing data of the released ~18 kDa fragment indicated that it is processed 
by two sequential cleavage events. The first occurs at the Gly284 – Gly285 peptide bond 
within the hinge region, which generates the ~44 kDa membrane-bound fragment. The 
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second proteolytic cleavage takes place at the Ala255 – Ile256 peptide bond within the active 
site of MT1-MMP, generating an inactive soluble fragment 100,106.  
Additionally, MT1-MMP undergoes non-autocatalytic processing, leading to the 
accumulation of soluble MT1-MMP forms in cell culture supernatants of breast carcinoma 
100,107,108, lung fibroblasts 107, endothelial cells 70,109 and fibrosarcoma cells 100. Soluble 
MT1-MMP fragments have also been identified in the supernatant of cells overexpressing 
recombinant MT1-MMP 100,110 or in human sputum and branchoalveolar lavage fluids 111. 
The major soluble form detected has a molecular mass of ~50 – 52 kDa corresponding to 
the entire ectodomain being shed from the cell surface 70,100,107,108. The 50 kDa from was 
found to activate pro-MMP-2 100, indicating that this soluble form sustains its catalytic 
activity. The non-autocatalytic cleavage has been shown to be a two-step process: the 
initial cleavage mediated by an unknown proteinase occurs within the stalk region of MT1-
MMP leading to the generation of the 52 kDa fragment whereas the second cleavage event, 
which generates the 50 kDa form was found to be ADAM-dependent 112. Additionally, a 
minor fraction of ~30 – 32 kDa forms of MT1-MMP was detected in the supernatant of a 
variety of cells 100,107, although the mechanism underlying the generation of these 
fragments remains to be investigated. 
 
1.3.4.5 Regulation by cellular trafficking 
 
Protein localisation that is affected by exocytosis, interacting proteins, endocytosis, 
recycling to the cell surface or degradation, is a further critical step in regulating MT1-
MMP activity. During cell migration, cells generate membrane protrusions, including 
lamellipodia and invadopodia, that facilitate local ECM degradation. Localisation of MT1-
MMP in these protrusive membrane structures is a key process for MT1-MMP proinvasive 
activity in migrating cells 4,36,97,113. The localisation of the enzyme is partly mediated by 
binding via its hemopexin domain to the widely expressed hyaluronan receptor CD44, 
which in turn associates with F-actin 58,114. This interaction was reported to promote cell 
motility 4. Studies using an intracellular domain deletion mutant of CD44 revealed a 
decreased localisation of MT1-MMP at lamellipodia, potentially due to an attenuated 
MT1-MMP interaction with F-actin 4. ?1 integrin has also been implicated to regulate 
MT1-MMP localisation 115,116, although it remains to be investigated whether both proteins 
are interacting directly.  
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However, MT1-MMP expression at the cell surface was usually shown to be weak in most 
tested cell types due to rapid internalisation of the protease to early and late endocytic 
structures 39,117. MT1-MMP accumulates in caveolae and in clathrin-coated regions of the 
membrane, which was shown to be important for endocytosis and recycling of MT1-MMP 
from the plasma membrane 39,117-120. Clathrin-dependent internalisation is mediated by the 
interaction between the MT1-MMP intracellular domain and the μ2 subunit of adaptor 
protein 2 (AP-2) 121 (chapter 1.3.5). A smaller fraction of total MT1-MMP has been shown 
to be associated with caveolae. Caveolae-dependent endocytosis was found to be 
dependent on Src induced phosphorylation of Caveolin-1 122. Subsequently, MT1-MMP 
binds phospho-Caveolin-1 and this interaction regulates MT1-MMP internalisation 119. The 
dynamic modulation of MT1-MMP localisation to invasive structures and its endocytosis 
emphasise the importance of spatiotemporal regulation of MT1-MMP. 
 
1.3.5 The intracellular domain of MT1-MMP 
 
In addition to the essential role of MT1-MMP mediated pericellular proteolysis in tumour 
cell migration, there is increasing evidence that the MT1-MMP intracellular domain (ICD) 
exerts important roles in regulating protein internalisation, cell surface localisation as well 
as inducing intracellular signalling pathways.  
The MT1-MMP ICD consists of 20 amino acids ranging from R563 to V582 (Figure 1.3). It 
was shown that the intracellular and the transmembrane domains are not only important for 
MT1-MMP localisation but are also required for the collagenolytic activity of the enzyme 
66,123. A chimera that expressed the extracellular MT1-MMP domain and the 
transmembrane and intracellular domains of interleukin-2 retained the ability to activate 
exogenous pro-MMP-2 124, but exhibited impaired cell surface localisation and degradation 
of the ECM 125. Expression of ICD deletion mutants led to a higher expression level of the 
enzyme at the cell surface, as shown by an increased level of pro-MMP-2 activation 110,117. 
These observations were found to be a consequence of decreased internalisation compared 
to the wild-type enzyme 67,117,121. In addition, the ICD deletion mutant failed to localise 
MT1-MMP at the leading edge of migrating cells and was thus found to decrease cell 
motility 38,110,125.  
As described, MT1-MMP endocytosis is mainly mediated by a clathrin-dependent 
mechanism, although a smaller fraction is associated with caveolae. Uekita et al. reported 
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that the ICD of MT1-MMP mediates its clathrin-dependent internalisation by recruiting the 
μ2 subunit of the adaptor protein 2 (AP-2) to its LLY573 sequence (Figure 1.3) 121. AP-2 is 
known to regulate incorporation of membrane proteins in clathrin-coated vesicles 121. This 
finding correlates with the observation that the cytoplasmic domain of MT1-MMP is 
essential for its trafficking, its recruitment to the cell surface and endocytosis 126. 
Interestingly, mutation of the LLY573 sequence or deletion of the intracellular domain 
resulted in decreased cell migration and invasion, indicating a link between regulated 
endocytosis of MT1-MMP and cell locomotion 121. Following internalisation of MT1-
MMP, a sub-fraction is transported to the trans-Golgi network through early endosomes 
and subsequently recycled back to the cell surface. This MT1-MMP recycling mechanism 
was shown to be dependent on the DKV582 sequence (Figure 1.3) 127. Interestingly, this 
carboxy-terminal motif (DKV582) has also been implicated in binding to the PDZ domain 
of neuronal nitric oxide synthase 128. PDZ motifs mediate protein-protein interactions 129, 
thus raising the possibility that this MT1-MMP ICD motif facilitates the assembling of 
signalling complexes.  
Recently, Labrecque et al. reported an association of MT1-MMP with phosphorylated 
caveolin-1 in Src-expressing cells dependent on the Cys574 and Val582 residues (Figure 1.3) 
119. Following Src-dependent phosphorylation, phospho-caveolin-1 interacts with integrins 
at focal adhesions 130, raising the possibility that the phospho-caveolin-1 – MT1-MMP 
complex is implicated in cell adhesion and migration. Furthermore, MT1-MMP undergoes 
palmitoylation at the C574 within the intracellular domain (Figure 1.3) 131. This lipid post-
translational modification was reported to affect cell migration and clathrin-mediated 
internalisation. Recent findings demonstrate that the Y573 is phosphorylated in a Src-
dependent manner and plays an important role in endothelial and tumour cell migration 132. 
Notably, stable transfection of fibrosarcoma cells with a non-phosphorylable MT1-MMP 
mutant showed an impaired proliferation level within 3D but not on 2D type I collagen 
gels 133, emphasising the importance of Src-dependent phosphorylation of the MT1-MMP 
intracellular domain. This reduction in proliferation has been shown to be independent of 
MT1-MMP catalytic activity and raises the possibility that signal pathways are induced 
depending on MT1-MMP phosphorylation. Interestingly, recent work by Moss et al. 
demonstrated that the MT1-MMP ICD is also phosphorylated at its Thr567 residue in a 
protein kinase C (PKC) dependent way, thus regulating collagenolytic activity 134 (Figure 
1.3). 
Introduction                                                                                                                                                     16 
Additionally, the MT1-MMP ICD is involved in the activation of the extracellular signal-
regulated protein kinase (ERK) signalling pathway, which was shown to depend on the 
YCQR576 sequence 61 (Figure 1.3, chapter 1.3.6). Another protein, MTCBP-1 (MT1-MMP 
cytoplasmic-binding protein-1), has been recently identified to bind to the MT1-MMP ICD 
at an unknown intracellular motif, and to co-localise with MT1-MMP at the plasma 
membrane 135. MTCBP-1 is a member of the cupin superfamily and was shown to decrease 
MT1-MMP induced cell migration but not to affect pro-MMP-2 activation levels.  
 
 
Figure 1.3: The cytoplasmic domain of MT1-MMP 
Schematic representation of the 20 amino acid comprising ICD with its reported functions. TMD, 
transmembrane domain. pCav-1, phosphorylated Caveolin-1. 
 
1.3.6 Transcriptional regulation by MT1-MMP 
 
The pro-angiogenic effect of MT1-MMP was shown to be at least partly driven by the 
MT1-MMP dependent up-regulation of VEGF-A expression at both the mRNA and protein 
level in MCF-7 and U251 cells 26,72,73. MT1-MMP overexpression in tumours stimulates 
angiogenesis in vivo by increasing VEGF-A synthesis within the tumour cells 26,72. A 
correlation between MT1-MMP and VEGF-A expression was confirmed by 
immunohistochemical staining and RT-PCR of human glioma tissue samples and have 
been found in early physiological cartilage formation 136,137. In contrast, the expression of 
other angiogenic factors including VEGF-B, -C, -D, P1GF, angiopoietin or their receptors 
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VEGFR-1, -2, neuropilin, Tie-1 and Tie-2 were not affected by MT1-MMP 73. MT1-MMP 
induced expression of VEGF-A was further shown to require the functional catalytic and 
intracellular domain as well as involving the activity of Src kinase 73.  
shRNA mediated MT1-MMP gene silencing in various cancer cell lines led to the 
identification of additional genes that were regulated by the proteinase. For instance, 
Smad1 expression was found to be decreased in MT1-MMP deficient cells compared to 
wild-type control, which correlated with reduced tumour growth 138. MT1-MMP silencing 
using RNAi in human urothelial cell carcinoma cell lines led to an increased level of the 
tumour suppressor Dickkopf-3 (DKK-3) 139. However, the identity of intracellular 
signalling pathways leading to the regulation of the described gene transcription remains to 
be investigated.  
Gingras et al. have shown an activation of the ERK signalling pathway in MT1-MMP 
expressing COS-7 cells. This ERK activation was found to be dependent on the MT1-
MMP ICD and its catalytic activity 61. Reporter assays performed on MT1-MMP 
expressing cells showed that activation of ERK correlated with an increase of transcription 
under the control of serum-response elements (SRE) 61. By using various MT1-MMP 
intracellular domain mutants, the YCQR576 sequence was found to be required for ERK 
signalling (Figure 1.3) 140. Thus, the ERK activation signal overlaps with the described 
LLY573 motif being involved in MT1-MMP internalisation (Figure 1.3). However, the role 
of the intracellular domain in ERK activation remains unclear, since ICD deletion mutants 
were found to increase ERK activation in another study 141. In contrast, adding TIMP-2 to 
MT1-MMP expressing MCF-7 cells, led to an ICD dependent but catalytically independent 
activation of the Ras-MEK-ERK signalling cascade 140. 
 
1.4 Membrane-tethered transcriptional regulators 
 
Various transcriptional regulators have been identified as latent transmembrane precursors, 
which have to be processed in order to translocate to the nucleus and regulate gene 
transcription. Recently, two different pathways (regulated intramembrane proteolysis and 
regulated ubiquitin/proteasome dependent proteolysis) have been reported in which 
transmembrane proteins are proteolytically released and their intracellular domains play a 
key role in different pathways and transcriptional regulation 142. 
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1.4.1 Regulated intramembrane proteolysis (RIP) 
 
A number of transmembrane proteins have recently been found to undergo regulated 
intramembrane proteolysis (RIP). The common characteristics of RIP involve ectodomain 
shedding of the transmembrane proteins, generating a membrane-bound fragment 
comprising of a short intracellular domain, which is subsequently cleaved within the 
transmembrane domain thus releasing the intracellular part. The first transmembrane 
proteins that were discovered to undergo RIP were Notch-1 143,144 and the amyloid 
precursor protein (APP) 145. Recently, additional surface proteins have been identified 
including SREBP (SRE-binding protein) 146, CD44 59, the Notch ligands Jagged and Delta 
147, ErbB4 148, E-cadherin 149, syndecan 3 150 and LRP1 151 .  
Transmembrane proteolysis occurring during RIP is mainly mediated by four families of 
proteinases: (i) the presenilin-type aspartyl proteinases, especially the presenilin-dependent 
?-secretase which mediates the Notch-1 and APP shedding, (ii) the site-2 protease family 
(S2P) that cleaves SREBP, (iii) the rhomboid serine proteinases cleaving the EGF ligand 
Spitz and (iv) the signal-peptide peptidase (SPP) involved in the processing of MHC (class 
I major histocompatibility complex) proteins 152-154. The presenilin-type aspartyl proteinase 
and S2P dependent RIP require a two-step proteolytic mechanism. Initially, the 
extracellular domain is cleaved off, typically by a metalloproteinase of the ADAM family 
(e.g. ADAM-9, -10, -17), enabling the second proteolysis within the transmembrane 
domain 155-161. In contrast, rhomboid serine proteinases are able to cleave intramembranous 
protein domains without prior ectodomain shedding. Cell surface proteins which are 
processed by presenilins and rhomboids belong to the type-I transmembrane proteins, 
whereas S2P and SPP cleave type-II transmembrane proteins 154,162-164. The proteolysis of 
transmembrane proteins results in the release of the intracellular domain, which acts as a 
bioactive molecule in different pathways or as transcriptional regulator. The mechanism 
underlying RIP of several key type-I transmembrane proteins is briefly described.  
 
1.4.1.1 ?-secretase dependent RIP 
 
?-secretase is a multiprotein complex comprising of presenilin-1, presenilin-2, APH-1 
(anterior pharynx-defective phenotype), nicastrin and PEN-2 (presenilin-enhancer 2). It is 
involved in the cleavage of various type-I transmembrane proteins including the ?-amyloid 
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precursor protein 165 (chapter 1.4.1.1.1), Notch receptor 144 (chapter 1.4.1.1.2), E-cadherin, 
N-cadherin 149, CD44 166,167, ErbB-4 148, the Notch ligands Delta and Jagged 147 and the 
low density lipoprotein (LDL) receptor related protein (LRP) 151,168. Presenilin depletion 
led to a decreased ?-secretase activity and reduced APP processing as well as inducing 
severe defects in embryonic development similar as observed in Notch1-deficient mice 169-
171.  
 
 
Figure 1.4: Regulated intramembrane proteolysis  
Schematic representation of Notch1, APP and SREBP RIP. The proteinases involved (furin, ?-, ?- and ?-
secretase, site-1 and site-2 protease) and the proteolytic cleavage fragments (NICD, ?- and ?-stubs) are 
indicated. Taken from 144. 
 
1.4.1.1.1 RIP of the ß-amyloid precursor protein (APP) 
 
The ?-amyloid precursor protein is a large type-I transmembrane glycoprotein, mainly 
expressed in neurons and vascular cells 172. It was shown to undergo proteolytic cleavage 
involving the sequential activity of ?-, ?- and ?-secretase (Figure 1.4) 173. Generally, an 
initial ?-secretase (e.g. TACE or ADAM-10) dependent cleavage event releases the APP 
ectodomain 158, although ectodomain shedding mediated by ?-secretase activity (e.g. 
BACE-1/2) was also observed 174-177. Both initial cleavage steps lead to the release of the 
extracellular domain and the generation of a membrane-bound COOH-terminal fragment. 
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Subsequent cleavage of the membrane-tethered peptide by ?-secretase leads to the release 
of the ?-amyloid protein (A?, following ?-secretase shedding) or the p3 peptide (following 
?-secretase shedding) and the APP intracellular domain 178. The released ICD domain 
enters the nucleus and modulates gene expression 179,180.  
 
1.4.1.1.2 RIP of Notch-1 
 
Notch-1 is a type-I transmembrane signalling protein, which plays an important role during 
early stages of embryonic development. It is cleaved by a furin-like proteinase in the Golgi 
during trafficking to the plasma membrane 181. Subsequent binding of its ligands, Delta and 
Jagged, triggers the proteolytic processing of Notch-1 by TACE (ADAM-17) 182 or by 
ADAM10 (Kuzbanian) 183 followed by a second ?-secretase-mediated cleavage which 
leads to the release of the Notch intracellular domain (NICD) (Figure 1.4). The released 
intracellular domain translocates to the nucleus where it regulates transcription of various 
target genes (e.g. HES-1) 184,185. 
 
1.4.1.2 Rhomboid-dependent RIP 
 
The rhomboid family consists of about 100 members, which are highly conserved from 
bacteria to humans. However, they are best characterized in the fruitfly Drosophila 
melanogaster. Rhomboids are serine proteinases with seven transmembrane domains 
which are involved in the regulated intramembrane proteolysis and release of EGF ligands 
including Spitz, Keren and Gurken 154,162-164. There are three human rhomboids described 
so far: RHBDL1 186, RHBDL2, a presenilin associated rhomboid-like protein (PARL) 187 
and RHBDL4 188. However, their biological function remains to be investigated. The 
human rhomboid, RHBDL2, is known to cleave Drosophila Spitz when both proteins are 
co-expressed in mammalian cells. Pascall & Brown suggested B-type ephrins as potential 
substrates of RHBDL2 189. 
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1.4.2 Regulated Ubiquitin/Proteasome-dependent processing (RUP) 
 
Recently, a novel proteolytic cleavage mechanism leading to the maturation of 
transcription factors was observed in yeast (Saccharomyces cerevisiae), which requires the 
activity of the ubiquitin/proteasome pathway 190. SPT23 and MGA2 are transcription 
factors tethered as latent forms to the membrane of the endoplasmatic reticulum (ER). 
Both play a key role in the OLE pathway (pathway that controls OLE1 desaturase levels) 
that regulates membrane fluidity and they are known to undergo proteolytic maturation in 
order to be released from the plasma membrane. The mechanism of SPT23 maturation is 
briefly summarised (Figure 1.5).  
The membrane-bound SPT23 transcription factor interacts with the RSP5 ubiquitin ligase 
(E3 enzyme) leading to ubiquitination, which induces proteasome-dependent processing 
(Figure 1.5A, B). Subsequently, the carboxy-terminal and the transmembrane domain are 
completely degraded by the proteasome whereas only a 90 kDa fragment of the NH2-
terminus is spared (Figure 1.5C). This 90 kDa peptide translocates subsequently to the 
nucleus to regulate gene transcription (Figure 1.5D).  
 
 
Figure 1.5: Regulated ubiquitin/proteasome-dependent processing 
(A) The latent membrane-bound SPT23 is tagged by the RSP5 ubiquitin-ligase, which initiates proteasome-
binding (B) and subsequent degradation of the COOH-terminus (C). Only a 90 kDa N-terminal fragment is 
spared from degradation and translocates to the nucleus as a transcription factor (D). Adapted from 142 . 
Introduction                                                                                                                                                     22 
Hoppe et al. suggested that a polypeptide loop of SPT23 enters the proteasome barrel 
entirely to contact the active site 190. The N-terminal fragment, by being tightly bound to 
another protein, is therefore spared from degradation. The following detachment of this 
protein will release and activate the transcriptional function of SPT23. 
The ubiquitination and subsequent processing of proteins by the proteasome is highly 
conserved. Emerging data reveal that besides degrading proteins that were tagged by 
ubiquitin, proteasomal function plays a key role in the regulation of various cellular 
processes, including gene transcription, DNA repair and chromatin remodelling 191. An 
example of transcription factor activation in humans and thus regulating gene transcription, 
is the proteasome-dependent processing of NF-?B. p105, which is a precursor of the p50 
subunit of the NF-?B transcription factor, is processed via a ubiquitin/proteasome-
dependent mechanism. NF-?B regulates immune and inflammatory responses, is involved 
in embryogenic development, apoptosis and malignant progression. In this process, the C-
terminal part of p105 is rapidly degraded by the proteasome whereas the N-terminal p50 
fragment remains stable 192,193, similar to the OLE-pathway in yeast.  
 
1.5 Tumour angiogenesis 
 
Angiogenesis, the generation of new blood supply from existing vessels, depends on the 
proper regulation of endothelial cell activation, proliferation, adhesion, migration and 
maturation 194,195. Following embryonic development, angiogenesis is restricted to 
processes of wound healing, ovarian and menstrual cycles as well as pregnancy 194. 
However, it also plays a key role during pathophysiological conditions including cancer, 
inflammatory and cardiovascular diseases 196. The growth of tumours is restricted by its 
need to provide sufficient nutrients and oxygen to the tumour cells. Under hypoxic 
conditions tumour cells induce the development of new blood vessels from pre-existing 
vasculature by secreting pro-angiogenic mitogens, in particular vascular endothelial 
growth factor. 
 
1.5.1 Vascular endothelial growth factor 
 
Vascular endothelial growth factor (VEGF) is a key pro-angiogenic mitogen that is 
secreted by endothelial as well as tumour cells to induce endothelial cell differentiation 
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(vasculogenesis) and sprouting of new capillaries from pre-existing vessels (angiogenesis) 
197,198. VEGF was shown to be a key player during phases of embryogenic development, 
wound healing and in human pathophysiological conditions including cancer, rheumatoid 
arthritis as well as cardiovascular disease 199,200. Expression of VEGF has been correlated 
with poor prognosis in patients with breast cancer 201. Recent therapeutic approaches 
targeting tumour angiogenesis are based on neutralising monoclonal anti-VEGF antibodies 
or small molecular weight inhibitors against their corresponding receptors. Inhibition of 
VEGF activity using the monoclonal antibody bevacizumab (Avastin) represents the first 
successful anti-angiogenic treatment strategy when given in combination with 
chemotherapy as recently shown in the treatment of lung, colon and breast cancer 202,203. 
However, it is crucial to understand the biology of pathologic angiogenesis as well as the 
development and survival of blood vessels under physiologic conditions when anti-
angiogenic therapies are applied in the long-term treatment of cancer. The attempt to 
develop selective therapeutic agents that are designed to attenuate only specific signalling 
pathways led to an increased interest in understanding VEGF receptor (VEGFR) induced 
signalling. 
VEGF (VEGF-A) belongs to a family of conserved growth factors including VEGF-B, -C, 
-D and placenta growth factor (PlGF), which are endogenously expressed in mammals 
204,205. Alternative splicing of human VEGF mRNA from a single gene generates various 
VEGF isoforms, including 121, 145, 165, 189 and 206 amino acid forms 206. Amongst 
these isoforms VEGF165 and VEGF121 are the most abundant splice variants and were 
found to be the most biologically active forms in in vitro studies. Both isoforms are 
secreted by various different tumour cells with particularly high mRNA levels being 
detected in breast cancer cell lines 207. Human VEGF165 is glycosylated at Asn
75 and forms 
typically 46 kDa homodimers 208. The expression of VEGF-A has been shown to be up-
regulated through the activation of tyrosine kinase receptors including receptors of the 
EGF family 209 as well as insulin 210, IGF 211, HGF 212, PDGF 213 and FGF receptors 214. 
These receptors were shown to induce two different canonical pathways leading to the 
activation of Ras – Raf – MEK – ERK as well as the phosphatidylinositol 3-kinase (PI3K) 
– Akt pathway. The Ras – Raf – MEK – ERK pathway is essential for the up-regulation of 
VEGF-A in fibroblasts, whereas the PI3K induced pathway is implicated in VEGF-A 
expression in epithelial cells 215. The main transcriptional regulation of the VEGF gene is 
mediated through the proximal region of the promoter, which contains GC-rich regions 
binding factors of the Sp family as well as AP-2 and Egr-1 transcription factors 
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(summarised in Figure 1.6). The expression of VEGF-A is furthermore rapidly induced 
under hypoxic conditions, which enables the binding of the transcriptional regulator 
hypoxia inducible factor 1 (HIF-1) to the corresponding hypoxia response elements (HRE) 
in the 5’ flanking region of the VEGF-A human promoter region (Figure 1.6) 216-218. A 
variety of external factors and stimuli have been shown to induce VEGF-A expression 
mainly via activation of the Sp proteins, including TNF-? 219, TGF-? 220, basic fibroblast 
growth factor (bFGF) 200, TGF-ß1 221, interferon ? 222 and interleukin-1ß 223 in various cell 
types. 
 
 
Figure 1.6: VEGF-A promoter region 
The entire VEGF-A promoter region is represented. The heavy arrow indicates the classical initiation of 
transcription, whereas another cryptic promoter was described within the 5’ UTR region (light arrow). Long 
arrows indicate a connection between cis-regulatory elements and trans-activating factors. Adapted from 224. 
 
1.5.2 VEGF signalling 
 
Members of the VEGF family of growth factors exhibit their biological functions through 
binding to corresponding receptor tyrosine kinases. Three VEGF receptors (VEGFR) have 
been identified: VEGFR-1 (flt-1), VEGFR-2 (KDR, flk-1) and VEGFR-3 (flt-4). VEGFR-
1 binds to VEGF-A, -B and PlGF, VEGFR-2 binds to VEGF-A and -E and VEGFR-3 
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interacts with VEGF-C and -D 225. Proteolytic processing of human VEGF-C and -D 
facilitates binding to VEGFR-2, however this binding occurs with a lower affinity than 
binding to VEGFR-3 226. In addition to the formation of homodimers, VEGFRs have also 
been described to form heterodimers, although the signal-transduction capacities of these 
heterodimers remain to be elucidated. The ligand specificities of the receptors are 
summarised in Figure 1.7.  
The three VEGFRs are structurally related to the PDGF family of receptors, sharing a 
similar domain structure consisting of an intracellular domain containing a split tyrosine 
kinase domain that is interrupted by a 70 amino acid kinase insert, a single hydrophobic 
transmembrane domain and seven immunoglobulin-like domains in the extracellular 
region. Their conserved structure is summarised for VEGFR-2 in Figure 1.8.   
 
 
Figure 1.7: The VEGFR family with ligands 
Mammalian vascular endothelial growth factors (VEGFs) bind to three VEGF receptor (VEGFR) tyrosine 
kinases (indicated by arrows), leading to the formation of VEGFR homodimers. Processing of VEGF-C and -
D allows for binding to VEGFR-2 (dotted arrow). Adapted from 226. 
 
Neuropilin-1 and -2 constitute another class of non-tyrosine kinase receptors for members 
of the VEGF family and bind to certain isoforms of VEGF-A, -B, -E and PlGF. 
Neuropilins are transmembrane glycoproteins that exhibit a short intracellular domain with 
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no known signalling function, suggesting that they are not functional receptors themselves. 
Notably, NRP-1 was shown to function as a critical co-receptor for VEGF165, resulting in 
an increased affinity of VEGF165 to VEGFR-2 
225. Furthermore, heparin was found to 
amplify the signalling of VEGF165, but not VEGF121, via VEGFR-2 
227. This NRP-1 and 
heparin dependent enhanced stimulation of VEGFR-2 is at least partly the reason that 
VEGF165 is the strongest signal transducer among the VEGF subtypes and it is generally 
accepted that VEGFR-2 is the major mediator of the mitogenic, angiogenic and 
permeability-enhancing activities of VEGF-A 228. 
VEGFR-1 is described as a positive regulator of monocyte and macrophage migration as 
well as a negative regulator of VEGFR-2 signalling activity. This negative regulatory 
capacity is at least partly mediated by an alternative soluble VEGFR-1 splice variant that 
binds to VEGF-A and thus prevents VEGF-A binding to VEGFR-2.  
 
 
Figure 1.8: VEGFR-2 induced signalling pathways 
Schematic representation of VEGFR-2 induced signalling pathways. Upon ligand binding VEGFR-2 forms 
homo-dimers leading to trans-phosphorylation of the indicated tyrosine residue within its intracellular part. 
Following binding of adapter proteins, various signalling cascades are activated including the Ras-Raf-MEK-
MAPK and the PI3K-Akt-mTOR pathway as well as activation of Src and RAC. VEGFR-2 signalling affects 
various cellular responses including cell proliferation, cell survival, migration as well as vascular 
permeability in endothelial cells. Adapted from 226. 
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VEGFR-2 is implicated in all physiological and pathological aspects of vascular 
endothelial cell function, whereas VEGFR-3 is selectively expressed on lymphatic 
endothelium and plays a key role in lymphatic-endothelial-cell development and function 
228. However, there is an increasing body of evidence that VEGFR-1 and particularly 
VEGFR-2 are also expressed in malignant epithelial cells, providing a mechanism for 
tumour cells to induce an autocrine VEGF-A signalling loop leading to cell survival and 
proliferation. Initial evidence for autocrine VEGF signalling has been found in melanoma 
cells 229, leukaemia cells 230, prostate carcinoma cells 231, colon carcinoma cells 232, bladder 
tumour 233 and breast carcinoma cells 234-236.  
It has been demonstrated that stimulation of the breast cancer cell line T47d induces cell 
invasion by activating intracellular MAP kinase, PI3K and Akt signalling pathways 235. 
Interestingly, suppression of VEGF expression promotes apoptosis of breast cancer cells 
by inhibition of PI3K activity. This autocrine VEGF loop was further shown to facilitate 
invasion of breast carcinoma cell lines 236, emphasising the importance of autocrine VEGF 
stimulation for breast carcinoma cell survival independent of angiogenesis. The molecular 
mechanisms by which receptor tyrosine kinases are activated have been studied 
extensively. Briefly, following ligand-stimulated dimerisation of receptor monomers the 
dimerised receptor undergoes transphosphorylation of tyrosine residues within its 
intracellular domain, leading to an assembly of signalling proteins to receptor 
phosphotyrosines. In contrast to VEGFR-1, phosphorylated VEGFR-2 can be readily 
detected in cells after VEGF-A stimulation and its phosphorylation sites have been mapped 
(summarised in Figure 1.8).  
Among these phosphorylation sites the tyrosine residues Y1054 and Y1059 within the 
activation loop were shown to be critical for the complete ligand-induced receptor tyrosine 
kinase activation 237,238. In recent publications, the PI3K signal transduction pathway has 
emerged as one of the main signalling pathways downstream of VEGFR-2 activation, 
leading to cell survival and proliferation. PI3K converts the plasma membrane lipid 
phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate 
(PIP3). Adapter proteins containing a pleckstrin-homology (PH) domain, including Akt, 
phosophoinositide-dependent kinase-1 (PDK-1) and PDK-2, are able to bind to PIP3. Akt 
is subsequently activated and induces cellular responses including cell proliferation, cell 
cycle progression and cell survival 239,240. VEGFR-2 phosphorylated at its Y1175 residue 
has been shown to bind the adapter protein Shb that induces the activation of the PI3K/Akt 
pathway. Phospholipase C?1 (PLC?1) also binds to phosphorylated Y1175 and induces the 
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activation of mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated 
kinase-1/2 (ERK1/2) pathway as well as proliferation of endothelial cells. Furthermore 
PLC? hydrolyses phosphoinositides to generate the second messengers inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 increases intracellular calcium levels, 
whereas DAG activates protein kinase C (PKC) leading to various cellular responses 241. 
Furthermore, phosphorylated Y1175 has been shown to bind to the adapter proteins 
Sck/ShcB, which are required for normal development 242. 
Phosphorylated Y951 is known to be a binding site for TSAd (T-cell specific adaptor; 
VEGF receptor-associated protein (VRAP)). Stimulation of cells with VEGF-A induces 
the complex formation between TSAd and Src, indicating a potential role of TSAd in Src 
activation or recruitment of active Src downstream of VEGFR-2. The third 
phosphorylation site, Y1214, has been implicated in VEGF-mediated actin remodelling 
through activation of Cdc42 and p38 MAPK 243. Focal adhesion kinase (FAK) and its 
substrate paxillin which are involved in the turnover of focal adhesions during cell 
migration have been shown to be downstream substrates of VEGFR-2 signalling 244,245. 
 
1.6 Aim of the thesis 
 
MT1-MMP has been shown to play a key role in various stages of tumourigenesis, 
including tumour initiation, progression, tumourigenic angiogenesis and cell migration. In 
addition to its function as an ectodomain sheddase, recent studies revealed a regulatory 
effect of MT1-MMP on the transcriptional level of various target genes, including VEGF-
A, DKK-3 and Smad1. The MT1-MMP dependent regulation of VEGF-A expression was 
reported to involve the MT1-MMP intracellular domain, its catalytic function as well as 
Src kinase activity 73. Various angiogenesis-related regulator proteins were reported to be 
synthesised as latent transmembrane precursors that have to be proteolytically processed in 
order to fulfil their regulatory activity, including transcriptional regulation of target genes. 
However, the molecular mechanisms underlying this regulation are not understood so far. 
 
The aim of this thesis was (i) to investigate how MT1-MMP induces signalling pathways, 
(ii) to define elements of a potential MT1-MMP induced pathway and in particular to 
dissect the molecular mechanism underlying the MT1-MMP dependent up-regulation of 
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VEGF-A and (iii) to get a better understanding of MT1-MMP mediated transcriptional 
regulation and its non-catalytic functions, facilitating MT1-MMP dependent signalling.  
Therefore, the mechanism of MT1-MMP induced VEGF-A expression, as described 
previously 73, was further investigated in detail by using the MT1-MMP deficient breast 
cancer cell line MCF-7 as a model system (chapter 3.1) followed by subsequent testing of 
various different breast cancer cell lines (chapter 3.2). It was further investigated whether 
the MT1-MMP intracellular domain, which was shown to be involved in a plethora of 
cellular responses (chapter 1.3.5), is released following MT1-MMP extracellular domain 
shedding in a process of regulated intramembrane proteolysis (RIP) or regulated 
ubiquitin/proteasome dependent processing (RUP) in order to modulate transcription 
(chapter 3.3). 
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2 Material and Methods 
2.1 Materials 
 
The water used for most applications was deionised, microfiltered through a Milli-Q 
membrane and autoclaved. The water for PCR was purchased from Sigma-Aldrich. All 
chemicals were analytical grade unless indicated otherwise and were purchased from 
Sigma-Aldrich, Fluka or Fisher Scientific. 
 
2.1.1 General materials 
 
2.1.1.1 Equipment 
 
Equipment  Model    Supplier 
 
Incubator  Heraeus HERAcell® 150 Thermo Scientific, Wilmslow, UK 
Gel electrophoresis Mini Protean® II xi  Bio-Rad, Hemel Hempstead, UK 
  (Acrylamide gels)   
   Mini-Sub® Cell GT  Bio-Rad, Hemel Hempstead, UK 
   (Agarose gels)    
Centrifuges  5810R    Eppendorf, Cambridge, UK 
   5415D    Eppendorf, Cambridge, UK 
   J6-M1    Beckman Coulter, High Wycombe, UK 
   Avanti® J-26 XPI  Beckman Coulter, High Wycombe, UK 
Microscopes   Axioplan 2 imaging  Zeiss, Göttingen, GER 
   microscope 
   iCys™ laser scanning   CompuCyte, Westwood, MA 
   cytometer 
   Tandem SP5 inverted  Leica Microsystems, Wetzlar, GER 
Confocal microscope 
Eclipse TS100   Nikon Instruments Inc., Düsseldorf, GER 
Fridges/Freezers -80˚C, -20˚C, +4˚C  New Brunswick Scientific, St. Albans,  
UK; Labcold, Basingstoke, UK 
Plate reader  Infinite® M200   Tecan, Reading, UK 
Power supply  PowerPac 200   Bio-Rad, Hemel Hempstead, UK 
VORTEX   Vortex-Genie 2   Scientific Industries, Bohemia, NY 
PCR cycler  DNA Engine Tetrad 2  Bio-Rad, Hemel Hempstead, UK 
   Peltier Thermal Cycler    
 Applied Biosystems 7900HT Applied Biosystems, 
Fast Real-Time PCR System Warrington, UK 
Serological Pipette Matrix Cell Mate II  Thermo Scientific, Wilmslow, UK 
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Spectrophotometer Nanodrop® ND-1000 UV-Vis  Thermo Scientific, Wilmslow, UK 
RNA quality control 2100 Bioanalyzer  Agilent Technologies, Stockport, UK 
Cell counter  Vi-CELL™   Beckman Coulter, High Wycombe, UK 
Flow cytometry  FACSCalibur™   BD Biosciences, Oxford, UK 
Pipettes   2 μl, 10 μl, 20 μl, 100 μl Gilson, Middleton, WI 
  200 μl, 1000 μl 
Rotator   Stuart SB3   Keison Products, Chelmsford, UK 
Rocker   Stuart SSL4   Keison Products, Chelmsford, UK 
Heat-stirrer  Stuart CB162   Keison Products, Chelmsford, UK 
Heating block  QBD4    Grant Instruments, Shepreth, UK 
Roller mixer  Stuart SRT9   Keison Products, Chelmsford, UK 
Film processor      Agfa, Düsseldorf, GER 
Hood   Bio MAT 2 Class II   Medical Air Technology 
Mirobiological Safety Cabinet Chadderton, UK 
UV    UVP-BioDoc It™  UVP Ltd., Cambridge, UK 
Imaging System 
Water baths  Universal SUB36  Grant Instruments, Shepreth, UK 
 
 
 
2.1.1.2 Consumables 
 
Consumable      Supplier 
 
Bacterial tubes (14 ml)     Sarstedt, Leicester, UK 
Syringes      BD Biosciences, Oxford, UK 
Cryotubes (1 ml, 1.8 ml)    Nunc, Roskilde, DK 
Petri dishes      Sarstedt, Leicester, UK 
Pipette tips      Star lab, Milton Keynes, UK 
Filter pipette tips     Star lab, Milton Keynes, UK 
Amersham Hybond™ ECL™ Nitrocellulose  GE Healthcare, Bucks, UK 
Membrane 
Amersham Hyperfilm ECL™    GE Healthcare, Bucks, UK 
Serological pipettes (5 ml, 10 ml, 25 ml, 50 ml)  Sarstedt, Leicester, UK 
Sterile filters (0.2 um), Sterile Acrodisc Syringe  BD Biosciences; Millipore 
3 MM Whatman paper     Schleicher & Schüll, Relliehausen, GER 
Centrifuge tubes (15 ml, 50 ml)    Sarstedt, Leicester, UK 
Tissue culture vessels (25 cm2, 75 cm2, 175 cm2)  Sarstedt, Leicester, UK 
Microtitre plates (96-well, 24-well, 12-well, 6-well) Nunc, Roskilde, DK 
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2.1.1.3 Chemicals 
 
Chemical      Supplier 
 
Acetic acid      Acros, Loughborough, UK 
Acetone      Acros, Loughborough, UK 
Acrylamide      Fisher Scientific, Loughborough, UK  
Agar       Fisher Scientific, Loughborough, UK 
Agarose      Fisher Scientific, Loughborough, UK 
Ammoniumpersulphate (APS)    Fisher Scientific, Loughborough, UK 
Ampicilin      Fisher Scientific, Loughborough, UK 
ß-mercaptoethanol     Sigma-Aldrich, Dorset, UK 
Bovine serum albumine (BSA)    Sigma-Aldrich, Dorset, UK 
Bromphenol blue     Fisher Scientific, Loughborough, UK 
Complete Protease Inhibitor Cocktail   Roche Applied Science, Welwyn, UK 
Coomassie G250     Fisher Scientific, Loughborough, UK 
DNA marker: 
  1 kB ladder    Invitrogen, Paisley, UK 
  DNA marker VIII   Roche Applied Science, Welwyn, UK 
dNTP’s       GE Healthcare, Bucks, UK 
Dulbecco’s modified Eagle’s Medium (DMEM)  Invitrogen, Paisley, UK 
Dynal® Magnteic Beads    Invitrogen, Paisley,  UK 
DTT (Dithiothreitol)     Fisher Scientific, Loughborough, UK 
EDTA (ethylenediaminetetraacetic)   Fisher Scientific, Loughborough, UK 
EGTA (thylene glycol tetraacetic acid)   Fisher Scientific, Loughborough, UK 
Ethanol       Acros, Loughborough, UK 
Foetal calf serum     Perbio, Thermo Scientific, Wilmslow, UK 
Fugene 6      Roche Applied Science, Welwyn, UK 
Glycine       Fisher Scientific, Loughborough, UK 
Glycerol      Fisher Scientific, Loughborough, UK 
HEPES       Fisher Scientific, Loughborough, UK 
Kalium chloride (KCl)     Fisher Scientific, Loughborough, UK 
Kanamycin      Fisher Scientific, Loughborough, UK 
L-alanyl-L-glutamine     Invitrogen, Paisley, UK 
Lithium chloride (LiCl)     Fisher Scientific, Loughborough, UK 
Magnesium chloride (MgCl2)    Fisher Scientific, Loughborough, UK 
Marvel       Fisher Scientific, Loughborough, UK 
Methanol      Acros, Loughborough, UK 
ONPG (o-Nitrophenyl-?-D-galactopyranoside)  Sigma-Aldrich, Dorset, UK 
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Nonidet® P40 (NP40)     Sigma-Aldrich, Dorset, UK 
Paraformaldehydes (PFA)    Fisher Scientific, Loughborough, UK 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1)  Sigma-Aldrich, Dorset, UK 
Potassium dihydrogen phosphate (KH2PO4)  Fisher Scientific, Loughborough, UK 
ProLong® Gold Antifade Reagent   Invitrogen, Paisley, UK 
Protein Marker: 
  BenchMark™ Protein Ladder  Invitrogen, Paisley, UK 
ReBlot™ Plus Strong Antibody Stripping Solution Millipore, Watford, UK 
Sodiumchloride (NaCl)     Fisher Scientific, Loughborough, UK 
Sodium deoxycholate     Fisher Scientific, Loughborough, UK 
Sodium dodecyl sulphate (SDS)    Fisher Scientific, Loughborough, UK 
Sodium Phosphate (Na2HPO4)    Fisher Scientific, Loughborough, UK 
Sodium vanadate     Fisher Scientific, Loughborough, UK 
SYBR® Safe DNA gel stain    Invitrogen, Paisley, UK 
TEMED (N,N,N’N’-Tetraethylmethyldiamine)  Thermo Scientific, Wilmslow, UK 
Tris-Base      Fisher Scientific, Loughborough, UK 
Tris-HCl      Fisher Scientific, Loughborough, UK 
Triton X-100      Fisher Scientific, Loughborough, UK 
Trypane blue      Sigma-Aldrich, Dorset, UK 
Tryptone      Fisher Scientific, Loughborough, UK 
Tween®20      Sigma-Aldrich, Dorset, UK 
Yeast extract      Fisher Scientific, Loughborough, UK 
 
 
2.1.1.4 Kits 
 
Kit        Supplier 
 
BCA™ Protein Assay      Pierce, Thermo Scientific,  
Wilmslow, UK 
Dual Luciferase® Reporter Assay System   Promega, Southampton, UK 
Amersham ECL™ Western Blotting Detection Reagents GE Healthcare, Bucks, UK 
Platinum® Taq DNA Polymerase    Invitrogen, Paisley, UK 
QuickChange® XL Site-Directed Mutagenesis Kit  Stratagene, Cheshire, UK 
Qiagen Plasmid Mini Kit     Qiagen, Crawley, UK 
Qiagen HiSpeed Plasmid Maxi Kit    Qiagen, Crawley, UK 
Qiagen Large-Construct Kit     Qiagen, Crawley, UK 
Qiagen RNeasy Plus Kit     Qiagen, Crawley, UK 
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QIAquick Gel Extraction Kit     Qiagen, Crawley, UK 
SigmaSpin™ Post-Reaction Clean-Up Columns   Sigma-Aldrich, Dorset, UK 
SuperScript® II Reverse Transcriptase    Invitrogen, Paisley, UK 
 
 
2.1.1.5 Buffers and solution 
 
Name     Components 
 
2 ? Assay Buffer   200 mM Sodium phosphate buffer (pH 7.3), 2  
mM MgCl2, 100 mM ?-Mercaptoethanol, 1.33  
mg/ml ONPG 
ChIP dilution buffer   1% (v/v) Triton X-100, 2 mM EDTA, 150 mM NaCl,  
20 mM Tris-HCl, pH 8.1 
Coomassie blue stain   0.25% (w/v) Coomassie G250, 10% (v/v) acetic acid 
Destain solution   10% (v/v) acetic acid 
DNA loading buffer (10 ?)   50% (v/v) Glycerin, 10 mM EDTA (pH 8.0), 0.1% (w/v) 
SDS, 0.025% (w/v) Bromphenol blue, 0.025% (w/v) 
Xylencyanole 
HEG buffer    10 mM HEPES (pH 7.5), 1 mM EDTA (pH 8.0), 
10% (v/v) Glycerol 
IP lysis buffer    10 mM Tris-HCl (pH 7.4), 150 mM NaCl,  
1% (v/v) Triton X-100, 0.5% (v/v) Nonidet® P40, 1 mM 
EDTA, 1 mM EGTA, 1 mM sodium 
vanadate 
Laemmli buffer (5 ?)   0.01% (w/v) Bromphenol blue, 250 mM DTT, 10% (w/v) 
SDS, 200 mM Tris-HCl (pH 8.0), 50% (v/v) Glycerol 
Protein fixation    50% (v/v) Methanol, 10% (v/v) acetic acid 
TAE      242 g Tris-Base, 57.1 ml acetic acid, 100 ml 0.5 
M EDTA (pH 8.0) 
TaqMan® Universal PCR Master Mix Applied Biosystems, Warrington, UK 
TBS     136.9 mM NaCl, 2.68 mM KCl, 24.76 mM Tris- 
Base, pH 7.8 
Paraformaldehyde (PFA) 4%  4% (w/v) PFA, pH 7.5 in PBS 
PBS     137 mM NaCl, 4.3 mM Na2HPO4, 2.7 mM KCl, 
1.47 mM KH2PO4, pH 7.4 
RIPA buffer    50 mM HEPES (pH 7.6), 1 mM EDTA, 0.7% (w/v) 
Sodium deoxycholate, 1% (v/v) NP-40, 0.5 M LiCl 
Sample buffer    1% (w/v) SDS, 50 mM Tris-HCl (pH 6.8), 8% 
(v/v) Glycerol, 4% (v/v) ß-mercaptoethanol 
SDS Lysis buffer   1% (w/v) SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 
8.1), Complete Protease Inhibitor Cocktail  
SDS-PAGE loading buffer  250 mM Tris-HCl (pH 6.8), 50% (w/v) Glycerol, 
Material and Methods                                                                                                                                     35 
10% (w/v) SDS, 0.5% (w/v) bromphenol blue 
SDS-PAGE running buffer  25 mM Tris-HCl, 1.44% (w/v) Glycine,  
1% (w/v) SDS 
SOC     0.5% (w/v) yeast extract, 2% (w/v) Tryptone, 10 mM  
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM Glucose 
Tris buffer pH 8.8   90.75 g Tris, 2 g SDS, pH 8.8 (500 ml) 
Tris buffer pH 6.8   30.25 g Tris, 2 g SDS, pH 6.8 (500 ml) 
TM-2 buffer    0.01M Tris-HCl (pH 7.4), 0.002 M MgCl2, 
Complete Protease Inhibitor Cocktail 
Transfer buffer    3.03 g Tris-HCl, 14.4 g Glycine, 200 ml  
Methanol (1 l) 
2 ? YT     16 g tryptone, 10 g yeast extract, 5g NaCl (1 l) 
 
 
2.1.2 Biological material 
2.1.2.1 Bacterial strains 
 
For cloning experiments E.cloni EXPRESS Escherichia coli (E.coli) cells (Lucigen) were 
used, whereas routine re-preparation of cDNA constructs was performed using Subcloning 
EfficiencyTM DH5?TM Chemically Competent E.coli (Invitrogen). 
 
E.cloni Express genotype:  EXPRESS BL21(DE3)pLysS: F- ompT hsdSB (rB- mB-) gal 
dcm (DE3) pLysS (CmR) 
DH5? genotype: F- ?80lacZ?M15 ?(lacZYA-argF)U169 deoR recA1 endA1 
hsdR17(rk
-, mk
+) phoA supE44 thi-1 gyrA96 relA1 ?- 
 
2.1.2.2 Human cell lines 
 
Breast carcinoma cell lines MCF-7, MDA-MB-231, MDA-MB-468 and MDA-MB-453 as 
well as HEK293 and HeLa cells were purchased from Cancer Research UK (London, UK). 
NAUT™ 293 cells were obtained from Microbix. All cell lines were routinely cultured in 
Dulbecco’s Medium with 10% (v/v) foetal calf serum (FCS) and glutamine (500 ?g/ml).  
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Cell line Primary tumour  Isolated from   Source 
 
MCF-7  Mammary gland epithelial  Pleural effusion  Cancer  
Adenocarcinoma     Research UK 
HeLa  Cervix epithelial     Cancer  
  Adenocarcinoma     Research UK 
MDA-MB-231 Mammary gland epithelial Pleural effusion  Cancer  
  Adenocarcinoma     Research UK 
MDA-MB-468 Mammary gland Adenocarcinoma   Cancer  
         Research UK 
MDA-MB-453 Mammary gland  Pericardial effusion Cancer  
  Adenocarcinoma     Research UK 
NAUT™ 293 Kidney       Microbix 
HEK293 Kidney       Cancer 
         Research UK 
 
Table 2.1: Used cell lines 
 
2.1.2.3 Plasmids 
 
In this study, the following plasmids were used to express various MT1-MMP constructs: 
pcDNA3.1 Zeo+ (Invitrogen), pEGFP-C1 (Clontech), pMstGV 179 and pEGFP-N1 
(Clontech). pAct, pBind and pG5luc were obtained from Promega. 
 
2.1.2.4 Oligonucleotide primers, TaqMan® probes and RNAi 
 
Oligonucleotides were purchased from MWG and Sigma-Genosys. TaqMan® probes were 
obtained from Applied Biosystems. The sequences of the primers used or the reference 
numbers for each TaqMan® probe are summarised in Appendix A (Table 8.1 and Table 
8.2). 
MT1-MMP gene silencing was performed using adenoviral expression of anti-sense RNA 
(asRNA) (chapter 2.2.2.11), MISSION® small hairpin RNA (shRNA) purchased from 
Sigma-Aldrich or Dharmacon® AccellTM siRNA obtained from Thermo Scientific. The 
sequences of the various probes used are summarised in Appendix B. 
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2.1.2.5 Enzymes, antibodies, peptides and recombinant proteins 
 
Restriction enzymes were purchased from New England Biolabs or Roche and used 
according to the manufacturer’s instruction with the supplied buffers. Platinum® Taq DNA 
Polymerase and SuperScript® II Reverse Transcriptase were obtained from Invitrogen. 
 
Recombinant TIMP-1 and TIMP-2 were prepared as previously described 246. Purified 
soluble and catalytic active MT1-MMP ectodomain (AA 21 – 541), MT1-MMP 
ectodomain E240A and MT1-MMP catalytic domain (AA 21 – 283) were kindly provided 
by M. Fogarasi (Cancer Research Institute, Cambridge, UK). The recombinant human 
VEGFR-2/KDR Fc Chimera was purchased from R&D Systems, recombinant VEGF-A 
was from Autogen Bioclear UK Ltd (Nottingham, UK). Control and MT1-MMP ICD 
biotinylated penetratin peptides (RQIKIWFQNRRMKWKK-COOH and 
RQIKIWFQNRRMKWKK- CRRHGTPRRLLYCQRSLLDKV) were obtained from 
Cancer Research UK.  
All primary and secondary antibodies, including the applications they were used for, are 
summarised in Table 2.2 and Table 2.3. 
 
Antigen Antibody Origin  Supplier Application 
 
ß-Actin    Rabbit  Abcam plc IB (1:5000) 
Akt    Rabbit  Cell Signaling IB (1:1000) 
Akt  5G3  Mouse  Cell Signaling ICC (1:50) 
Phospho-Akt   Rabbit  Cell Signaling IB (1:1000), ICC (1:25) 
(Ser473) 
Phospho-Akt   Rabbit  Cell Signaling IB (1:1000) 
(Thr308) 
Biotin  212.26.A2 Mouse  Jackson   IB (1.25 μg/ml), ChIP (3 μg) 
      ImmunoResearch 
Caveolin-1   Rabbit  Abcam plc IB (1 μg/ml) 
CTGF    Rabbit  Abcam plc IB (1:5000) 
FLAG  M2  Mouse  Sigma-Aldrich IB (2.5 μg/ml), ICC (5 μg/ml) 
Gal4  8C-1  Mouse  Calbiochem IB (2 μg/ml) 
HA  F-7  Mouse  Santa Cruz IB (1:5000) 
Lamin B1   Rabbit  Abcam plc IB (0.1 μg/ml) 
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MT1-MMP   Rabbit  Abcam plc IB (0.5 μg/ml), IP (3 μg) 
MT1-MMP LEM-2/15.8 Mouse  Chemicon IB (0.5 μg/ml), IP (3 μg), ELISA  
(1 μg/ml), FC (10 μg/ml), IHC (2 
μg/ml) 
 
MT1-MMP N175/6  Sheep  Murphy lab ICC (5 μg/ml), IB (2.5 μg/ml) 
Myc  9B11  Mouse  Cell Signaling IB (1:1000), ICC (5 μg/ml) 
Myc  4A6  Mouse  Millipore IB (1.5 μg/ml) 
Pol II  H-224  Rabbit  Santa Cruz ChIP (3 μg/ml) 
RhoB  M-19  Goat  Santa Cruz ICC (5 μg/ml) 
Src  327  Mouse  Abcam plc IB (2.5 μg/ml), IP (3 μg), ICC  
        (5 μg/ml) 
Src (phospho 9A6  Mouse  Upstate  IB (2 μg/ml), ICC  
416)         (5 μg/ml) 
Src (phospho 416)  Mouse  Invitrogen IHC (1:100) 
mTOR    Rabbit  Cell Signaling IB (1:1000) 
pS2448-mTOR   Rabbit  Cell Signaling IB (1:1000) 
Tubulin    Mouse  Sigma-Aldrich ICC (1:1000) 
VEGF-A 26503  Mouse  R&D Systems IB (2 μg/ml), ELISA (0.5  
        μg/ml) 
VEGFR-2 55B11  Rabbit  Cell Signaling IB (1:1000), ICC (1:100),  
        IP, FC (1:200), IHC (1:75) 
VP16    Rabbit  Abcam plc IB (1:1000) 
 
  
Table 2.2: List of primary antibodies 
ChIP, chromatin immunoprecipitation; ELISA, enzyme-linked immunosorbent assay; FC, flow cytometry; 
IB, immunoblot; ICC, immunocytochemistry. 
 
Antibody   Origin  Supplier   Appl 
 
Anti-goat HRP conjugated  Donkey  Jackson ImmunoResearch  IB 
Anti-mouse HRP conjugated Sheep  Jackson ImmunoResearch  IB 
Anti-rabbit HRP conjugated Donkey  Jackson ImmunoResearch  IB 
Anti-sheep HRP conjugated Donkey  Jackson ImmunoResearch  IB 
AlexaFluor® 488 anti-mouse Goat  Molecular Probes   ICC 
AlexaFluor® 488 anti-rabbit Goat  Molecular Probes   ICC 
AlexaFluor® 488 anti-sheep Donkey  Molecular Probes   ICC 
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AlexaFluor® 546 anti-mouse Goat  Molecular Probes   ICC 
AlexaFluor® 546 anti-rabbit Goat  Molecular Probes   ICC 
AlexaFluor® 546 anti-sheep Donkey  Molecular Probes   ICC 
Cy5 anti-mouse   Donkey  Jackson ImmunoResearch  ICC 
Cy5 anti-sheep   Donkey  Jackson ImmunoResearch  ICC 
APC anti-mouse   Goat  Invitrogen   FC 
PE anti-mouse   Donkey  Abcam plc   FC 
 
 
Table 2.3: List of secondary antibodies. 
Appl, Application; ELISA, enzyme-linked immunosorbent assay; FC, flow cytometry; IB, immunoblot; ICC, 
immunocytochemistry. 
 
2.1.3 Other Reagents 
 
Compound -   Compound -   Conc. Supplier 
Abbreviation  Name 
 
31C   ?-secretase Inhibitor XVII  300 nM Calbiochem, Nottingham, UK 
AG-1296      10 μM Calbiochem 
Akt Inhibitor II  SH-5    20 μM Calbiochem 
ALLN       1 μM Calbiochem 
Clasto-Lactacystin ?-Lactone    1 μM Calbiochem 
CT1746       various Calbiochem 
Cytochalasin D      1 μg/ml Calbiochem 
DAPT   ?-secretase Inhibitor IX  250 nM Calbiochem 
DCI   3,4- Dichloroisocoumarin  10 μM Calbiochem 
Dimethyl Bisphenol A     50 μM Marligen Biosciences, 
Ijamsville, MD 
Epoxomicin      1 μM Calbiochem 
Gefitinib      5 μM Biaffin, Kassel, GER 
IGF-1R Inhibitor II N-(2-Methoxy-5-chlorophenyl)- 20 μM Calbiochem 
N’ -(-methylquinolin-4-yl)-urea 
IGF-1R Inhibitor II PPP    100 nM Calbiochem 
IKK Inhibitor III  BMS-345541   4 μM Calbiochem 
JNK Inhibitor II  SP006125   1 μM Calbiochem 
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Lactacystin      1 μM Calbiochem 
Leptomycin B      10 nM Calbiochem 
LY294002      2 μM Calbiochem 
MG-132   Carbobenzoxy-L-leucyl-L- 10 μM Calbiochem 
leucyl-L-leucinal 
Nocodazole      0.2 μM Calbiochem 
Proteasome Inh. I      10 μM Calbiochem 
Rapamycin      25 nM Calbiochem 
PD98059      50 μM Calbiochem 
PMA   Phorbol 12-myristate 13-acetate 100 nM Fluka, Sigma-Aldrich 
PP2   4-Amino-5-(4-chlorophenyl)-7- 5 μM Calbiochem 
(t-butyl)pyrazolo[3,4-d]pyrimidine 
SB203580  4-(4-Fluorophenyl)-2-  20 μM Calbiochem 
(4-methylsulfinylphenyl)-5- 
(4-pyridyl)-1H-imidazole 
SU4312       1.5 nM Sigma-Aldrich 
Tarceva   Erlotinib   5 μM Genentech, San Francisco, CA 
Wortmannin      250 nM Calbiochem 
 
 
Table 2.4: Summary of used inhibitors 
Conc, concentration. 
 
2.2 Methods 
2.2.1 Cell Culture 
 
All cell culture was carried out with autoclaved and 70% ethanol wiped material in a Class 
II laminar flow hood. Adherent cells were routinely cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) foetal calf serum (FCS) and L-
alanyl-L-glutamine (500 ?g/ml) and maintained in a Hera cell incubator with 5.2% CO2-
atmosphere at 37°C. The gradual growth as well as potential contamination of the cells was 
surveyed daily and medium was changed if required. All cell lines used are summarised in 
Table 2.1. 
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2.2.1.1 General mammalian cell culture procedures 
 
All cell culture plastic ware was purchased from BD Biosciences, Falcon or Sarstedt unless 
indicated otherwise. 
 
2.2.1.2 Cell freezing and thawing 
 
Cell stocks were ordered from Cancer Research UK or Microbix (Table 2.1) and stored in 
cryotubes in liquid nitrogen. In order to grow cells, the cell suspensions were partly thawed 
at 37°C and transferred with the ten-fold volume of pre-warmed cell culture medium 
(DMEM + L-alanyl-L-glutamine and FCS) in 15 ml tubes. Cells were centrifuged at 300 ? 
g for 5 minutes, the DMSO-containing supernatant was discarded and the cell pellets were 
subsequently resuspended in DMEM and transferred into a T25 flask. Viable cells adhered 
within 24 hours to the bottom of the plastic vessels.  
In order to freeze cell aliquots, the cells were resuspended in 90% FCS (v/v) and 10% 
DMSO (v/v) freezing medium after trypsination. The cell suspension was aliquoted into 
three 1.8 ml cyotubes (Nunc) per 80% confluent 175 cm2 flasks. The vials were initially 
frozen in a pre-cooled Nalgene Cryo 1°C Freezing Container at -80°C for 24 hours and 
transferred to liquid nitrogen for long-term storage. 
 
2.2.1.3 Cell passage 
 
All cells were passaged at 70 – 80% confluence. The used medium was discarded and the 
cells were rinsed once with 1 ? PBS to remove the remaining medium, dead cells and cell 
debris. 1 – 2 ml Trypsin/EDTA was added to cover the cells and the flask was incubated at 
37°C for 5 – 10 minutes until the cells started to detach. The cells were then washed off the 
surface with 5 ml pre-warmed culture medium, transferred into a 15 ml tube and 
centrifuged at 300 ? g for 5 minutes. The pellet was resuspended and seeded into a new 
cell culture vessel containing pre-warmed culture medium. 
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2.2.1.4 Cell counts and viability test 
2.2.1.4.1 Haematocytometer 
 
In order to obtain cell numbers and test for viability, cells were stained with Trypan blue 
(Sigma-Aldrich) and counted in a haematocytometer (Improved Neubauer, Weber 
Scientific). Therefore, 70 – 80% confluent cells were trypsinised, resuspended in 1 ml 
DMEM and 10 ?l of this cell suspension was mixed 1:10 with Trypan Blue (0.4%). Only 
vital colourless cells, which are able to exclude the dye, were counted. All counts were 
done in duplicate and each count enumerated at least 100 cells to obtain an average value ? 
dilution factor ? 104/ ml. 
 
2.2.1.4.2 Vi-CELL™ 
 
The Vi-CELL™ series cell viability analyser was used to count cells and test for viability 
in an automated manner. The Vi-CELL™ was primarily used to size cells and to perform 
quality controls prior flow cytometry and is based on the trypan blue dye exclusion 
method.  
 
2.2.1.5 Transfection and cell treatments 
 
For treatment with various inhibitors (Table 2.4), cells were seeded in 6-well plates to a 
density of 5 ? 105 cells/well and cultured for 24 hours. Cells were then transfected with 1 
μg cDNA of various MT1-MMP constructs per well using FuGene6TM (Roche Applied 
Science) according to manufacturer’s instructions. Three hours after transfection, inhibitors 
were added for 24 hours at concentrations indicated in Table 2.4. rh-TIMP-1 and rh-TIMP-
2 were used at 1 μM, rh-MMP-2 was used at indicated concentrations for 24 hours. rh-
VEGF165 stimulation was performed for 30 minutes at 100 ng/ml. Penetratin peptides were 
used at 25 μM and cells were incubated for 3 hours. 
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2.2.2 Molecular biology methods 
2.2.2.1 Quantification of DNA 
 
The amount of DNA was quantified using the Nanodrop® ND-1000 UV-Vis 
spectrophotometer. Following background correction with 1 ?l of H2O, 1 ?l of DNA was 
quantified by measuring the absorbance at OD260 nm. 
 
2.2.2.2 RNA isolation 
 
RNA was isolated with the Qiagen RNeasy Mini Plus Kit according to the manufacturer’s 
protocol. Cells of a 6-well plate were used per RNA isolation and RNA was eluted in 50 ?l 
of RNAse-free water. The concentration of the total RNA was measured using the 
Nanodrop® ND-1000 UV-Vis spectrophotometer at a wavelength of 260 nm. RNA quality 
was assessed with the Agilent 2100 Bioanalyzer, according to manufacturer’s instructions. 
 
2.2.2.3 Reverse Transcription 
 
First strand cDNA synthesis was performed by using SuperScript® II Reverse 
Transcriptase. Therefore, 1 ?g RNA was diluted in 10 ?l RNAse-free H2O (Invitrogen) 
and was initially heated and linearised at 70°C for 10 minutes. 10 ?l RT-Mastermix (5 ? 
First-Strand Buffer (Invitrogen), 10 mM DTT (Invitrogen), 10 ?M dNTPs (10 ?M each, 
Amersham Biosciences), 200 U Superscript (Invitrogen) and 1 ?l random hexamers (GE 
Healthcare)) were added and the mixture was heated at 42°C for 1 hour, followed by a 5 
minute incubation at 95°C. The cDNA was diluted in RNAse-free H2O and stored at -
20°C. 
 
2.2.2.4 Polymerase chain reaction 
 
The protocol for standard PCR is based on Saiki et al. 247. 2 ?l (10 ng) cDNA were diluted 
in 28 ?l PCR-Mastermix (10 ? Buffer (BioLabs), dNTPs (10 ?M each, Amersham 
Biosciences), 200 nM Primer (purchased from MWG Biotech), 2.5 mM MgCl2 (BioLabs) 
and 1U Platinum® Taq DNA Polymerase (Invitrogen)) and initially denatured at 95°C for 
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2 minutes, followed by 20 – 35 cycles of (i) denaturation for 45 seconds at 95°C, (ii) 
annealing of oligonucleotides at (Tm - 1-2)°C and (iii) elongation at 72°C for 45 seconds. 
The samples were separated on a 1% agarose gel after a final elongation step (12 minutes 
at 72 °C). 
 
2.2.2.4.1 TaqMan® Real-Time PCR 
 
The pre-made TaqMan® probes were obtained from Applied Biosystems, containing pre-
mixed primers and a FAM dye labelled TaqMan® probe. All used probes are summarised 
in Appendix A (Table 8.2).  
TaqMan® Real-Time PCR gene expression profiling was done by using the Applied 
Biosystems 7900HT Fast Real-Time System. All experiments were performed in technical 
triplicates for each of the three biological replicates in 384 well plates. The used 
fluorogenic probes were labelled at the 5’ end with FAM and at the 3’ end with MGB 
(minor groove binder) nonfluorescent quencher. Reactions were performed in a 12.5 μl 
final volume containing 6.25 ng cDNA, 100 nM of forward and reverse primers, 200 nM 
fluorogenic probe (Applied Biosystems) and TaqMan® Universal PCR Master Mix. The 
fluorescent signal detection used ROX as the internal passive reference dye. The 
parameters of the PCR reaction were 2 minutes at 50°C, 10 minutes at 95°C followed by 
40 cycles of 15 seconds at 95°C and 1 minute at 60°C. During the elongation step the 
endonuclease activity of the Taq-polymerase causes the cleavage of the probe. This leads 
to the release of the fluorescent dye from the quencher and to an increase in fluorescence 
that is proportional to the exponentially amplified amount of cDNA. The CT (cycle 
threshold)-value of a sample indicates the number of cycles needed to reach defined 
fluorescence intensity above background levels.  
The relative expression of each sample was calculated using the 2-??CT method: 
 
Relative Expression = 2 - (S? CT – C? CT)  
 
 ?CT = (GOICT – HKGCT) 
S? CT – C? CT = control value (C) is subtracted from sample value (S) 
 GOI = gene of interest, HKG = house-keeping gene, S = sample, C = control 
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2.2.2.4.2 SYBR® Green Real-Time PCR 
 
gDNA samples obtained by chromatin immunoprecipitation (chapter 2.2.4.7) were 
amplified by SYBR® Green Real-Time PCR using specific primers from the promoter and 
up-stream region of VEGF-A and XBP-1 (X Box-binding protein 1; primer sequences in 
Appendix A, Table 8.1). Real-Time PCR gene expression profiling was carried out using 
the Applied Biosystems 7900HT Fast Real-Time PCR System. All experiments were 
performed in technical triplicates for each sample in 96 well plates. Reactions were 
performed in 20 μl final volume containing 5 ?l gDNA, 100 nM of forward and reverse 
primer, and 10 μl SYBR® Green PCR Master Mix (Applied Biosystems). The parameters 
of the PCR reaction were 10 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C 
and 1 minute at 60°C. The SYBR® Green dye incorporates into dsDNA strands and 
therefore increases the amount of fluorescence corresponding to the production of 
amplificates per cycle. A melting curve was performed at the end of every run to 
distinguish non-specific double-stranded nucleotides including primer-dimers from the 
specific product. Unlike longer completely complimentary amplificates, short nucleotide-
nucleotide pairings will dissociate with increasing temperature. The relative expression of 
each sample was calculated using the 2-??CT method (chapter 2.2.2.4.1). 
 
2.2.2.5 Agarose gel electrophoresis 
 
PCR products were separated and analysed by electrophoresis using agarose gels. 1 – 2% 
(w/v) agarose was prepared in TAE buffer (chapter 2.1.1.5) with SYBR® Safe DNA gel 
stain to visualise DNA by using ultraviolet (UV) light. Gels were poured into Mini-Sub® 
Cell GT electrophoresis chambers and samples mixed with 10 ? gel-loading buffer 
(chapter 2.1.1.5) were loaded. Samples were run next to DNA markers (Marker VIII and 1 
kb ladder) for approximate size calculation.  
 
2.2.2.6 DNA ligation  
 
200 ng vector (summarised in chapter 2.1.2.3) were mixed with the insert at a 1:3 molar 
ratio (vector : insert) in 2 ?l 10 ? ligation buffer and 1 ?l T4 ligase (NEB). The ligation 
was carried out at room temperature (RT) for 16 hours. 
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Molar ratios were calculated using the equation: 
 
2 ? 106  ?g dsRNA  = pmol of ends of dsRNA 
Nbp ? 660 kDa 
 
with N = total number of nucleotides 
 
2.2.2.7 Transformation of competent bacteria 
 
A vial of 50 ?l chemically competent E.coli per construct was thawed on ice and 2 ?l of 
the ligation reaction was added. Bacteria were incubated on ice for 30 minutes, heat-
shocked for 45 seconds in a 42˚C water-bath to facilitate plasmid uptake into the cells and 
subsequently put back on ice. Following transformation 800 ?l SOC medium was added 
and transferred to a sterile 15 ml culture tube. E.coli were incubated for 1 hour at 37˚C 
with shaking. The bacteria were briefly centrifuged (30 seconds, 5000 ? g), resuspended in 
100 ?l SOC medium, plated onto agar plates containing the appropriate antibiotic selection 
and incubated at 37˚C for 16 hours. 
 
2.2.2.8 PCR screen of bacterial colonies 
 
Bacterial colonies were routinely screened for the correct gene insertion into the plasmid 
backbone. Various single colonies were picked and transferred to 4 ml 2 ? TY medium 
containing the appropriate antibiotic selection. E.coli were grown for at least 6 hours at 
37˚C with shaking and 2 ?l bacteria suspension were used as a template in a 30 ?l PCR 
assay (chapter 2.2.2.4). 
 
2.2.2.9 Preparation of plasmid DNA 
 
Plasmid DNA was prepared with either the Qiagen Plasmid Mini or Maxi kit according to 
manufacturer’s instructions. Purification of the adenoviral backbone vector was performed 
using the Qiagen Large-scale Plasmid DNA Purification kit.  
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2.2.2.10 Generation of MT1-MMP constructs 
 
All plasmids used are summarised in Table 2.5 and primer sequences are listed in 
Appendix A (Table 8.1). 
Full-length MT1-MMP (MT1-WT), EGFP tagged MT1-MMP (MT1-?ECD-EGFP, 
comprising of MT1-MMP amino acids 508 - 582), L571A/L572A/Y573A MT1-MMP 
(MT1-571AAA573), the intracellular domain deleted MT1-MMP mutant (MT1-?ICD, 
deletion of amino acids 561 – 582), the hemopexin domain deletion mutant (MT1-?HPX, 
deletion of amino acids 318 - 509), the Myc tagged full-length MT1-MMP (MT1-Myc, 
Myc tag inserted between amino acids 312 and 313) and the catalytic inactive MT1-MMP 
(MT1-E240A) were described elsewhere 39,73,248,249. The LRP1 GAL4/VP16 (GVLRP1) 
construct was kindly provided by P. May, (Department of Molecular Genetics, University 
of Texas Southwestern Medical Centre, Dallas, TX) 151, the GVAPP construct was 
provided by T.C. Südhof (University of Texas Southwestern Medical Centre, Dallas, TX) 
179. Ubiquitin and Ubiquitin K11,27,29,48,63A were a gift from K. Fujita (University 
College London, UK). MT1-MMP point mutations at C574 (MT1-C574A), Y573 (MT1-
Y573A), DKV582 (MT1-580AAA582) as well as the double catalytic inactive mutants MT1-
E240A-571AAA573 and MT1-E240A-?ICD were kindly provided by C.H. Roghi 
(Cambridge Research Institute, Cambridge, UK). The MT1-MMP construct containing a 
GAL4/VP16 fusion domain inserted between the transmembrane and intracellular domain 
of MT1-MMP (GVMT1) was also generated by C.H. Roghi. 
The orientation and sequence of all constructs was verified by DNA sequencing (Cancer 
Research UK, Cambridge, UK). 
 
Construction of a truncated MYC – FLAG double-tagged MT1-MMP 
MT1-MYC (Table 2.5) was amplified by PCR using the CHR521s and BGH2as primer, 
which insert a PinAI restriction site at position 90 (from the signal sequence) and a FLAG 
tag at position 96. The PCR fragment was purified using the SigmaSpin™ Post-Reaction 
Clean-Up Columns. Both, the PCR fragment and MT1-?ECD-EGFP (Table 2.5) were 
digested with PinAI and subsequently with PstI (Roche). The PCR fragment and the 
pEGFP-C1 vector, containing only the MT1-MMP signal sequence were purified from a 
1% (w/v) agarose gel using the QIAquick Gel Extraction Kit. The insert comprising of a C-
terminal MYC-tag, the MT1-MMP ICD, TMD, the extracellular stalk-region and the 
Material and Methods                                                                                                                                     48 
FLAG tag was fused in the vector with the MT1-MMP signal sequence (MT1MYC-
FLAG). 
 
Construction of MT1-MMP Lysine and extracellular domain deletion mutants 
The MYC-FLAG double tagged construct containing a point mutation of K518 to Alanine 
(MT1-MYC-FLAG-K581A), the full-length MT1-MMP K581 mutant (MT1-K581A) and 
the FLAG tagged MT1-MMP mutant (MT1-?ECD-FLAG) were generated by site-directed 
mutagenesis as previously described 119, using the QuickChange® XL Site-Directed 
Mutagenesis Kit. Briefly, the QuickChange® XL system is used to generate point 
mutations as well as to switch or delete amino acids by combining a supercoiled dsRNA 
vector with an insert of interest and two oligonucleotide primers containing the desired 
mutation. The primers are complementary to opposite strands of the vector and are 
extended by pfuTurbo DNA Polymerase during a PCR. The mutation is integrated within 
the sequence and the parental DNA template is degraded following PCR by Dpn I 
treatment. DNA isolated from almost all E.coli strains is methylated or hemimethylated 
and thus targeted by Dpn I. The new generated DNA template containing the mutation of 
interest is transformed as previously described (chapter 2.2.2.7). The thermocycling 
conditions for mutagenesis were: 1 minute at 95˚C; 18 cycles of 50 seconds at 95˚C, 50 
seconds at 60˚C and x minutes at 68˚C following 7 minutes at 68˚C with x = 1 minute/ kb 
of the plasmid used. The primers used for the K581 mutants made from either MT1-WT or 
MT1-MYC-FLAG constructs were 115.K/As and 115.KAas (Table 8.1). The MT1-?ECD-
FLAG was generated from the MT1-MYC-FLAG template with 115.Stps and 115.Stpas 
(Table 8.1), inserting a new stop codon downstream of the MT1-MMP ICD (amino acid 
583).  
 
Construction of the MT1-MMP APP plasmids 
For construction of the MT1-MMP GAL4/VP16 mutant containing an APP ICD or an APP 
TMD, the MT1-MMP (ECD) - APP (TMD, ICD) – GAL4/VP16 (construct N-MT1-APP, 
kindly provided by C.H. Roghi) and the GVMT1 construct were used. Both plasmids were 
cut with BsrGI (Qiagen) and PstI (Roche). Purification was carried out by using the 
SigmaSpin™ Post-Reaction Clean-Up Columns and the QIAquick Gel Extraction Kit for 
isolation of fragments from an agarose gel.  
The insert of the MT1-MMP GAL4/VP16 vector (GVMT1), containing the MT1-MMP 
intracellular domain as well as the VP16 domain, was cloned into the pcDNA3.1 Zeo+ 
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vector containing the MT1-MMP extracellular domain, the APP TMD and the GAL4 
domain. The insert of the N-MT1-APP, comprising the APP ICD and the VP16 domain 
was fused in the digested GVMT1 vector (pMstGV) that contains the MT1-MMP 
extracellular and transmembrane domain as well as the GAL4 domain. For generation of 
the MT1-TMD-APP consisting of the full-length MT1-MMP containing the APP 
transmembrane domain, the APP TMD (amino acids 700-723) was subcloned in frame 
with the full-length MT1-MMP construct (amino acids 542 - 562), thus replacing the MT1-
MMP TMD. 
 
pBind-Src 
The coding sequence of Src was amplified with the CHR508 and CHR509 primer (Table 
8.1) which insert a BamHI cleavage site at the 5’-terminus and a XbaI cleavage site at the 
3’-end. The 1.6 kb fragment was extracted and purified from a 1% (w/v) agarose gel. pAct 
and pBind vectors and the Src fragment was digested with BamHI (Roche) and XbaI 
(Roche) followed by purification of vectors and insert. The coding sequence of Src was 
subsequently cloned in the pAct and pBind vectors. 
 
pBind-MT1-MMP ICD mutants 
For the construction of the pBind-MT1-MMP triple mutations (Table 2.5), the mutated 
ICDs were re-cloned from pAct-MT1-MMP ICD mutants (kindly provided by C.H. Roghi) 
in the pBind vector. Therefore, pAct-MT1-MMP ICD triple mutants were amplified with 
pACTs1200 and pACTas1446 primer (Table 8.1) and purified from a 1% (w/v) agarose 
gel. Both, inserts and the pBind vector were digested with BamHI (Roche) and XbaI 
(Roche) and MT1-MMP ICD mutants were cloned in the vector. 
 
Name               Source  Vector   Insert  
              (N => C-terminus) 
 
MT1-WT  CH Roghi pcDNA3.1 Zeo+  WT MT1-MMP 
MT1-E240A  CH Roghi pcDNA3.1 Zeo+  WT MT1-MMP: E240A  
point-mutation 
MT1-?ECD-FLAG CH Roghi pEGFP-C1  S - FLAG - stalk - TMD -  
ICD 
MT1-?ECD-EGFP PA Eisenach pEGFP-N1  S - EGFP - stalk - TMD -  
ICD 
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MT1-?HPX  CH Roghi pcDNA3.1 Zeo+  S - CAT - EGFP - stalk - 
TMD - ICD 
MT1-TMD-APP  PA Eisenach pcDNA3.1 Zeo+  S - CAT - HPX - stalk -  
APP TMD - ICD 
MT1-C574A  CH Roghi pcDNA3.1 Zeo+  WT MT1-MMP: C574A 
point-mutation 
MT1-Y573A  CH Roghi pcDNA3.1 Zeo+  WT MT1-MMP: Y573A 
point-mutation 
MT1-571AAA573  CH Roghi pcDNA3.1 Zeo+  WT MT1-MMP: LLY573 
=> AAA573 mutation 
MT1-580AAA582  CH Roghi pcDNA3.1 Zeo+  WT MT1-MMP: DKV582 
=> AAA582 mutation 
MT1-?ICD  PA Eisenach pcDNA3.1 Zeo+  S - CAT - HPX - stalk - 
TMD 
MT1-K581A  PA Eisenach pEGFP-C1  WT MT1-MMP: K581A  
point-mutation 
MT1-MYC-FLAG PA Eisenach pEGFP-C1  S - FLAG - stalk - TMD -  
ICD - MYC  
MT1-MYC-FLAG PA Eisenach pEGFP-C1  S - FLAG - stalk - TMD - 
K581A        ICD - MYC: K581A point 
        Mutation 
GVMT1   CH Roghi pMstGV   S - CAT - HPX - stalk - 
TMD - GAL4/VP16 - ICD 
GVMT1-APP-ICD PA Eisenach pMstGV   S - CAT - HPX - stalk - 
TMD - GAL4/VP16 - APP 
ICD 
GVMT1-APP-TMD PA Eisenach pcDNA3.1 Zeo+  S - CAT - HPX - stalk -  
APP TMD - GAL4/VP16 - 
ICD 
GVAPP   TC Südhof pMstGV   WT-APP - GAL4/VP16 
GVLRP1  P May  pMstGV   WT-LRP1 - GAL4/VP16 
pAct   Promega 
pBind   Promega 
pAct-MT1  CH Roghi pAct   ICD 
pAct-Src  PA Eisenach pAct   Src 
pBind-Src  PA Eisenach pBind   Src 
pB-MT1-LLY/AAA PA Eisenach pBind   ICD LLY573 => AAA573 
pB-MT1-CQR/AAA PA Eisenach pBind   ICD CQR576 => AAA576 
Material and Methods                                                                                                                                     51 
pB-MT1-DKV/AAA PA Eisenach pBind   ICD DKV582 = > AAA582 
ß-Gal   Promega ß-Gal 
pG5luc   Promega pG5luc 
Src   R Béliveau pcDNA3.1 Zeo+  WT-Src 
 
Table 2.5: DNA constructs 
S, signal sequence; CAT, catalytic domain; HPX, hemopexin domain; stalk, stalk region (amino acids 508 – 
541); TMD, transmembrane domain; ICD, intracellular domain, WT, wild-type. 
 
2.2.2.11 Generation of adenoviral expression constructs 
 
Recombinant adenovirus (Ad5 ?E1/E3) expressing MT1-WT was prepared as previously 
described 76. MT1-, MT2-, MT3- and MT4-MMP anti-sense (as) RNA expressing 
constructs were generated as described in the following sections. 
 
2.2.2.11.1 Subcloning of MT1-, MT2-, MT3- and MT4-MMP anti-sense cDNAs 
into the adenoviral backbone vector 
 
Anti-sense sequences for MT1-, MT2-, MT3- and MT4-MMP (summarised in Appendix 
B, Table 9.1, kindly provided by C.H. Roghi) were subcloned into the adenoviral shuttle 
vector pDC516 (Microbix).  
 
2.2.2.11.2 Viral recombination 
 
As shown in Figure 2.1, recombination of the MT1-MMP anti-sense sequences into the 
adenoviral backbone was performed by co-transfecting Naut™ 293 cells (Microbix) with 
genomic adenoviral plasmid and MT-MMP containing pDC516 shuttle vector. Naut™ 293 
cells express the E1 gene that has been removed from the adenoviral backbone vector to 
induce viral replication. 
For recombination, cells were co-transfected with 50 ?g genomic adenoviral backbone 
vector and 10 ?g shuttle vector using 180 ?l Fugene, as previously described. For each 
recombination, one 80% confluent T175 flask of Naut™ 293 cells was trypsinised and 
cells were resuspendend in 10 ml serum-free medium. The DNA – lipid complex was 
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added to the cells and incubated in solution for 10 minutes at RT. The cells of each 
transfectant were split and transferred into ten T25 flasks containing DMEM with 10% 
(v/v) FCS. The cells were incubated for 5 days at 37ºC. Subsequently, the medium was 
exchanged every two days until 30 – 40% of the cell monolayer showed a cytopathic 
effect. Without changing the medium, the cells were further incubated until all cells died. 
Cells were collected by centrifugation and freeze-thawed 3 ? to free the virus contained in 
the cells. Lysates were stored at -20ºC.  
 
2.2.2.11.3 Cloning and titration of the adenoviral expression constructs 
 
For titration of each viral construct obtained, a confluent T75 flask of HEK293 cells was 
trypsinised, resuspended into 20 ml of medium and pipetted into a 96-well plate (100 
?l/well). Cells were allowed to adhere by incubation at 37ºC for 16 hours.  
 
 
Figure 2.1: AdMax system for adenoviral recombination (Microbix) 
NAUT™ 293 cells were co-transfected with the adenoviral genomic plasmid and the shuttle plasmid 
containing the sequence of interest (MT-MMP anti-sense sequences). The recombinase expressed by the 
genomic vector induces recombination between the insert and the recombinant viral vector. Taken from 
AdMax system manual (Microbix).  
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Viral lysates were centrifuged at 400 ? g for 10 minutes at RT and serial dilutions (10-2, 
10-3, 10-4, 10-5, 10-6, 10-7, 10-8 and 10-9) were prepared in DMEM containing 10% (v/v) 
FCS. 100 ?l of each dilution was added in 10 wells of a prepared HEK293 containing 96-
well plate. DMEM containing 10% (v/v) FCS was added to control for potential cross-
contamination.  
The medium was exchanged every other day for 9 days. The same titration was carried out 
with HeLa cells to screen for replication competent viruses. Since HeLa cells do not 
express the E1 gene, the virus is not able to replicate in these cells. Thus, no cell death 
should be observed in HeLa cells. However, low MOI of virus (100 – 200 pfu/cell) as well 
as overexpression of transgenes have been shown to be toxic for cells. Hence, only death 
of HeLa cells at dilutions greater than 10-3 is regarded as indicating replication competent 
virus. 
To obtain working stocks from plaque purified isolates, cells from three wells of the 
highest concentration that underwent complete cytopathic effect (cpe) were collected, 
freeze-thawed as described before and used in a second round of cloning. After titration for 
9 days three clones were collected per construct, freeze-thawed and 40 ?l were added to a 
confluent T175 flask of HEK293 cells. When these cells showed 80% cpe, the lysate was 
used as a seed stock to infect ten 80% confluent T175 flasks of HEK293 cells. The cells 
were cultured until they reached 80% cpe and they were harvested by centrifugation at 300 
? g for 5 minutes at RT. Cells were resuspended in 10 ml of PBS, freeze-thawed 3 ? and 
then centrifuged at 4,000 ? g for 10 minutes. The supernatant was subsequently purified 
using a CsCl gradient. 
 
2.2.2.11.4 Caesium chloride purification of adenoviruses 
 
For each adenoviral expressing construct a 15 ml plastic ultracentrifuge tube (Becton 
Dickinson) was used, rinsed with 70% (v/v) ethanol and washed with sterile H2O. 2 ml of 
high-density caesium chloride solution (Solution 1, Table 2.6) was added to the tube and 
was overlayed by the CsCl solution 2 (Table 2.6). 2 ml of 40% glycerol were added as the 
last layer (Table 2.6). 10 ml of the adenoviral lysate was carefully applied on top of the 
gradient followed by centrifugation in a Sorval ultracentrifuge for 1.5 hours at 2.5 ? 104 
rpm (without deceleration).  
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Solution 1   Solution 2   40% Glycerol 
20.5 g CsCl   32g CsCl   40 g Glycerol 
2.9 ml 0.5 M Tris pH 7.9  6.8 ml 0.5 M Tris, pH 7.9  2 ml 0.5 M Tris pH 7.9 
25.8 ml H2O   61.2 ml H2O   0.5 ml 0.2 M EDTA 
        ad 100 ml H20 
    sterile filter before use 
Table 2.6: Solutions for adenovirus purification 
 
After centrifugation a distinct white pure virus band was visible in the tube, that was 
removed with a 2 ml syringe (23 gauge needle) piercing the tube just below the virus layer. 
The virus solution was dialysed using a Slide-A-Lyzer Dialysis Cassette (Pierce) vs. 5 l 
PBS for 16 hours at 4ºC. The purified virus was aliquoted and stored at -80ºC. 
 
2.2.2.11.5 Calculation of the viral titre 
 
To determine the titre of the purified virus, a 96-well plate of HEK293 cells was infected 
with a range of serial dilutions as described before (chapter 2.2.2.11.3). After 9 days, the 
proportionate distance (PD) was calculated as: 
PD = (x - 50%) / (x - y) 
with x = dilution where more than 50% of the infected wells died (number of wells in%) 
and y = dilution where less than 50% of the infected wells died (number of wells in%). 
 
Subsequently, the infectivity dose (ID50) was calculated using: 
ID50 = 10(z + (PD ? -1)) ? Fd 
With z = the dilution factor used, where more than 50% of the infected cells showed cpe 
and Fd = Dilution factor.  
100 ?l virus lysate were used for the titration. To obtain the infectivity dose per 1 ml, the 
Fd is 10.  
 
Finally, the titre of the virus solution in plaque forming units (pfu)/ml could be obtained: 
MOI (pfu/ml) = 0.7 x  10-ID50  
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2.2.2.11.6 Infection of cells with adenovirus 
 
For transduction of cells with adenoviral expressing MT-MMP constructs, cells were 
seeded in 6-well plates 16 hours prior to infection. Cells from one well were counted after 
trypsination allowing the MOI to be calculated in pfu/cell. Different MOI, as indicated in 
the results section, were added to the cell culture medium for 2 hours followed by 
exchange of the medium. The cells were cultured for 48 hours and protein or RNA was 
isolated as previously described.  
 
2.2.2.12 Lentiviral shRNA transduction 
 
For stable knockdown of MT1-MMP expression in MDA-MB-231 and MDA-MB-468 
cells as well as VEGFR-1 and VEGFR-2 gene silencing in MCF-7 cells, a lentiviral 
shRNA approach was used (MISSION® shRNA, Sigma-Aldrich). Prior to lentiviral 
transduction, a puromycin titration (kill curve) was performed on all cell lines used, using 
puromycin at concentrations from 0.5 – 10 ?g/ml according to manufacturer’s instructions.  
Cells were seeded in a 6-well plate at 2.5 ? 105 cells/well (MDA-MB-231 and MDA-MB-
468) or 5 ? 105 cells/well (MCF-7) and were transduced 24 hours later with 2 pfu/cell of 
MISSION® shRNA lentiviral particles (5 sequences per target gene), empty pLKO.1-puro 
control particles or virus expressing a non-targeting control shRNA. The medium was 
exchanged the following day and puromycin selection with the determined concentration 
was started 24 hours later. Cells were cultured for 48 hours followed by protein or RNA 
extraction. Used shRNA sequences are summarised in Appendix B (Table 9.2). 
 
2.2.2.13 MT1-MMP knockdown using siRNA 
 
The expression of MT1-MMP was silenced in MDA-MB-231 cells using Dharmacon® 
AccellTM siRNA (Thermo Scientific). This approach was shown to reduce off-target effects 
and cytotoxicity by avoiding the use of transfection reagents. 
MDA-MB-231 cells were seeded at 2.5 ? 105 cells/well in a 6-well plate and were 
incubated for 16 hours at 37˚C. The indicated concentrations (0.25 ?M or 1 ?M) of MT1-
MMP targeting or control siRNA, pre-diluted in 1 ? siRNA buffer (Thermo Scientific), 
were prepared in 750 ?l AccellTM delivery medium (Thermo Scientific). The growth 
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medium was removed from the cells and 100 ?l of the delivery mix was added to each 
well. The cells were incubated for 72 hours and MT1-MMP knockdown was verified by 
TaqMan® Real-Time PCR. 
 
2.2.3 Biochemical methods 
2.2.3.1 Western Blot analysis 
2.2.3.2 Preparation of protein samples from cell lysates 
 
Cells were seeded in triplicate in 6-well plates and were transfected or stimulated as 
described previously (chapter 2.2.1.5). 16 hours after treatment the culture medium was 
removed and the cells were washed 2 ? in PBS. 250 ?l of sample buffer or SDS lysis 
buffer was added to the wells and the cells were removed from the wells with a cell 
scraper. Protein concentration was determined (chapter 2.2.3.5) and equal amounts were 
loaded by diluting samples in HEG buffer. After adding 5 ? reducing Laemmli buffer, 
samples were heated at 95˚C for 10 minutes, centrifuged at maximum speed in a microfuge 
for 5 minutes and loaded on a SDS-PAGE gel or stored at -20˚C.  
 
2.2.3.3 Preparation of protein samples from nuclei 
 
To separate MCF-7 nuclei from the cytoplasmic and membrane protein fractions, cells 
were seeded in 6-well plates and nuclei were obtained by a combination of Triton X-100 
mediated detergent lysis and mechanical disruption. 16 hours after cell treatment 
microtubules and the actin cytoskeleton were disrupted by adding Nocodazole (0.2 ?M) 
and 1 ?g/ml Cytochalasin for 1 hour at 37˚C. The medium was removed and cells were 
washed 2 ? in PBS. Cells were scraped in 0.5 ml PBS and three wells were pooled per 
sample. Following centrifugation at 1200 ? rpm at RT for 2 minutes, cells were 
resuspended in 1 ml TM-2 buffer (chapter 2.1.1.5) and incubated at RT for 1 minute. The 
tubes were transferred on ice and incubated for 5 minutes. Triton X-100 was added to each 
sample to a final concentration of 0.5% (v/v) and cells were incubated for 10 minutes on 
ice. Subsequently, cells were mechanically disrupted by shearing through a 23-gauge 
needle. The samples were subjected to another round of incubation on ice for 10 minutes 
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and shearing by passing through a 23-gauge needle until nuclei were sufficiently separated 
from the cytoplasm as determined by examination on a phase contrast microscope. To 
isolate nuclei from the cytosol, the cell lysate was layered on top of a 30% (w/v) sucrose 
cushion (4.5 ml in a round 15 ml tube, BD Biosciences) and centrifuged at 800 ? rpm at 
4˚C for 10 minutes. Samples from the cyoplasmic fraction were taken and nuclei were 
washed 2 ? in TM-2 buffer and subsequently lysed in 300 ?l SDS lysis buffer (chapter 
2.1.1.5). 
 
2.2.3.4 Concentration of proteins from conditioned medium 
 
MCF-7 cells were seeded at 5 ? 105 cells/well, the medium was exchanged after 16 hours 
to serum-free medium and the cells were treated as indicated in the results chapter. 
Following incubation for 24 hours, the conditioned medium was removed and proteins or 
RNA was isolated from the corresponding cells. Medium was centrifuged for 5 minutes at 
8,000 ? g to remove residual dead cells and the remaining soluble protein was 
concentrated. 2-3 vol. of ice-cold acetone was added to the medium, vortexed thoroughly 
and protein was precipitated at -20˚C for at least 6 – 16 hours. Samples were centrifuged at 
16,000 ? g for 10 minutes at 4˚C, the supernatant was carefully removed and the pellet was 
air-dried until residual acetone evaporated. Pellet was resuspended in 20 ?l of 2 ? Laemmli 
buffer and subjected to immunoblotting. 
 
2.2.3.5 Measurement of protein concentration by the BCA assay 
 
Protein concentration was measured using the BCA™ Protein Assay, according to the 
manufacturer’s instructions (Pierce, Thermo Scientific). Briefly, aliquots of protein 
samples were diluted 1:10 and pipetted in duplicate in a 96-well plate. Serial BSA-
dilutions were used as a concentration reference. Samples and reference protein were 
coated with the protein assay reagent. The plate was subsequently incubated for 1 hour at 
37˚C. Proteins in the sample wells are reducing Cu2+ to Cu1+ in the alkaline medium 
(Biuret reaction), which form a purple complex with bicinchoninic acid (BCA). The 
BCA/copper complex is water-soluble and exhibits a proportional absorbance at 562 nm 
with increasing protein concentration. The absorbance obtained using the Infinite® M200 
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plate reader was converted to protein concentration using BSA standards of known 
concentration.  
 
2.2.3.6 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), Western Blotting and antibody detection 
 
Protein lysates were loaded with 5 ? SDS-PAGE loading buffer on a 10% (w/v) SDS 
polyacrylamide gel (SDS-PAGE, Table 2.7). The gel was running in a 135 V electric field 
for ~1.5 hours in 1 ? SDS running buffer in a Mini Protean® II xi chamber. BenchMark™ 
Protein Ladder was used for estimation of molecular weight of proteins of interest in the 
sample. The gel was subsequently transferred onto a nitrocellulose membrane at 400 mA 
for 1 hour using a Trans-Blot cell transfer system. Membranes were blocked for 1 hour in 
3% (w/v) fat free powdered milk (Marvel) in 1 ? TBS containing 0.1% (v/v) Tween®20 
(TBS-T) followed by an incubation with the primary antibody at the indicated dilution 
(Table 2.2) in 3% (w/v) milk in TBS-T at 4°C for 16 hours. The membranes were washed 
three times with TBS-T and subsequently incubated with the secondary antibody (Table 
2.3) in 3% (w/v) milk in TBS-T, for 1 hour at RT. The blots were washed three times with 
1 ? TBS-T. Detection was performed using the Enhanced Chemi-Luminescence kit 
(Amersham) according to the manufacturer’s protocol. Where required, membranes were 
stripped by incubating for 10 minutes at RT in ReBlot™ Plus Strong Antibody Stripping 
Solution, blocked for 5 minutes in 3% (w/v) milk in TBS-T and re-probed with a different 
primary antibody.  
 
Stacking gel     Separating gel (10%) 
 
0.125 M Tris-HCl, pH 6.8   0.375 M Tris-HCl, pH 8.8 
3% (v/v) Acrylamide    10% (v/v) Acrylamide 
0.1% (v/v) SDS     0.1% (v/v) SDS 
0.1% (v/v) APS     0.1% (v/v) APS 
 
Table 2.7: Preparation of PAGE-gels 
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2.2.4 Immunological methods 
2.2.4.1 Immunostaining of human breast carcinoma cells 
 
For immunostaining cells were seeded onto glass coverslips in 12-well dishes (105 
cells/well) and transfected as previously described (chapter 2.2.1.5). After 24 hours, cells 
were washed in pre-warmed PBS and fixed at RT for 20 minutes with 4% (w/v) PFA in 
PBS. PFA was quenched using 50 mM Glycine (pH 8.0). Cells were subsequently washed 
in PBS, permeabilised in PBS containing 0.1% (v/v) Triton X-100 and incubated with the 
primary antibody for 1 hour at RT (antibodies used are summarised in Table 2.2). Cells 
were washed 3 times for 5 minutes with PBS and were incubated with species-specific 
AlexaFluor® 488, AlexaFluor® 546 or Cy5 conjugated secondary antibodies (summarised 
in Table 2.3). Slides were mounted in ProLong® Gold Antifade Reagent with DAPI.  
 
2.2.4.2 Immunostaining of human mammary carcinomas 
 
Immunohistochemical analyses were performed in collaboration with Dr. Bence Sipos 
(Department of Pathology, Universitätsklinikum Schleswig-Hostein, Campus Kiel; current 
affiliation: Department of Pathology, University of Tübingen). Breast carcinoma sections 
were obtained from surgical specimens, according to a protocol approved by the ethics 
committee of the University Hospital, Kiel. Tumour tissues were fixed in formalin and 
routinely processed for paraffin sectioning. Three-μm-thin paraffin sections were 
deparaffinized, rehydrated and immunostained according to routine methods. Antigen was 
demasked by heating the sections under high pressure in Tris-EDTA-citrate buffer (pH 
7.8). Antibody were diluted in 2% (w/v) fat free powdered milk in PBS. The dilutions used 
are summarised in Table 2.2. After incubation for 16 hours at 4˚C, the reaction was 
detected with a biotinylated anti-mouse or anti-rabbit antibody (5 μg/ml, Vector 
Laboratories, Burlingame, CA) and avidin-biotin-peroxidase (ABC-ELITE, Vector 
Laboratories). Diaminobenzidine served as chromogen.  
For negative control the primary antibody was omitted. After staining, sections were 
counterstained in 50% haemalaun (Merck, Darmstadt, Germany). 
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2.2.4.3 Microscopy analysis 
2.2.4.3.1 Fluorescent microscopy 
 
Images of fluorescently labelled cells were acquired using a Photometrics Coolsnap HQ 
CCD camera (Roper Scientific, Harlow, UK) attached to a Zeiss Axioplan 2 imaging 
microscope using a 40 ? or 63 ? immersion objective as well as by using a differential 
interference contrast (DIC) prism. Taken images were analysed and processed using the 
Metamorph software (Universal Imaging Corporation, Downington, PA) as well as by the 
Photoshop imaging software (Adobe Systems, San Jose, CA).  
 
2.2.4.3.2 Confocal microscopy 
 
Series of optical sections were acquired using a Leica Tandem SP5 Confocal laser 
microscope (Leica Microsystems, Germany) with a 63 ? oil immersion objective at 1024 ? 
1024 dpi or 2048 ? 2048 dpi for co-localisation studies. Various optical sections were 
imaged every 0.2 ?m along the z-axis of the cell. Files were transferred to the Volocity 3D 
imaging and analysis software to generate three-dimensional reconstructions of obtained z-
stacks or to perform co-localisation analyses.  
For co-localisation quantification, a cytofluorogram was generated per optical confocal 
section of each cell (Figure 2.2A), by plotting the paired fluorescent intensities obtained 
per voxel (volume pixel) of two different channels in a histogram (Figure 2.2B). As shown 
in Figure 2.2A, fluorescence is detected for both channels in every voxel of the selected 
image, leading to double positive voxels as demonstrated in the cytofluorogram (Figure 
2.2B). Following background-subtraction performed for every channel, the specific pattern 
of the antibody-staining remains (Figure 2.2C), while the amount of positive voxels within 
the selected image decreases (Figure 2.2D). Based on this background-corrected 
cytofluorogram, the Pearson’s linear co-localisation co-efficient (CL) is calculated, which 
indicates the degree of overlap between two channels in a microscopy image: 
 
CL = ?((Xi – Xavg)(Yi – Yavg) / sqrt(?Xi – Xavg)2?(Yi – Yavg)2) 
 
With Xavg and Yavg the averages of the X and Y channel, respectively and the summations 
with index i are over the entire image voxels. 
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The obtained CL value lies between -1 and 1. Negative values occur when the majority of 
values of X above Xavg coincide with values of Y below Yavg. A CL close to 1 indicates an 
extensive overlap of the two analysed channels. Since the averages are included in the 
calculation of the Pearson’s co-localisation co-efficient, the CL obtained is generally not 
affected by the image background. However, the background independence only occurs 
when a constant value is added to either channel, and introduces a significant bias in the CL 
analysis (CL indicated in Figure 2.2B,D). Therefore, all images analysed were background-
corrected prior to calculation of CL.  
 
 
Figure 2.2: Co-localisation analysis using Volocity 
(A) Detected pY416-Src staining is indicated without background correction. (B) Corresponding 
cytofluorogram shows the co-localisation of MT1-MMP and pY416-Src without background correction. The 
calculated co-localisation co-efficients are CL(pY416-Src) ~ 1 and CL(MT1-MMP) ~ 1. (C) pY416-Src (AlexaFluor® 
488 secondary) specific fluorescence as detected after background correction. (D) To (C) corresponding 
cytofluorogram of MT1-MMP and pY416-Src co-localisation after correcting for non-specific background 
for each channel. The calculated co-localisation co-efficients are CL(pY416-Src) = 0.517 and CL(MT1-MMP) = 0.596. 
 
2.2.4.3.3 iCys™ quantification of MT1-MMP nuclear staining 
 
MT1-MMP nuclear staining intensities were quantified using the iCys™ laser scanning 
cytometer. Cells were stained as previously described (chapter 2.2.4.1) with either an 
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antibody directed against the MT1-MMP ICD (ab28209, AlexaFluor® 488 secondary) or 
an antibody raised against the MT1-MMP ECD (N175/6, AlexaFluor® 488 secondary) and 
counterstained with DAPI. Figure 2.3B shows a magnification of the scanned area (Figure 
2.3A), obtained within the 405 nm channel. The fluorescent intensities of the AlexaFluor® 
488 labelled cells within that nuclear contour were detected and normalised to non-specific 
background noise (Figure 2.3C). Approximately 10,000 cells were scanned per condition, 
each in biological triplicates (Figure 2.3A). 
 
 
Figure 2.3: iCys quantification of nuclear staining 
(A) 5 ? 105 cells were seeded on a glass coverslip, transfected with MT1-WT and immunostained with an 
anti-MT1-MMP ICD (ab28209, AlexaFluor® 488 secondary) or an anti-MT1-MMP ECD (N175/6, 
AlexaFluor® 488 secondary) antibody. Cells of both conditions were counterstained with DAPI. 
Representation of the scanning area on the glass coverslip obtained with the iCys™ laser scanning cytometer. 
(B) Magnification of the scanned area showing DAPI staining as indicated (dashed square). (C) Automated 
generation of a 1st contour around the DAPI stained nuclear region of each cell. Detected fluorescent 
intensities were normalised to background level, which was set by default 8 pixels off the primary contor. 
One or more peripheral contours could be manually defined to quantify cytoplasmic staining.  
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2.2.4.4 Flow cytometry  
 
MCF-7 cells were transfected with various cDNAs and/or stimulated with 100 ng/ml rh-
VEGF165 for 30 minutes where indicated. Cells were then washed, lifted off using 5 mM 
EDTA/PBS for 5 minutes at 37°C and fixed with PFA (4% (w/v) in 5 mM EDTA/PBS). 
Cell surface VEGFR-2 and MT1-MMP were labelled for 1 hour at RT. The cells were 
washed three times in PBS and incubated for 1 hour at RT with 10 μg/ml PE-conjugated 
anti-mouse or allophycocyanine (APC) anti-rabbit secondary antibodies (Table 2.3). Cells 
were washed as previously described, sieved through a 70 μm filter and analysed on a 
FACSCalibur™ flow cytometer. 10,000 events were acquired per sample and the mean 
fluorescence intensity of four independent experiments was analysed using FlowJo Flow 
Cytometry analysis software. 
 
2.2.4.5 ELISA assay 
 
Wells of a microtitre plate were coated either with VEGFR-2-Fc (10 ?g/ml) or low-fat 
milk (10 ?g/ml) for 16 hours at 4˚C and blocked with 3% (w/v) low-fat milk in wash buffer 
(50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 0.05% (v/v) Tween®20) for 1 hour at 
RT. After three washes in washing buffer, rh-MT1-Ecto, rh-MT1-Ecto-E240A, rh-MT1-
Cat (all at 2 ?M) or rh-VEGF165 (1 ?M) were added in wash buffer for 1 hour at RT. 
Protein complexes were washed 3 ? in wash buffer. Bound rh-MT1-MMP domains or rh-
VEGF165 were detected using the LEM-2/15.8 or VEGF-A antibodies (1 hour at RT), 
respectively, followed by an HRP-conjugated anti-mouse secondary antibody (1 hour at 
RT) and incubation with the TMB High Sensitivity Substrate Solution according to the 
manufacturer’s instructions. Reactivity was measured by absorbance at 450 nm using the 
Infinite® M200 plate reader. OD obtained from wells without rh-MT1-MMP domain or 
rh-VEGF165 incubation was subtracted from OD of each sample well. Samples were 
assayed in triplicates. 
 
2.2.4.6 Recombinant protein binding assay 
 
Soluble rh-VEGFR-2-Fc – rh-MT1-Ecto or rh-VEGFR-2-Fc – rh-MT1-Cat complexes 
were generated by incubation of 10 μg VEGFR-2 with MT1-MMP domains at a 1:1 molar 
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ratio at 37˚C for 30 minutes in 50 mM Tris-HCl, 200 nM NaCl and 5 mM CaCl2 (pH 7.4). 
Where indicated, 10 μg rh-MT1-Ecto was pre-incubated with 10 μg/ml catalytic activity 
blocking anti-MT1-MMP antibody LEM-2/15.8 before adding rh-VEGFR-2-Fc. Following 
complex formation, 15 μl of each sample was taken as Input control. VEGFR-2 antibody 
(55B11) pre-coated Dynal magnetic beads (Protein G) were added to the remaining sample 
and the lysates were immunoprecipitated as described in chapter 2.2.4.7. 
Immunoprecipitates and Input controls were separates by SDS-PAGE followed by 
coomassie staining of total protein.  
 
2.2.4.7 Immunoprecipitation (IP) 
 
Cells were seeded in 6-well plates and transfected and stimulated as indicated in the results 
chapter. Following 16 hours incubation, cells were washed 3 ? in PBS and lysed in IP lysis 
buffer (chapter 2.1.1.5). All following steps were conducted at 4˚C. Antibodies (3 ?g) were 
bound to Dynabeads protein G at 4˚C for 16 hours in 5 mg/ml BSA in PBS (chapter 
2.2.4.8). Cell lysates were subsequently incubated with antibody-bound Dynabeads for 2 
hours at 4˚C under constant rotation. Beads were subsequently washed 4 ? 10 minutes with 
immunoprecipitation buffer and resuspended in 2 ? Laemmli buffer. Denatured proteins 
were separated on 10% SDS- PAGE and electro-transferred onto nitrocellulose membrane 
as described previously (chapter 2.2.3.6).  
 
2.2.4.8 Chromatin Immunoprecipitation (ChIP) 
 
MCF-7 cells were seeded in a 150 cm2 dish and 25 ?M penetratin peptide was added. 3 
hours after treatment, the medium was removed and cells were fixed in 1% (w/v) 
formaldehyde in serum-free medium for 10 minutes at 37˚C. The fixation medium was 
removed, the cells were washed 2 ? in cold PBS and scraped in 500 ?l ice-cold PBS 
containing protease inhibitors (Complete Tablets). The cells were collected by 
centrifugation at 5000 ? rpm for 2 minutes and washed 2 ? in PBS containing protease 
inhibitors. After another centrifugation step at 5000 ? rpm for 2 minutes, the PBS was 
removed and cells were resuspended in freshly prepared 300 ?l SDS lysis buffer 
containing protease inhibitors. The samples were sonicated 3 ? 10 seconds and centrifuged 
in a microcentrifuge for 10 minutes at maximum speed at 4˚C. The supernatant containing 
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total chromatin and protein was collected and 20 ?l were taken to use as Input control. The 
supernatant volume was increased with ChIP dilution buffer (chapter 2.1.1.5) to 2 ml total 
volume and added to pre-bound magnetic beads. Briefly, for magnetic bead coating 40 ?l 
Protein G coated Dynal magnetic beads were washed 3 ? in PBS containing 5 mg/ml BSA. 
3 ?g of antibody was added in PBS containing 5mg/ml BSA for 16 hours on a mixer at 
4˚C. The beads were washed 3 ? in PBS containing 5 mg/ml BSA and the chromatin 
samples were added. Protein – chromatin complexes were immunoprecipitated on a mixer 
at 4˚C for 2 hours and magnetic beads were collected. Immunocomplexes were washed 6 ? 
in RIPA buffer on a mixer for 20 minutes between every second wash and subsequently 
washed 2 ? in TE buffer (pH 7.6). The immunoprecipitated samples as well as the Input 
controls were either resuspended in 5 ? Laemmli buffer for immunoblotting or subjected to 
reverse cross-linking to perform Real-Time PCR. Therefore, 100 ?l of 1% SDS and 0.1 M 
NaHCO3 were added to the immunoprecipitates and Input controls. The samples were 
vortexed every few minutes for 30 minutes at RT. Reverse cross-linking was performed at 
65˚C for 16 hours. DNA was extracted by phenol:chloroform:IAA precipitation and used 
for SYBR® Green Real-Time-PCR (chapter 2.2.2.4.2).  
 
2.2.5 Cell-based functional assays 
2.2.5.1 Luciferase assay 
 
The cells were seeded in 6-well plates (1 ? 105 HeLa cells/well, 5 ? 105 MCF7 cells/well) 
and were transiently co-transfected 24 hours later with the reporter gene construct pG5luc, 
?-Galactosidase for normalisation and different MT1-MMP constructs  (Table 2.5). The 
cells were inhibited or stimulated 3 hours after transfection (inhibitors used: Table 2.4) and 
harvested 24 hours later. The culture medium was removed and the cells were rinsed twice 
in 1 ? PBS to remove used medium, dead cells and debris. After addition of 200 ?l 
Reporter Lysis Buffer (Promega), the cells were lysed for 15 minutes and processed 
according to manufacturer’s instructions. The reporter gene expression was detected by 
using the Luciferase Assay System by Promega. Luciferase activity was normalised by 
measuring ?-Galactosidase as an internal control for transfection efficiency. 50 ?l 2 ? 
Assay Buffer, containing the substrate ONPG (o-nitrophenyl-?-D-galactopyranoside), were 
added and the samples were incubated for at least 30 minutes at 37°C. During that time ?-
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Galactosidase hydrolyses the colourless substrate to o-nitrophenyl, causing a change of 
colour to yellow. The reaction was terminated by addition of 1 M Tris-base, and the 
absorbance at 420 nm was measured by spectrophotometry. 
Luciferase expression was normalised to ?-Galactosidase activity by dividing the relative 
light units values obtained from the Luciferase assay by those from the latter assays. The 
reporter gene assay was performed in two biological and technical replicates and repeated 
at least 3 times in independent experiments. 
 
2.2.5.2 Dual Luciferase Assay 
 
For the mammalian two-hybrid assay the Dual Luciferase® Reporter Assay System was 
used. It allows the simultaneous measurement of two individual reporter enzymes within a 
single assay, the activities of Firefly (Photinus pyralis) and Renilla (Renilla reniformis) 
Luciferases. Src and MT1-MMP ICD were both sub-cloned in the pAct and pBind vectors 
(Table 2.5). The pBind vector contains the GAL4 DNA-binding domain and expresses 
Renilla Luciferase under the control of a SV40 promoter, which allows normalisation of 
the transfection efficiency. The pAct vector contains the VP16 transactivation domain.  
 
 
Figure 2.4: Mammalian-two hybrid system 
Cells were co-transfected with the pG5luc vector, which contains 5 GAL4 binding sites upstream from the 
Firefly Luciferase gene, the VP16 domain containing pAct vector and the GAL4 expressing pBind vector. 
Interaction between the two proteins of interest leads to the assembling of the GAL4 and VP16 domains, 
which enhances Firefly Luciferase activity. Expression of Renilla Luciferase by the pBind vector is detected 
in order to normalise for transfection efficiency. Taken from: Dual-Luciferase® Reporter Assay System 
technical manual (Promega). 
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Src and MT1-MMP ICD were expressed as fusion proteins with the GAL4 and VP16 
domains, respectively. MCF-7 and HeLa cells were co-transfected with these constructs 
and the pG5luc vector. The pG5luc vector contains five GAL4 binding sites followed by a 
minimal TATA box and the firefly Luciferase gene (Figure 2.4). An interaction between 
the two genes of interest leads to an interaction between the GAL4 and VP16 domains, 
which in turn induces the expression of the Luciferase gene. Firefly Luciferase activity is 
normalised by Renilla activity, which is expressed from the pBind vector. 
The assay was performed according to the manufacturer’s instruction. Briefly, cells were 
seeded in 12-well plates (1 ? 105 MCF-7 cells/well, 5 ? 104 HeLa cells/well) and 
transiently co-transfected with 1 ?g pG5luc, 1 ?g pAct- and 1 ?g pBind-constructs the 
following day. The cells were stimulated for ~6 hours with 100 nM PMA where indicated 
and harvested for the gene reporter assay 24 hours after transfection. The culture medium 
was removed and the cells were rinsed twice in 1 ? PBS to remove used medium and dead 
cells. 200 ?l 1 ? Passive Lysis Buffer (PLB, Promega) was added per well and cells were 
lysed for 15 minutes on a rocking platform. Firefly Luciferase activity was detected by 
adding 20 ?l of Luciferase Assay Reagent II (Promega). After quantification of the Firefly 
Luciferase luminescence, the reaction is quenched while Renilla Luciferase reaction is 
initiated within in the same step. Firefly Luciferase expression was normalised to Renilla 
Luciferase activity by dividing the relative light units values obtained from the Firefly 
Luciferase assay by those from the latter measurement. Transfection efficiency of the pAct 
vector was determined by Western Blotting using an anti-VP16 antibody. Each assay was 
performed in three biological and two technical replicates and repeated at least 2 times in 
independent experiments. 
 
2.2.6 In silico analyses 
2.2.6.1 Computer programs 
 
The analysis and presentation of the data showed in this thesis, was performed using the 
Microsoft® Office 2004 for Mac Version 11.5.3 (Microsoft, Redmond, WI). Image 
acquisition and analysis were performed with the Leica Application Suite AF version 1.7.0 
(Leica), Volocity 3D imaging and analysis software (improvision, Perker Elmer, Coventry, 
UK), iNovator Application Development Toolkit (CompuCyte, Westwood, MA), 
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MetaMorph® software (Universal Imaging Corporation, Downigtown, PA) and Adobe® 
Photoshop® Professional CS3 version 10.0.1 (Adobe, San Jose, CA). Analysis of flow 
cytometry data were conducted with the FlowJo Flow Cytometry Analysis Software 
(v.8.8.4, Tree Star Inc., Olten, Switzerland). FinchTV version 1.4.0 (Geospiza Inc., Seattle, 
WA) and Vector NTI (Invitrogen) have been used for sequence analyses, while the SDS 
software v2.3 (Applied Biosystems) was used for acquisition and analysis of Real-Time 
PCR data obtained with the ABI 7900HT Fast Real-Time PCR System. Statistical data 
analysis was performed using the GraphPad Prism® 5 Software (GraphPad Software, Inc, 
San Diego, CA) and general data presentation and organisation was carried out using 
Adobe® InDesign® CS3 version 5.0.4, Adobe® Acrobat 8 Professional CS3 version 8.1.3 
and EndNote X2.0.1 (Thomson Reuters, Carlsbad, CA) as well as the Microsoft Office 
package for Mac v 11.5.3 (Microsoft, Redmond, WA). 
 
2.2.6.2 Statistical analysis 
 
Statistical analysis was performed using the GraphPad Prism® 5 Software. Statistical 
significance was assessed by one-way ANOVA with the Student Newman-Keuls post-test, 
unless indicated otherwise. All numerical values shown are the means ± standard error 
(S.E.M). Statistical significance was defined as P < 0.05 (*), P < 0.001 (**) and P < 
0.0001 (***). 
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3 Results 
 
Although MT1-MMP expression is widely distributed in normal physiology, its expression 
is frequently increased in malignant or inflamed tissue. MT1-MMP expression has been 
detected in tumour cells and adjacent stromal cells in a variety of human tumours, 
including breast, cervical, colon, bladder, gastric, pancreatic, liver, ovarian, prostate and 
thyroid cancer and MT1-MMP expression has been shown to correlate with a poor 
prognosis in tumours of various origins (reviewed in 250). Recently, new non-catalytic roles 
for MT1-MMP have emerged, which include the induction of intracellular signalling 
pathways and the regulation of gene expression of various target genes. MT1-MMP has 
been implicated in regulating the transcription of VEGF-A, Dickkopf-3 (DKK-3) and 
Smad-1. However, the molecular mechanisms underlying the MT1-MMP induced 
transcriptional regulation are not understood so far.  
 
MT1-MMP dependent induction of VEGF-A expression has been previously reported to 
involve MT1-MMP catalytic activity, its intracellular domain as well as Src activity 73 
(Figure 3.1A). However, various transcription-regulating proteins were recently reported to 
be synthesised as transmembrane precursors, which have to be activated by proteolytic 
processing (chapter 1.4), raising another possibility of MT1-MMP mediated transcriptional 
regulation (Figure 3.1B). During this process, the ectodomain is shed from the cell surface, 
whereas the intracellular part is released and translocates to the nucleus to regulate gene 
expression.  
In this study the following questions were addressed: (i) how does MT1-MMP induce 
intracellular signalling cascades, (ii) what are the elements of an MT1-MMP induced 
signalling pathway and (iii) what are the target genes regulated by MT1-MMP expression.  
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Figure 3.1: Potential MT1-MMP induced signalling pathways 
Schematic representation of potential MT1-MMP induced signalling pathways. (A) MT1-MMP was reported 
to induce the expression of VEGF-A in a Src dependent way, involving the MT1-MMP catalytic and 
intracellular domain. (B) Representation of an alternative mechanism, in which the intracellular domain of 
MT1-MMP is released from the plasma-membrane and translocates to the nucleus to regulate gene 
transcription. 
 
3.1 MT1-MMP dependent regulation of VEGF-A expression in MCF-
7 cells 
 
MT1-MMP activity has been implicated in various studies to be involved in the formation 
of new blood vessels in both physiological and pathological conditions (chapter 1.3.3.3). 
The development of new blood vessels within tumours is an important step in 
carcinogenesis and is predominantly initiated by secretion of the pro-angiogenic factor 
VEGF-A (chapter 1.5.1). Many tumour cells have been shown to express and secrete 
VEGF-A, thus inducing paracrine and/or autocrine signalling leading to angiogenesis as 
well as cell survival and proliferation in cells expressing VEGF receptors.  
MT1-MMP is highly expressed in some tumour cells and MCF-7 and U251 cells, which 
stably overexpress MT1-MMP, have been shown to enhance the expression of VEGF-A at 
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the transcriptional level 26,73. This up-regulation has been shown to be dependent on the 
catalytic and intracellular domains of MT1-MMP as well as on Src activity 73. However, 
the molecular mechanism underlying this transcriptional up-regulation is not understood in 
detail so far. The aim of the first part of this thesis was to identify the molecular 
mechanisms linking MT1-MMP expression to VEGF-A transcription and thus refining the 
role of MT1-MMP in tumourigenic angiogensis.  
 
MCF-7 cells, which are deficient in MT1-MMP expression 251, were used as a model 
system for breast carcinoma cells in this study to selectively investigate the effect of MT1-
MMP in transfected cells as well as to study the role of the different MT1-MMP domains. 
 
3.1.1 Transient transfection or adenoviral transduction of MT1-MMP 
cDNA increases VEGF-A transcription 
 
In order to confirm the role of MT1-MMP in VEGF-A transcription reported previously 
26,73, MT1-MMP was expressed in MCF-7 cells either by transient transfection or by using 
an adenoviral delivery system. By using these transient transfection techniques, the 
formation of artefacts resulting from the adaptation to the selection process, which might 
occur during the generation of stable expressing clones, as described previously 73, may be 
avoided. Furthermore, the transient expression systems used in this study enabled the 
observation of early effects following MT1-MMP expression, which might mimic 
molecular responses in early phases of tumour growth and metastasis. 
Thus, MCF-7 cells were either transiently transfected with full-length MT1-MMP (MT1-
WT, Figure 3.2A, B) or transduced with multiplicities of infection (MOI) of 150 pfu/cell of 
MT1-WT expressing adenovirus (Figure 3.2C, D). Total RNA was isolated and the 
expression levels of MT1-MMP and VEGF-A mRNA were determined by TaqMan® 
Real-Time PCR. The VEGF-A TaqMan® probe used detected all isoforms derived from 
alternative splicing (chapter 1.5.1).  
As expected, transient expression of MT1-WT in MCF-7 cells led to a significant increase 
of MT1-MMP mRNA (P < 0.0001 compared to pcDNA3.1 control, Student t-test, Figure 
3.2A) as well as an increase in VEGF-A mRNA expression (P < 0.001, Student t-test) 
compared to the empty vector control (pcDNA3.1) transfected cells (Figure 3.2B). 
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Figure 3.2: MT1-MMP expression increases the VEGF-A mRNA level  
(A,B) MCF-7 cells were transfected with either empty pcDNA3.1 control vector or MT1-WT and expression 
levels of MT1-MMP (A) and VEGF-A (B) were detected by TaqMan® Real-Time PCR. MT1-MMP and 
VEGF-A relative expression levels were normalised to the mRNA levels of the house-keeping gene GAPDH. 
Data represent the mean expression in fold change compared to pcDNA3.1 empty vector control (dotted line) 
of 16 independent experiments ± 95% confidence intervals. (C,D) MCF-7 cells were transduced with a MOI 
of 150 pfu/cell of MT1-WT expressing adenovirus or 150 pfu/cell of empty adenoviral vector control (Rad). 
Expression levels of MT1-MMP and VEGF-A were detected by TaqMan® Real-Time PCR and normalised 
to the mRNA levels of the house-keeping gene GAPDH. Data correspond to the mean expression in fold 
change compared to Rad control (dotted line) of 5 independent experiments ± 95% confidence intervals.  
 
Accordingly, the level of VEGF-A expression was found to be increased in cells 
transduced with MT1-WT expressing adenovirus (Figure 3.2C, D). For both transient and 
adenoviral expression of MT1-WT in MCF-7 cells, an increase of VEGF-A mRNA could 
be observed (Figure 3.2B, D), indicating that the MT1-MMP induced expression of VEGF-
A is independent of the expression system used. 
To test whether VEGF-A expression is directly proportional to the MT1-MMP expression 
level, MCF-7 cells were transduced with increasing MOI of MT1-WT expressing 
adenovirus. As shown in Figure 3.3A and B, addition of increasing MOI of MT1-WT 
expressing adenovirus led to a significant increase of MT1-MMP (P < 0.0001; 150 pfu/cell 
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MT1-WT compared to Rad control) and VEGF-A mRNA levels (P < 0.05; 150 pfu/cell 
MT1-WT compared to Rad control) as compared to empty adenoviral vector control (Rad). 
 
Figure 3.3: VEGF-A mRNA expression is proportional to MT1-MMP mRNA levels  
(A,B) MCF-7 cells were transduced with increasing MOI of MT1-WT expressing adenovirus or 150 pfu/cell 
of Rad empty adenoviral vector control. mRNA levels of MT1-MMP (A) and VEGF-A (B) were detected by 
TaqMan® Real-Time PCR and the relative expression levels were normalised to the mRNA levels of the 
house-keeping gene GAPDH. Data represent the mean expression in fold change compared to Rad control 
(dotted line) of 5 independent experiments ± S.E.M. with P < 0.05 (*) and P < 0.0001 (***). (C) MCF-7 cells 
were transduced with MT1-WT expressing adenovirus as described before. The MT1-MMP mRNA levels in 
fold change compared to Rad control are plotted against the corresponding VEGF-A mRNA expression 
levels in fold change compared to Rad control. Data represent the mean expression in fold change compared 
to Rad of 20 independent experiments ± 95% confidence intervals.  
 
By plotting the relative mRNA expression of MT1-MMP and VEGF-A, both in fold 
change compared to empty adenoviral vector control (Rad), a direct correlation between 
VEGF-A and MT1-MMP mRNA expression could be observed (Figure 3.3C; y = 0.0014x 
+ 1.016, best-fit values). 
These data are consistent with previous observations showing that MT1-MMP expression 
increases the mRNA level of VEGF-A 73 and further emphasise that this observation is 
independent of the expression system used (Figure 3.2).  
 
In addition to the MT1-MMP dependent increase in VEGF-A transcription we could also 
observe a dose-dependent effect on VEGF-A translation. As shown in Figure 3.4A cellular 
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VEGF-A protein accumulated with increasing MOI of transduced MT1-MMP (up to 150 
MOI). To test whether the amount of secreted VEGF-A is also affected by MT1-MMP, 
proteins of the conditioned medium of cells transduced with MT1-WT expressing 
adenovirus were concentrated and immunoblotted. With increasing levels of MT1-MMP 
protein an increasing amount of VEGF-A was found to be secreted into the medium 
(Figure 3.4.A). 
 
 
Figure 3.4: Dose-dependent expression of VEGF-A protein and its secretion into the 
medium with increasing concentrations of MT1-MMP  
 
(A) MCF-7 cells were transduced with the indicated MOI of MT1-WT expressing adenovirus and the protein 
levels in the cell lysates as well as in the conditioned medium were analysed by immunoblotting with an anti-
MT1-MMP (LEM-2/15.8), anti-VEGF-A or an anti-?-Actin antibody. (B) MCF-7 cells were transfected with 
pcDNA3.1 vector control or MT1-WT and were incubated for 24 hours with 1 ?M rh-TIMP-1, 1 ?M rh-
TIMP-2 or CT1746 at the indicated concentrations. VEGF-A expression levels were determined by 
TaqMan® Real-Time PCR and normalised to the mRNA levels of the house-keeping gene GAPDH. The data 
represent the mean expression in fold change compared to pcDNA3.1 (dotted line) of 3 independent 
experiments ± S.E.M. with P < 0.001 (**) and P < 0.0001 (***) compared to DMSO treated control (for 
CT1746 treated samples) or compared to untreated (-) MT1-WT control (for TIMP stimulated samples). 
 
To address whether the up-regulation of VEGF-A transcription is dependent on 
metalloproteinase (MP) function, as described previously 73, MT1-WT transfected MCF-7 
cells were treated with 5 ?M or 10 ?M of the broad-spectrum MP inhibitor CT1746 or 
with 1 ?M of the physiological recombinant human (rh-) MP inhibitor Tissue Inhibitor of 
Metalloproteinase -1 (TIMP-1) or rh-TIMP-2. The expression level of VEGF-A in MT1-
MMP transfected cells was found to be elevated by ~2 fold compared to pcDNA3.1 control 
transfected cells, as routinely observed (Figure 3.4B and Figure 3.2B). VEGF-A 
expression levels were not significantly affected in MT1-MMP expressing cells following 
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treatment with 5 or 10 ?M CT1746 (P < 0.001 compared to DMSO control) or rh-TIMP-2 
(P < 0.0001 compared to untreated (-) control). In contrast, treatment of MT1-WT 
expressing cells with rh-TIMP-1, which does not inhibit MT1-MMP function 252, increased 
the level of VEGF-A expression to the level of wild-type control (Figure 3.4B). These 
findings confirm that a metalloproteinase, possibly MT1-MMP itself, is needed for the 
transcriptional up-regulation of VEGF-A in MCF-7 cells.  
 
3.1.2 VEGFR-2, PI3 Kinase, mTOR, Src and HIF-1?  activities are 
required for the MT1-MMP induced VEGF-A expression 
 
To obtain a better understanding of the cellular signalling mechanism underlying the MT1-
MMP induced up-regulation of VEGF-A, MT1-WT transfected MCF-7 cells were treated 
with different inhibitors of key signalling pathways (summarised in Table 3.1) and VEGF-
A expression levels were assessed by TaqMan® Real-Time PCR. As previously reported 
inhibition of Src, by using PP2, ablated the MT1-MMP induced up-regulation of VEGF-A 
mRNA levels (Figure 3.5A) 73. A similar observation was obtained following inhibition of 
phosphatidylinositol 3 (PI3) kinase (Wortmannin, LY294002), Akt (SH-5) and mTOR 
(Rapamycin) (each P < 0.0001 compared to DMSO control; Figure 3.5A). Treatment of 
cells with SU4312 was also found to inhibit MT1-MMP mediated VEGF-A expression in 
MCF-7 cells. As this compound inhibits both VEGFR and PDGFR activities, the more 
selective PDGFR inhibitor AG-1296 was used in order to distinguish between these two 
receptors. As presented in Figure 3.5A, AG-1296 did not affect the MT1-MMP induced 
VEGF-A mRNA expression compared to DMSO control, thus suggesting that the SU4312 
mediated down-regulation of VEGF-A mRNA was due to VEGFR inhibition. To identify 
candidate members of the Src and VEGFR families a gene-expression profile of the in 
tumours ubiquitously expressed Src, Fyn, VEGFR-1 and VEGFR-2 was conducted in 
MCF-7 cells (Figure 3.5B). Src and VEGFR-2 were the only genes to be detected within 
their respective gene families and were therefore studied further. 
 
Treatment of MT1-WT expressing MCF-7 cells with inhibitors of MEK (PD98059), JNK 
(SP006125), EGFR (Gefitinib, Tarceva/Erlotinib), IKK (BMS-345541), IGF-1R (PPP, N-
(2-Methoxy-5-chlorophenyl)-N’-(-methylquinolin-4-yl)-urea), p38 (SB 203580/4-(4-
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Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole), or the proteasome 
(Lactacystin) did not affect VEGF-A mRNA levels (summarised in Table 3.1).  
 
 
Figure 3.5: The MT1-MMP induced VEGF-A expression depends on Src, VEGFR-2, 
PI3 Kinase, Akt and mTOR activity 
(A) MCF-7 cells were transiently transfected with MT1-WT and treated for 24 hours with DMSO, PP2, SH-
5, LY294002, Rapamycin, SU4312 or AG-1296. VEGF-A expression levels were detected by TaqMan® 
Real-Time PCR and normalised to mRNA levels of the house-keeping gene GAPDH. Data represent the 
mean VEGF-A expression of three independent experiments in fold change compared to pcDNA3.1 control 
(dotted line) ± S.E.M. with P < 0.0001 (***) compared to DMSO control. ns, non-significant. (B) Gene 
expression profile of pcDNA3.1 and MT1-WT transfected MCF-7 cells was assessed by TaqMan® Real-
Time PCR. Gene expression levels were normalised to mRNA levels of the house-keeping gene GAPDH. 
Data represent the mean gene expression of three independent experiments in arbitrary units (AU).  
 
To confirm the profiling data, which imply the involvement of VEGFR-2 (VEGFR-1 was 
expressed at low levels in MCF-7 cells, Figure 3.5B), lentiviral shRNA knock-down was 
assessed for VEGFR-1 and VEGFR-2 (MISSION® shRNA, Sigma-Aldrich). However, all 
shRNA sequences tested targeting either VEGFR-1 or VEGFR-2 were found to generate 
unspecific depletion of either receptor (discussed in chapter 3.2.1.3). 
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VEGF-A Expression 
Fold change vs. MT1-WT (DMSO control) 
Decreased ?      Unchanged ?  
 
 
Src (PP2)     MEK (PD98059) 
PI3 kinase (Wortmannin, LY294002)  JNK (SP006125) 
VEGFR / PDGFR (SU4312)   PDGFR (AG-1296) 
Akt (SH-5)     EGFR (Tarceva/Erlotinib; Gefitinib) 
mTOR (Rapamycin)    IKK (BMS-345541) 
HIF-1? (Dimethyl Bisphenol A)  IFG-1R (IGF-1R Inh. II) 
      Proteasome (Lactacystin) 
      P38 (SB203580) 
 
Table 3.1: Summary of inhibitors tested  
MCF-7 cells were transfected with MT1-WT and various inhibitors were added at concentrations indicated in 
Material and Methods. VEGF-A expression levels were assessed by TaqMan® Real-Time PCR and 
normalised to the mRNA levels of the house-keeping gene GAPDH. The data representing each inhibitor set 
have been derived from three independent experiments. VEGF-A mRNA levels have been defined as 
decreased if P < 0.05 compared to MT1-WT transfected control treated with DMSO. 
 
3.1.3 MT1-MMP expression induces activation of Akt and mTOR 
 
The previously described requirement for Akt and mTOR activities in MT1-MMP 
mediated VEGF-A expression (Figure 3.5A), led to the hypothesis that MT1-MMP 
expression might affect the phosphorylation state of these kinases. In order to test this 
hypothesis, cells were transfected either with the pcDNA3.1 empty vector control or MT1-
WT and total protein extracts were immunoblotted. As shown in Figure 3.6, the expression 
of MT1-WT augmented the level of Akt phosphorylation at S473 and T308, whereas total 
levels of Akt were not affected. Accordingly, the phosphorylation of mTOR was also 
increased in MT1-WT expressing cells compared to the pcDNA3.1 transfected control 
(Figure 3.6).  
In order to further analyse the MT1-MMP induced signalling pathway and to obtain 
information on the signalling hierarchy, MT1-WT transfected MCF-7 cells were incubated 
for 24 hours with PP2, SH-5, LY294002, SU4312 or DMSO as control. As shown in 
Figure 3.6, mTOR phosphorylation at S2448 and Akt phosphorylation at S473 and T308 was 
ablated with all the inhibitors used, suggesting that the mTOR and Akt phosphorylation 
events were down-stream of Src, PI3 Kinase and VEGFR-2 activation.  
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Figure 3.6: MT1-MMP expression increases phosphorylation of Akt and mTOR  
MCF-7 cells were transfected with either pcDNA3.1 or MT1-WT, as indicated. DMSO, PP2, SH-5, 
LY294002 or SU4312 were added for 24 hours. Lysates were immunoblotted with an anti-pS473-Akt, anti-
pT308-Akt, anti-Akt, anti-pS2448-mTOR, anti-mTOR, anti-MT1-MMP (LEM2/15.8) or an anti-ß-Actin 
antibody. The increase of Akt and mTOR phosphorylation in the presence of MT1-MMP protein is 
furthermore shown in Figure 3.7 and Figure 3.8A. 
 
As the treatment of cells with SH-5 showed a reproducible reduction of MT1-MMP 
protein, which was also observed using Triciribine (API-2), a different Akt inhibitor, the 
interpretation of the role of Akt inhibition in this system is difficult.  
Based on these findings, an MT1-MMP induced signalling pathway is proposed that 
requires the activity of VEGFR-2, Src, PI3 Kinase, Akt and mTOR (summarised in Figure 
3.31).  
To test whether Akt phosphorylation is directly dependent on the presence of MT1-MMP, 
various concentrations of MT1-WT were expressed in MCF-7 cells. As shown in Figure 
3.8A, expression of MT1-WT led to a dose-dependent increase of Akt phosphorylation at 
S473 and T308. Accordingly, transduction with various MOI of MT1-WT expressing 
adenovirus led to an increase in mTOR phosphorylation at S2448 (Figure 3.7).  
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Figure 3.7: MT1-MMP expression increases mTOR phosphorylation 
MCF-7 cells were transduced with indicated MOI of MT1-WT expressing adenovirus. Cell lysates were 
immunoblotted with an anti-pS2448-mTOR, anti-mTOR, anti-MT1-MMP (LEM-2/15.8) or an anti-ß-Actin 
antibody. Rad, empty adenoviral control vector.  
 
Consistent with the immunoblotting results (Figure 3.8A), immunofluorescence analyses 
of MT1-WT transfected MCF-7 cells showed an increase in Akt phosphorylation at S473 
compared to the untransfected control cell (Figure 3.8B, i). MT1-MMP and pS473-Akt 
were routinely found to co-localise in intracellular vesicles and mainly at membrane 
protrusions of MCF-7 cells, potentially at the leading edge of the cell (Figure 3.8B, iv, 
arrows). Figure 3.8B, v shows the strong co-localisation of MT1-MMP, Akt and pS473-
Akt within the orthogonal z/x- section along the y-axis of these protrusive membrane 
structures.  
The co-localisation between MT1-MMP and Akt or MT1-MMP and pS473-Akt, 
respectively, are presented in cytofluorograms using the Volocity 3D imaging and analysis 
software (Figure 3.8C). Following correction of background fluorescence (as described in 
chapter 2.2.4.3.2), co-localisation co-efficients were calculated for each of the proteins. 
Thus, 90% of total MT1-MMP was found to co-localise with pS473-Akt or Akt, 
respectively, and 53.8% of phosphorylated Akt co-localised with MT1-MMP. Only 12.3% 
of total Akt was found in the same complex with MT1-MMP, since MT1-MMP was only 
expressed in one of the two analysed cells (Figure 3.8B). As expected, the antibody against 
phosphorylated Akt was able to detect an active subpopulation of Akt (with co-localisation 
co-efficient (CL): CL(Akt) = 0.179 and CL(pS473-Akt) = 0.757).  
 
These data indicate that MT1-MMP expression increases activation of Akt in MCF-7 cells, 
and therefore suggest a role for MT1-MMP in the Akt signalling pathway. 
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Figure 3.8: MT1-MMP expression increases Akt phosphorylation 
(A) MCF-7 cells were transfected with increasing concentrations of MT1-WT and cell extracts were 
immunoblotted with an anti-pS473-Akt, anti-pT308-Akt, anti-Akt, anti-MT1-MMP (LEM-2/15.8) or an anti-
ß-Actin antibody. (B) MT1-WT transfected MCF-7 cells were immunostained with an anti-pS473-Akt 
(AlexaFluor® 488 secondary, i), anti-Akt (AlexaFluor® 546 secondary, ii) and an anti-MT1-MMP antibody 
(N175/6; Cy5 secondary, iii). Arrows in the merged picture indicate co-localisation of Akt, phosphorylated 
Akt and MT1-MMP within the perinuclear region and at membrane protrusions (iv). Inset panels show 
magnified portions of each merged image, as indicated (dashed squares). Serial images present orthogonal 
sections along the y-axis of the merged confocal laser scanning micrograph (v). The white scale bars present 
a distance of 25 μm. (C) Co-localisation histograms between MT1-MMP and pS473-Akt or Akt. Similar 
expression and co-localisation is shown by accumulation of pixels along the y = x axis.  
 
3.1.4 MT1-MMP increases phosphorylation of Src 
 
The previously described requirement for Src 73 (Figure 3.5A) in the MT1-MMP mediated 
VEGF-A expression and the observed MT1-MMP dependent phosphorylation of Akt and 
mTOR, led to the hypothesis that MT1-MMP expression could affect the phosphorylation 
level of Src. Src is consistently expressed at low levels in wild-type MCF-7 cells and 
especially its phosphorylation form (pY416-Src) was difficult to detect using 
immunological detection methods (Figure 3.9A). In order to increase the level of pY416-
Src detection, Src was routinely expressed in MCF-7 cells in a transient manner. 
Src expressing MCF-7 cells were transfected with MT1-WT and immunoblotted with an 
anti-pY416-Src and an anti-Src antibody. As shown in Figure 3.9B MT1-WT expression 
increased the level of Src phosphorylation at its Y416 residue significantly compared to Src 
only expressing cells, while total Src was expressed at similar levels. 
To obtain a better understanding of the signalling hierarchy leading to increased VEGF-A 
expression, MT1-WT and Src expressing cells were incubated for 24 hours with PP2, SH-
5, LY294002, SU4312 or DMSO control to define the position of Src phosphorylation 
within the proposed pathway (summarised in Figure 3.31). As shown in Figure 3.9B, Src 
phosphorylation at Y416 was effectively inhibited by PP2, SU4312 and SH-5 treatment. As 
incubation of cells with SH-5 led to a reproducible knockdown of MT1-MMP protein 
levels, making the interpretation of the role of Akt difficult as described before (chapter 
3.1.3), these data indicate that Src is activated down-stream of VEGFR-2. 
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Figure 3.9: MT1-MMP expression increases the phosphorylation of Src at Y416 
(A) MCF-7 cells were transfected with either pcDNA3.1 vector control or MT1-WT and cell extracts were 
immunoblotted with an anti-pY416-Src, anti-Src, anti-MT1-MMP (LEM-2/15.8) or an anti-ß-Actin antibody. 
(B) Src expressing MCF-7 cells were transfected with either pcDNA3.1 or MT1-WT, as indicated. DMSO, 
PP2, SH-5, LY294002 or SU4312 were added for 24 hours. Lysates were immunoblotted with an anti-
pY416-Src, anti-Src, anti-MT1-MMP (LEM-2/15.8) or an anti-ß-Actin antibody. (C) MCF-7 cells were 
transfected with either pcDNA3.1 or MT1-WT, as indicated, Total Src was immunoprecipitated with an anti-
Src antibody (clone 327) and immunoprecipitates were immunoblotted with an anti-pY416-Src antibody 
(clone 100F9). Asterisk indicates the size of the IgG heavy chain. 
 
The same increase in Src phosphorylation was also observed in only MT1-WT transfected 
cells compared to pcDNA3.1 control after immunoprecipitating endogenous Src and 
subsequently detecting pY416-Src by immunoblot (Figure 3.9C).  
These findings indicate, that Src transfection is not necessary to observe the MT1-MMP 
increase in Src phosphorylation at Y416, and that transfection is used in this system to 
increase the detection level of pY416-Src. In order to visualise the observed effect of MT1-
MMP transfection on Src phosphorylation (Figure 3.9B, C), MCF-7 cells were co-
transfected with Src and MT1-WT and the spatial distribution of pY416-Src, total Src and 
MT1-MMP was assessed by immunofluorescence (Figure 3.10). 
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Figure 3.10: MT1-MMP increases Src phosphorylation on Y416 and co-localises with 
pY416-Src 
Src expressing MCF-7 cells were either transfected with pcDNA3.1 (A – C) or MT1-WT (D – I). 
Localisation of active Src was detected using the anti-pY416-Src antibody (AlexaFluor® 488 secondary), 
total Src using an anti-Src antibody (AlexaFluor® 546 secondary) and MT1-MMP was detected with an 
antibody raised to the MT1-MMP extracellular domain (N175/6, Cy5 secondary). Arrows indicate pY416-
Src at the cell periphery and total Src localising at the perinuclear region of the cell, revealing a Src 
activation gradient (H). The orthogonal section along the indicated line from the nucleus to the cell surface 
(G) demonstrates the distribution of both, pY416-Src (green) and total Src (red) (I). The white scale bars 
present a distance of 10 μm. 
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In MCF-7 cells expressing only Src, the kinase was detected throughout the cell cytoplasm 
with a higher intensity of staining observed within the perinuclear region (Figure 3.10B). 
In these cells, the pY416-Src form was difficult to detect (Figure 3.10A). In contrast, in 
cells expressing Src and MT1-WT, the pY416-Src form could be clearly detected (Figure 
3.10D) and was found to co-localise with MT1-MMP at or close to the plasma membrane 
(white arrow, Figure 3.10D, F). A clear gradient of pY416-Src staining across the 
cytoplasm of MCF-7 cells was observed (Figure 3.10H). By cutting an optical orthogonal 
section along the x/y-axis of the cell from the nuclear region towards the cell surface, the 
relative fluorescence intensity in relation to localisation can be depicted in a histogram 
(Figure 3.10I). The phosphorylated form of Src was increasingly enriched towards the cell 
surface, whereas the level of total Src was higher in the perinuclear region of the cell 
(Figure 3.10I). Since Src and pY416-Src were detected with two antibodies conjugated to 
different fluorochromes, and being poly- and monoclonal, respectively, the absolute 
fluorescence intensities could not be compared directly. The co-localisation of pY416-Src 
and Src was determined with CL(pY416-Src) = 0.792 and CL(Src) = 0.269, indicating that ~80% 
of the pY416-Src antibody co-localised with Src and therefore detected a subset (27%) of 
total Src protein.  
 
3.1.5 MT1-MMP is found in a complex with Src 
 
Src activity has been implicated in various aspects of MT1-MMP functions. Recently, 
Labrecque et al. reported that Src-dependent phosphorylation of caveolin-1 in bovine 
aortic endothelial cells (BAEC) induced its association with MT1-MMP 119. The MT1-
MMP – phosphorylated caveolin-1 complex was found to recruit Src and subsequently 
inhibit its kinase function as a negative feedback loop. It has been further shown that the 
MT1-MMP intracellular tyrosine residue (Y573) is phosphorylated in a Src-dependent way 
249.  
In the MCF-7 system, inhibition of Src activity was found to reduce VEGF-A mRNA 
levels in MT1-MMP transfected cells (Figure 3.5A, Table 3.1). Furthermore, expression of 
MT1-WT in MCF-7 cells induced phosphorylation of Src at its Y416 residue (Figure 3.9B,C 
and Figure 3.10), and confocal immunofluorescent microscopy revealed the co-localisation 
of MT1-MMP with Src and especially with pY416-Src (Figure 3.10). In order to test 
whether MT1-MMP can directly associate with Src, a mammalian-two hybrid assay was 
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performed. cDNAs of the MT1-MMP intracellular domain (ICD) and full-length Src were 
sub-cloned into pAct and pBind vectors, containing a GAL4 DNA binding or a VP16 
transactivation domain, respectively (Figure 3.11A). Analysis of binding between the two 
proteins of interest is achieved by co-transfecting cells with the Luciferase reporter gene 
construct (pG5luc) and both expression vectors followed by detection of luminescence 
(Figure 3.11B). As shown in Figure 3.11C, expression of the MT1-MMP ICD in the pAct 
and Src in the pBind vector increased luminescence significantly compared to cells 
transfected with the empty control vectors (P < 0.0001) in both HeLa and MCF-7 cells.  
 
 
Figure 3.11: The intracellular domain of MT1-MMP interacts with Src 
(A) Representation of the GAL4 domain containing pAct and the VP16 domain containing pBind vectors. 
cDNAs of the MT1-MMP ICD and Src were sub-cloned into each vector. MCR, multiple cloning region. (B) 
Schematic presentation of the mammalian-two hybrid assay. Cells were co-transfected with 1 ?g Luciferase 
reporter gene construct pG5luc, 1 ?g pAct and 1 ?g pBind vector, containing the genes of interest (x and y), 
and the expression of the Luciferase reporter gene was detected by luminescence. (C) HeLa and MCF-7 cells 
were co-transfected with pG5luc, pAct and pBind constructs, containing Src and MT1-MMP ICD mutants, as 
indicated. Data represent the mean luminescence in arbitrary units (AU) ± S.E.M. of 6 independent 
replicates. pA, pAct; pB, pBind. 
 
As recommended by the manufacturer, protein-protein interactions were tested in both 
directions (i.e. exchange the inserts between pAct and pBind), due to the possible 
inhibitory effect of the fused domains (Promega). These data suggest that the MT1-MMP 
ICD is directly binding to Src.  
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To identify the motifs within the MT1-MMP ICD that are involved in the interaction 
between MT1-MMP and Src, MT1-MMP ICD triple amino acid mutants were generated 
(Figure 3.12). The MT1-MMP C574 residue 73 as well as the LLY573 and DKV582 motifs 
have been shown to play a role in MT1-MMP mediated VEGF-A expression (Figure 
3.25B) and were therefore tested in the mammalian-two hybrid system. As shown in 
Figure 3.12, transfection of pAct (pA)-Src expressing MCF-7 cells with pBind (pB)-MT1-
ICD or the pB-MT1-DKV582 mutant induced a significant increase in reporter gene 
expression as compared to the empty vector control (P < 0.001 and P < 0.0001, 
respectively). In contrast, mutation of the LLY573 or CQR576 motifs did not affect 
Luciferase expression compared to the empty vector control, suggesting that the 
LLYCQR576 sequence is involved in the interaction with Src (Figure 3.12). 
 
Figure 3.12: The interaction between the MT1-MMP ICD and Src in a mammalian 
two-hybrid system depends on the LLY573 and CQR576 sequence 
MCF-7 cells were transfected with either empty pAct and pBind vectors as control or with pAct-Src and 
pBind-MT1-ICD cDNA constructs, and were co-transfected with the reporter gene vector pG5luc. Interaction 
between MT1-MMP ICD and Src was detected by luminescence of Luciferase expression. Data represent the 
mean luminescence of 6 independent replicates ± S.E.M with P < 0.001 (**) and P < 0.0001 (***) compared 
to empty vector control. AU, arbitrary units.  
 
To confirm that the interaction between MT1-MMP and Src observed in the mammalian-
two hybrid assay occurs in a cellular system using full-length MT1-MMP, a co-
immunoprecipitation assay was performed. Src expressing MCF-7 cells were transfected 
with or without MT1-WT and Src was immunoprecipitated with an anti-Src antibody 
(Clone 327). MT1-MMP was immunoprecipitated with an anti-MT1-MMP antibody raised 
against the ICD as control (Figure 3.13A). Immunoprecipitates were immunoblotted with 
an anti-MT1-MMP antibody. As shown in Figure 3.13A MT1-MMP was found to co-
immunoprecipitate with Src. 
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Figure 3.13: MT1-MMP co-immunoprecipitates with Src independent of its 
intracellular domain 
(A) Src expressing MCF-7 cells were transfected with either pcDNA3.1 or MT1-WT and 
immunoprecipitated with an anti-Src antibody or an anti-MT1-MMP ICD specific antibody (ab28209) as a 
control. Immunoprecipitates were detected with an anti-MT1-MMP antibody (N175/6). The asterisk indicates 
the IgG heavy chain. (B) Src expressing MCF-7 cells were transfected with pcDNA3.1, MT1-WT or 
different MT1-MMP extra- and intracellular domain mutants and immunoprecipitated with an anti-Src 
antibody. Immunoblots show MT1-MMP levels (LEM-2/15.8) of the immunoprecipitates and Input control.  
 
To investigate the role of the MT1-MMP intracellular domain in forming a complex with 
Src, various MT1-MMP intracellular domain mutants were generated (summarised in 
Figure 3.25A). Src expressing MCF-7 cells were co-transfected with the MT1-MMP 
catalytic inactive MT1-E240A as well as various MT1-MMP ICD mutants (MT1-C574, 
MT1-Y573A, MT1-571AAA573, MT1-580AAA582) and cell extracts were co-
immunoprecipitated with an anti-Src antibody as previously described. As presented in 
Figure 3.13B, none of the constructs tested inhibited the formation of the MT1-MMP – Src 
complex, suggesting that the interaction in this system does not depend on the MT1-MMP 
ICD and may involve a third party protein. MT1-MMP did not bind unspecifically to the 
magnetic beads as shown for cells which did not express Src (Figure 3.13B). The total 
amount of MT1-MMP present in the various complexes was not quantifiable due to the 
variation of transfection efficiencies observed for the various constructs, as shown in the 
Input control (Figure 3.13B).  
 
3.1.6 MT1-MMP Y573 is required for Src phosphorylation 
 
MT1-MMP expression in MCF-7 cells has been shown previously to induce 
phosphorylation of Src at its Y416 residue (Figure 3.9B, C and Figure 3.10). To determine 
the MT1-MMP motif involved in the phosphorylation of Src, MCF-7 cells were transfected 
with the MT1-MMP catalytic inactive MT1-E240A as well as various MT1-MMP ICD 
Results                                                                                                                                                             88 
mutants (MT1-C574, MT1-Y573A, MT1-571AAA573, MT1-580AAA582) and the spatial 
distribution of pY416-Src and MT1-MMP was assessed by immunofluorescent staining 
(Figure 3.14). As expected, expression of MT1-WT induced an increase in pY416-Src 
staining throughout the cell and at distinct regions at or close to the plasma membrane. A 
similar result was observed in cells expressing MT1-MMP with mutations of the E240 
(MT1-E240A) or C574 (MT1-C574A) residue or the DKV582 (MT1-580AAA582) motif 
(Figure 3.14; arrowheads). Interestingly, phosphorylation of Src at Y416 was ablated in 
cells expressing the MT1-?ICD, MT1-Y573A or MT1-571AAA573 mutants (arrows). 
The co-localisation between MT1-MMP and pY416-Src was quantified using the Volocity 
3D imaging and analysis software. Single optical sections of various MT1-MMP 
transfectants were obtained by confocal microscopy and analysed for n = 15 cells per 
transfectant. Each pixel was analysed per confocal laser scanning micrograph for the 
fluorescence of pY416-Src and MT1-MMP, plotted in a two-dimensional cytofluorogram 
as described previously and each channel was corrected for background fluorescence (as 
described in chapter 2.2.4.3.2). The cytofluorograms in Figure 3.14 represent scatter plots 
of co-localisation prior to background correction. The co-localisation co-efficients were 
calculated and plotted in Figure 3.15. MT1-MMP was found to co-localise with pY416-Src 
in MT1-WT and MT1-E240A, MT1-C574A and MT1-580AAA582 mutants, whereas 
mutation of the Y573 (MT1-Y573A) residue, the LLY573 (MT1-571AAA573) motif or 
deletion of the intracellular domain (MT1-?ICD) ablated co-localisation due to the reduced 
phosphorylation level of Src in cells expressing these constructs (Figure 3.14; Figure 3.15, 
P < 0.0001 compared to MT1-WT transfected cells). 
 
Taken together, these data suggest a role of the intracellular MT1-MMP Y573 residue in Src 
activation.  
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Figure 3.14: MT1-MMP Y573 modulates Src phosphorylation in MCF-7 cells 
MCF-7 cells were transfected with various MT1-MMP intracellular domain mutants as well as the catalytic 
inactive MT1-E240A construct. The localisation of active Src (pY416-Src) was detected using the anti-
pY416-Src antibody (AlexaFluor® 488 secondary, green) and MT1-MMP was detected with an antibody 
raised to the MT1-MMP extracellular domain (N175/6, Cy5 secondary, blue). Empty arrowheads indicate 
pY416-Src at the cell periphery, whereas arrows show the decreased phosphorylation of Src in MT1-MMP 
Y573 mutants. Cytofluorograms of co-localisation were generated with the Volocity 3D imaging and analysis 
software. Similar expression and co-localisation is shown by accumulation of pixels along the y = x axis. The 
white scale bars present a distance of 25 μm. 
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Figure 3.15: Quantification of pY416-Src – MT1-MMP co-localisation 
MCF-7 cells were co-transfected with Src and various MT1-MMP mutants. The co-localisation co-efficients 
of different MT1-MMP transfectants with active Src (pY416-Src) was determined by using the Volocity 3D 
imaging and analysis software of single optical confocal sections. Data represent the co-localisation co-
efficients of 15 cells ± S.E.M. with P < 0.0001 (***).  
 
3.1.7 MT1-MMP and Src co-localise in RhoB positive endosomes 
 
Sandilands et al. have reported that Src is phosphorylated during transit from the 
perinuclear region towards the plasma membrane 253. This activation was shown to take 
place in RhoB positive cytoplasmic endosomes associated with the perinuclear recycling 
compartment. The previously described requirement for MT1-MMP, especially its 
intracellular Y573 residue, in Src phosphorylation led to the hypothesis that MT1-MMP 
dependent Src phosphorylation might occur in RhoB positive endosomes. 
To test whether MT1-MMP co-localises with Src in RhoB positive endosomes, Src 
expressing MCF-7 cells were transfected with MT1-WT and the localisation of MT1-
MMP, RhoB and Src was assessed by confocal microscopy. As shown in Figure 3.16E, 
MT1-MMP was found to co-localise with RhoB in MCF-7 cells and was also detected 
within the same structure as RhoB and pY416-Src (Figure 3.16F, black arrows). The white 
arrow confirms the co-localisation between MT1-MMP and pY416-Src, as observed before 
(Figure 3.16F and Figure 3.14). MT1-MMP has been shown to be redistributed to invasive 
structures during cell migration in Rab8 positive exocytic endosomes 36. However, there is 
no evidence so far that MT1-MMP is present in RhoB containing intracellular vesicles.  
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These data suggest that MT1-MMP and Src may co-traffic to the plasma membrane in 
RhoB positive endosomes and that MT1-MMP might play a role in Src phosphorylation 
during this transit. 
 
 
Figure 3.16: MT1-MMP co-localises with the active phosphorylated form of Src 
(pY416-Src) in RhoB positive endosomes  
Src expressing MCF-7 cells were transfected with MT1-WT. The localisation of pY416-Src (AlexaFluor® 
488 secondary), RhoB (AlexaFluor® 546 secondary) and MT1-MMP (N175/6, Cy5 secondary) was detected 
by confocal microscopy. Inset panels show magnified portions of each merged image, as indicated (dashed 
squares). The white scale bars present a distance of 10 μm. 
 
3.1.8 MT1-MMP is found in a complex with active Src and VEGFR-2 
 
The indirect interaction observed between MT1-MMP and Src in the immunoprecipitation 
assay (Figure 3.13B) led to the hypothesis that another protein was involved in the 
formation of a higher order complex. Since VEGFR-2 activity was shown to be required in 
MT1-MMP induced VEGF-A expression (Figure 3.5A) and it is a key receptor in the 
VEGF-A signalling pathway, it was tested whether VEGFR-2 can be found in a complex 
with both MT1-MMP and Src.  
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Figure 3.17: MT1-MMP, VEGFR-2 and the phosphorylated form of Src (Y416) are 
found in a complex 
(A) MCF-7 cells were transfected with pcDNA3.1 or MT1-WT and immunoprecipitated with an anti-
VEGFR-2 antibody. Immunoprecipitates as well as Input control samples were immunoblotted with an anti-
MT1-MMP (LEM-2/15.8), anti-Src or an anti-ß-Actin antibody. (B) MCF-7 cells were transfected with 
pcDNA3.1 or Src and cell lysates were immunoprecipitated with an anti-VEGFR-2 antibody. 
Immunoprecipitates and Input control samples were immunoblotted with an anti-Src or an anti-pY416-Src 
antibody. (C) MCF-7 cells were co-transfected with MT1-WT and Src. The localisation of pY416-Src 
(AlexaFluor® 488 secondary, i), VEGFR-2 (AlexaFluor® 546 secondary, ii) and MT1-MMP (Cy5 
secondary, iii) was detected. Arrows in the merged picture (iv) indicate co-localisation of pY416-Src, 
VEGFR-2 and MT1-MMP at or close to the plasma membrane. Inset panel shows magnified portion of the 
merged image, as indicated (dashed square). Cytofluorograms show co-localisation of pY416-Src (green) and 
MT1-MMP (blue) (v) or VEGFR-2 (red) and MT1-MMP (blue) (vi). Similar expression and co-localisation 
is shown by accumulation of pixels along the y = x axis. The white scale bars present a distance of 25 μm. 
 
To test this hypothesis, lysates prepared from cells transfected with pcDNA3.1 or MT1-
WT (Figure 3.17A) as well as pcDNA3.1 or Src (Figure 3.17B) were immunoprecipitated 
with an anti-VEGFR-2 antibody. As shown in Figure 3.17A and B, MT1-MMP, Src and in 
particular the pY416-Src phosphorylation form of Src were found to co-immunoprecipitate 
with VEGFR-2. 
In order to visualise the co-localisation between these proteins, MCF-7 cells expressing 
MT1-MMP and Src were stained for pY416-Src, VEGFR-2 and MT1-MMP. All proteins 
co-localised in MCF-7 cells, primarily at or close to the plasma membrane (Figure 3.17C, 
arrows), as visualised by the cytofluorograms between MT1-MMP and pY416-Src (Figure 
3.17C v) and between MT1-MMP and VEGFR-2 (Figure 3.17C vi). The co-localisation 
between MT1-MMP – VEGFR-2 – pY416-Src was also routinely observed in membrane 
protrusions, as seen within three-dimensional reconstructions of z-stacks taken every 0.2 
?m as confocal images (Figure 3.18A, B). This co-localisation could be visualised by 
cutting optical sections either along the z-axis (Figure 3.18C, D) or by cutting an 
orthogonal z/x- section along the y-axis through these protrusive structures (Figure 3.18E, 
F).  
Membrane protrusions such as podosomes and invadopodia are found in various tumour 
cell lines in in vitro systems and were shown to play a key role in cell migration, matrix 
degradation and cell signalling (reviewed in 254). Both membrane structures were found to 
exhibit a distinct expression of protein components. However, the data obtained on the 
MT1-MMP – VEGFR-2 – pY416-Src complex in this study are not sufficient to 
unambiguously identify these protrusive structures as podosomes or lamellipodia. 
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Figure 3.18: The MT1-MMP – VEGFR-2 – pY416-Src complex is expressed in dorsal 
membrane protrusions 
MCF-7 cells were transfected with MT1-WT and Src. The localisation of active Src was detected with an 
anti-pY416-Src (AlexaFluor® 488 secondary), VEGFR-2 was detected with an anti-VEGFR-2 antibody 
(AlexaFluor® 546 secondary) and MT1-MMP was detected with an antibody raised to the MT1-MMP 
extracellular domain (N175/6, Cy5 secondary). (A,B) Three-dimensional reconstruction of confocal optical 
images taken every 0.2 ?m along the z-axis. (C,D) Series of confocal images taken along the z-axis. (E,F) 
Series of confocal images taken from the orthogonal sections along the x/y-axis  
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In order to identify which regions of MT1-MMP were involved in the complex formation 
with VEGFR-2, MCF-7 cells expressing various MT1-MMP extracellular, intracellular and 
transmembrane domain mutants were tested by immunoprecipitation (constructs 
summarised in Figure 3.25A). The MT1-E240A mutant as well as all the ICD mutants 
tested co-immunoprecipitated with VEGFR-2 (Figure 3.19A). In contrast, replacement of 
the MT1-MMP transmembrane domain with that of APP (MT1-TMD-APP), which is a 
type-1 transmembrane protein with a transmembrane domain of 24 amino acids that is 
functionally unrelated to MT1-MMP, ablated the complex formation between MT1-MMP 
and VEGFR-2 (Figure 3.19B). 
 
Figure 3.19: The MT1-MMP – VEGFR-2 complex formation depends on the MT1-
MMP transmembrane domain, but is independent of its catalytic and intracellular 
domains 
(A) MCF-7 cells were transfected with pcDNA3.1, MT1-WT or MT1-MMP extra- and intracellular domain 
mutants and cell extracts were immunoprecipitated with an anti-VEGFR-2 antibody. Immunoprecipitates and 
Input controls were immunoblotted with an anti-MT1-MMP (LEM-2/15.8), anti-Src or an anti-?-Actin 
antibody. (B) Cells were transfected with either MT1-WT or MT1-TMD-APP. Lysates were 
immunoprecipitated with an anti-VEGFR-2 antibody and immunoprecipitates and Input samples were 
immunoblotted with an anti-MT1-MMP antibody (LEM-2/15.8), an anti-Src antibody or an anti-?-Actin 
antibody. 
 
A similar result was observed when most of the MT1-MMP ECD (MT1-?ECD-FLAG and 
MT1-?ECD-EGFP) was deleted or when the MT1-MMP hemopexin domain was replaced 
by GFP (MT1-?HPX) (Figure 3.20A, B). These findings suggest that the MT1-MMP 
hemopexin and transmembrane domains are required for the MT1-MMP – VEGFR-2 
complex formation.  
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In order to confirm the role of the MT1-MMP extracellular domain (ECD) and in 
particular the role of the hemopexin domain, in the formation of the MT1-MMP – 
VEGFR-2 complex, an ELISA assay was performed. Immobilised rh-VEGFR-2-Fc or milk 
control proteins were incubated with purified recombinant MT1-MMP extracellular 
domain (rh-MT1-Ecto), recombinant catalytic inactive extracellular domain (rh-MT1-Ecto-
E240A) or recombinant catalytic domain (rh-MT1-Cat). rh-VEGF165 was used as a positive 
control for binding to rh-VEGFR-2-Fc (Figure 3.20C). Binding of proteins to rh-VEGFR-
2-Fc or control protein was detected using the anti-MT1-MMP catalytic domain (LEM-
2/15.8) or the anti-VEGF antibody. The rh-MT1-Ecto and rh-MT1-Ecto-E240A were 
found to bind to rh-VEGFR-2 significantly over control (P < 0.0001; Figure 3.20C), 
confirming the cell based co-immunoprecipitation data (Figure 3.20A,B and Figure 
3.19A). In contrast, no interaction between rh-VEGFR-2 and rh-MT1-Cat was detected in 
this assay, despite the binding of rh-MT1-Cat to TIMP-2 (data not shown), thus suggesting 
that the MT1-MMP hemopexin domain/stalk region is required for MT1-MMP binding to 
VEGFR-2. The difference in binding observed between rh-MT1-Ecto and rh-MT1-Ecto-
E240A to rh-VEGFR-2 probably resulted from the partial autocatalytic degradation of rh-
MT1-Ecto which occurs during the preparation of the recombinant protein (Figure 3.20D, 
Input control). Thus, degradation products, which lack the catalytic domain and were not 
detected by the anti-MT1-MMP catalytic domain antibody, could compete with the full-
length MT1-MMP ECD for VEGFR-2 binding.  
The role of the MT1-MMP extracellular domain in VEGFR-2 binding could be confirmed 
by co-immunoprecipitating recombinant VEGFR-2-Fc – MT1-MMP complexes. rh-
VEGFR-2-Fc and rh-MT1-MMP domains were mixed at a 1:1 molar ratio and a complex 
was formed after 30 minutes incubation at 37˚C, as described in chapter 2.2.4.6. These 
complexes were immunoprecipitated with an anti-VEGFR-2 antibody, subjected in 
addition to Input control samples to SDS-PAGE and total protein was visualised by 
coomassie staining. As shown in Figure 3.20D, rh-MT1-Ecto, rh-MT1-Cat and rh-
VEGFR-2-Fc could be detected in the Input control, although at varying levels. As 
expected, VEGFR-2 was found within the immunoprecipitates, indicating the successful 
immunoprecipitation. Furthermore, the rh-MT1-MMP extracellular domain was found to 
co-immunoprecipitate with rh-VEGFR-2 whereas the MT1-MMP catalytic domain was not 
found in a complex with VEGFR-2. The MT1-MMP – VEGFR-2 complex formation was 
not affected by incubation of rh-MT1-Ecto with the function-blocking anti-MT1-MMP 
catalytic domain antibody LEM-2/15.8 (Figure 3.20D).  
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Figure 3.20: MT1-MMP interaction with VEGFR-2 depends on the MT1-MMP 
extracellular domain, potentially on the hemopexin domain 
(A,B) MCF-7 cells were transfected with either MT1-?ECD-FLAG or MT1-?ECD-EGFP (A) or MT1-
?HPX (B). Lysates were immunoprecipitated with an anti-VEGFR-2 antibody and immunoprecipitates and 
Input samples were immunoblotted with an anti-FLAG, anti-EGFP, anti-Src or an anti-MT1-MMP (LEM-
2/15.8) antibody. (C) A microtiter plate was either coated with 10 ?g/ml rh-VEGFR-2-Fc (black bars) or 
milk control protein (white bars). rh-MT1-Ecto, rh-MT1-Ecto-E240A, rh-MT1-Cat or rh-VEGF165 as positive 
control were added in an ELISA assay. Binding of rh-MT1-MMP domains and rh-VEGF165 to rh-VEGFR-2-
Fc and control protein is directly proportional to measured absorbance. Data represent mean absorbance ± 
S.E.M. with P < 0.0001 (***). AU, arbitrary units; ns, non-significant . (D) Complexes of rh-VEGFR-2-Fc 
and rh-MT1-Ecto or rh-MT1-Cat with or without pre-incubation with 10 μ/ml LEM-2 antibody were formed 
in solution for 30 minutes at 37ºC. Complexes were immunoprecipitated with an anti-VEGFR-2 antibody. 
Total protein of immunoprecipitates and Input control were visualised by Coomassie blue staining.  
 
Src has been reported to associate with VEGFR-2 in human vascular endothelial cells 255. 
As expected, Src as well as its pY416-Src phosphorylation form was shown to co-
immunoprecipitate with VEGFR-2 in MCF-7 cells (Figure 3.17B). The Src – VEGFR-2 
complex formation was impaired in protein extracts from cells transfected with MT1-MMP 
ECD or transmembrane domain deletion mutants (Figure 3.19 and Figure 3.20).  
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Accordingly, co-localisation between VEGFR-2 and pY416-Src was also found to be 
decreased in MT1-MMP Y573 mutants (MT1-Y573A, MT1-571AAA573 and MT1-?ICD), 
which showed little Src phosphorylation, as detected by immunofluorescence of various 
MT1-MMP mutants expressing MCF-7 cells (Figure 3.21). 
 
 
Figure 3.21: Quantification of VEGFR-2 – pY416-Src co-localisation 
MCF-7 cells were transfected with Src and various MT1-MMP mutants. The co-localisation co-efficients of 
VEGFR-2 with active Src (pY416-Src) were determined by using the Volocity 3D imaging and analysis 
software of single optical confocal sections. Data represent the co-localisation co-efficients of 15 cells ± 
S.E.M. with P < 0.001 (**) and P < 0.0001 (***).  
 
3.1.9 MT1-MMP expression induces VEGFR-2 cell surface localisation 
 
The interaction between MT1-MMP and VEGFR-2 led to the hypothesis that MT1-MMP 
expression in MCF-7 cells could affect the subcellular distribution of VEGFR-2. To test 
this hypothesis, Src expressing MCF-7 cells were transfected with either MT1-WT, various 
MT1-MMP extra- and intracellular domain mutants or a vector control and the localisation 
of VEGFR-2, pY416-Src and MT1-MMP was assessed by immunofluorescence. In Src 
expressing cells, VEGFR-2 was mainly localised in intracellular vesicles throughout the 
cell cytoplasm (Figure 3.24A, ii, arrow head). In contrast, expression of MT1-WT and Src 
increased staining of the phosphorylated form of Src at Y416, as previously observed 
(Figure 3.9, Figure 3.10, Figure 3.22, Figure 3.24A, iv). In addition, a clear cellular 
redistribution of VEGFR-2 was observed in these cells (Figure 3.24A, v).  
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Figure 3.22: Co-localisation between MT1-MMP and VEGFR-2 is not affected by 
MT1-MMP catalytic or intracellular domain mutations 
Src expressing MCF-7 cells were transfected with various MT1-MMP intracellular domain mutants as well 
as the catalytic inactive MT1-E240A construct. The localisation of VEGFR-2 and MT1-MMP was detected 
with an anti-VEGFR-2 (AlexaFluor® 546 secondary, red) and an anti-MT1-MMP (N175/6, Cy5 secondary, 
blue) antibody. Cytofluorograms of co-localisation were generated with the Volocity 3D imaging and 
analysis software. Similar expression and co-localisation is shown by accumulation of pixels along the y = x 
axis. The white scale bars present a distance of 25 μm. 
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VEGFR-2 was found to co-localise with pY416-Src (Figure 3.24A, iv, arrows) and MT1-
MMP (Figure 3.22, Figure 3.24A, vi, arrows). Quantification of the co-localisation 
revealed similar results for the MT1-E240A and all intracellular domain mutants tested 
(Figure 3.22, Figure 3.23). Expression of the MT1-?ICD construct led to a similar 
VEGFR-2 staining pattern as MT1-WT expressing cells, however the co-localisation co-
efficient of VEGFR-2 versus MT1-MMP was slightly decreased (Figure 3.23).  
 
 
Figure 3.23: Quantification of MT1-MMP co-localisation with VEGFR-2 
MCF-7 cells were transfected with Src and various MT1-MMP mutants. The co-localisation co-efficients of 
different MT1-MMP transfectants with VEGFR-2 were determined by using the Volocity 3D imaging and 
analysis software of single optical confocal sections. Data represent the co-localisation co-efficients of 15 
cells ± S.E.M. with P < 0.0001 (***). 
 
Interestingly, expression of the MT1-MMP extracellular domain deletion mutant (MT1-
?ECD-FLAG) did not seem to significantly affect the VEGFR-2 localisation pattern in 
these cells when compared to vector control transfected cells (Figure 3.24B, ii).  
The MT1-MMP extracellular domain dependent staining of VEGFR-2 observed at or close 
to the plasma membrane led us to test whether MT1-MMP regulates localisation of 
VEGFR-2 at the cell surface. Therefore, MT1-WT, MT1-?ECD-FLAG, MT1-?ICD or 
MT1-TMD-APP constructs were expressed in MCF-7 cells and the cell surface expression 
of VEGFR-2 was analysed by flow cytometry. As a positive control, VEGFR-2 cell 
surface expression was analysed in MCF-7 cells transfected with pcDNA3.1 and 
stimulated for 30 minutes with 100 ng/ml rh-VEGF165, as this has been shown to increase 
VEGFR-2 expression at the cell surface of endothelial cells 256.  
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Figure 3.24: MT1-MMP expression increases the cell surface localisation of VEGFR-2 
(A) Src expressing MCF-7 cells were transiently transfected with either pcDNA3.1 (i – iii) or MT1-WT (iv – 
vi) and the localisation of pY416-Src (AlexaFluor® 488 secondary, i, iv), VEGFR-2 (AlexaFluor® 546 
secondary, ii, v) and MT1-MMP (N175/6, Cy5 secondary, iii, vi) was detected. Empty arrowhead indicates 
the vesicular staining pattern of VEGFR-2 in only Src expressing cells, whereas arrows show the common 
localisation of pY416-Src, MT1-MMP and VEGFR-2 at or close to the cell surface of cells expressing MT1-
WT and Src. The white scale bars present a distance of 10 μm. (B) MCF-7 cells were transfected with MT1-
?ECD-FLAG and the localisation of VEGFR-2 and MT1-MMP was assessed using an anti-FLAG (Cy5 
secondary, i) and an anti-VEGFR-2 (AlexaFluor® 488, ii) antibody. Panel iv shows magnified portion of the 
merged image, as indicated (dashed square). The white scale bars present a distance of 10 μm. (C) Cells were 
transfected with pcDNA3.1, MT1-WT, MT1-?ECD-FLAG, MT1-?ICD or MT1-TMD-APP and the cell 
surface localisation of VEGFR-2 was assessed by flow cytometry. As a positive control pcDNA3.1 
transfected cells were stimulated for 30 minutes with 100 ng/ml rh-VEGF165. Data represent the mean 
fluorescence of 4 independent biological replicates ± S.E.M. with P < 0.05 (*) and P < 0.0001 (***) 
compared to pcDNA3.1 control. 10,000 events were counted per sample. AU, arbitrary units.  
 
As observed by others in endothelial cells, treatment with rh-VEGF165 significantly 
increased the localisation of VEGFR-2 at the cell surface by 50.5% (Figure 3.24C, P < 
0.0001 compared to pcDNA3.1 transfected cells). VEGFR-2 cell surface localisation was 
also increased in MT1-WT and MT1-?ICD expressing cells by ~40% (P < 0.0001) and 
33% (P < 0.05), respectively, compared to cells transfected with vector control. In contrast, 
expression of MT1-?ECD-FLAG and MT1-TMD-APP did not affect the cell surface 
expression of VEGFR-2 (Figure 3.24C), suggesting that the increased cell surface 
expression of VEGFR-2 is dependent on the extracellular and transmembrane domains of 
the protease. 
 
3.1.10 MT1-MMP induced VEGF-A mRNA expression depends on its 
extracellular, transmembrane and intracellular domains 
 
MT1-MMP activity as well as the intracellular cysteine residue (C574) has previously been 
found to be involved in the MT1-MMP-modulated VEGF-A expression 73. In order to 
identify if other regions of MT1-MMP were required, deletion and substitution cDNA 
constructs were generated and tested for their effect on VEGF-A mRNA expression 
(summarised in Figure 3.25A). The point mutation of the glutamic acid to alanine (E240A) 
has been previously shown to ablate catalytic activity of MT1-MMP 88. As expected, MT-
E240A was unable to stimulate VEGF-A expression in MCF-7 cells (Figure 3.25B). A 
similar result was obtained when most of the MT1-MMP extracellular domain was 
replaced with a Flag (MT1-?ECD-FLAG) or an EGFP (MT1-?ECD-EGFP) tag.  
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Figure 3.25: Deletion and substitution mutants of MT1-MMP catalytic, hemopexin, 
transmembrane and intracellular domain ablate MT1-MMP induced VEGF-A 
expression 
(A) Schematic representation of various MT1-MMP extracellular, transmembrane and intracellular domain 
deletion and substitution mutants. S, signal sequence; Pro, Propeptide; CAT, catalytic domain; HPX, 
hemopexin domain; stalk, amino acids P509 - S538; TMD, transmembrane domain; ICD, intracellular domain; 
APP, ß-amyloid precursor protein; FLAG, FLAG tag (DYKDDDDK); EGFP, Enhanced Green Fluorescent 
Protein. (B) Various MT1-MMP mutants were transiently expressed in MCF-7 cells and VEGF-A mRNA 
levels were detected by TaqMan® Real-Time PCR. Relative expression levels of VEGF-A were normalised 
to mRNA levels of the house-keeping gene GAPDH. Data represent the mean VEGF-A expression in fold-
change compared to pcDNA3.1 vector control (dotted line) ± S.E.M. with P < 0.05 (*) and P < 0.001 (**) 
compared to MT1-WT transfected control. Data show the mean expression of at least 5 independent 
experiments (MT1-WT, n = 16; MT1-E240A, n = 11; MT1-?ECD-FLAG, n = 5; MT1-?HPX, n = 6; MT1-
TMD-APP, n = 6; MT1-C574A, n= 14; MT1-Y573A, n = 5; MT1-571AAA573, n= 14; MT1-580AAA582, n = 9; 
MT1-?ICD, n = 5, MT1-?ICD + MT1-?ECD-FLAG, n = 6. 
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Both constructs still contained the extracellular stalk region. Interestingly, replacement of 
the MT1-MMP transmembrane domain with that of the ß-amyloid precursor protein 
(APP), also did not increase VEGF-A expression (Figure 3.25B). Deletion of the 
hemopexin and the intracellular domain as well as mutation of the C573 and Y574 residues 
and the LLY573 and DKV582 motifs led to a similar result (Figure 3.25B). This was also 
observed with adenoviral transduction of various MT1-MMP mutants (data not shown). 
Taken together, these findings are consistent with previous data 73 and furthermore identify 
Y573, LLY573 and DKV582 as new intracellular motifs involved in the transcriptional 
regulation of VEGF-A. The data further show that the MT1-MMP hemopexin and 
transmembrane domains are also necessary for the MT1-MMP induced VEGF-A 
expression. 
 
3.1.11 The MT1-MMP catalytic activity is needed to enhance the 
bioavailability of VEGF-A by cleaving CTGF/VEGF165 complexes 
 
The findings so far suggest an MT1-MMP mediated signalling pathway that is induced via 
VEGFR-2 (summarised in Figure 3.31). 
It has been reported previously that both MT1-MMP and MMP-2 are able to cleave 
CTGF/VEGF165 and HARP/VEGF165 complexes in an in vitro system 
54,257. Both 
complexes are abundant within the extracellular milieu and HARP as well as CTGF 
sequesters VEGF165 function. It is possible that MP activity is required to release VEGF-A 
and activate VEGFR-2 feeding into an autocrine signalling loop, which increases VEGF-A 
mRNA expression. Thus, it was tested whether the previously described requirement for 
the MT1-MMP catalytic activity 73 (Figure 3.25B, Figure 3.4B) is explained by its ability 
to cleave CTGF or HARP and thus increase the bioavailability of VEGF165.  
The MCF-7 cells used in this study are described to be deficient in both MT1-MMP and 
MMP-2 expression 251. Similar results were obtained within a gene expression profile of 
MCF-7 cells transfected with either empty vector control or MT1-WT (Figure 3.26A and 
Figure 3.5B). HARP mRNA was not detected, whereas CTGF mRNA was readily 
expressed in MCF-7 cells (Figure 3.26B and Figure 3.5B), suggesting a possible role of the 
MT1-MMP catalytic activity in cleaving a CTGF/VEGF165 complex in the system used. 
It was initially tested whether MT1-MMP is able to cleave soluble CTGF in the 
conditioned medium of MCF-7 cells. Therefore, cells were transduced with increasing 
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MOI of MT1-WT expressing adenovirus or 150 pfu/cell of empty adenoviral control 
vector (Rad) and cell lysates as well as conditioned medium was immunoblotted for CTGF 
and MT1-MMP, respectively. As shown in Figure 3.26C increasing expression of MT1-
MMP induced an accumulation of CTGF cleavage products detected within the 
conditioned medium (arrows).  
These results show that MT1-MMP processes CTGF in MCF-7 cells (Figure 3.26C) which 
is consistent with previous findings showing that MT1-MMP cleaves CTGF/VEGF165 
complexes in vitro 54.  
 
Figure 3.26: MT1-MMP cleaves CTGF and has a potential role in increasing 
VEGF165 bioavailability in MCF-7 cells 
(A) MCF-7 cells were either transfected with pcDNA3.1 empty vector control (white bars) or MT1-WT 
(black bars). Relative mRNA expression levels of MT1-MMP and MMP-2 were detected by TaqMan® Real-
Time PCR and normalised to the house-keeping gene GAPDH. Data represent the mean expression in 
arbitrary units (AU) of 6 independent experiments ± min to max with P < 0.001 (**) on a log10 axis. ns, non-
significant. (B) MCF-7 cells were either transfected with pcDNA3.1 empty vector control (white bars) or 
MT1-WT (black bars). Relative mRNA expression levels of CTGF and HARP were detected by TaqMan® 
Real-Time PCR and normalised to the house-keeping gene GAPDH. Data represent the mean expression in 
arbitrary units (AU) of 6 independent experiments ± min to max with P < 0.001 (**). ns, non-significant. (C) 
MCF-7 cells were transduced with the indicated MOI of MT1-WT expressing adenovirus and protein levels 
in the cell lysates as well as in the conditioned medium were analysed by immunoblotting with an anti-MT1-
MMP (LEM-2/15.8), an anti-CTGF or an anti-ß-Actin antibody. Arrows indicate CTGF cleavage products 
whereas the asterisk correspond to full-length CTGF. Rad, empty adenoviral vector control. 
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Subsequently, it was tested whether the MT1-MMP catalytic activity is needed to cleave 
extracellular CTGF/VEGF165 complexes and thus possibly increase the bioavailability of 
VEGF165 in order to induce the signalling pathway characterised previously in this thesis. 
As MMP-2 has also been shown to cleave CTGF/VEGF165 complexes, cells were 
transfected with either MT1-WT or the catalytic inactive MT1-E240A and increasing 
concentrations of rh-MMP-2 were added. Addition of various concentrations of rh-MMP-2 
did not affect VEGF-A transcription in MT1-WT transfected cells as detected by 
TaqMan® Real-Time PCR (Figure 3.27A). MT1-E240A expression decreased VEGF-A 
mRNA levels compared to MT1-WT expressing cells, as shown previously (Figure 3.27B 
and Figure 3.25B). However, adding increasing concentrations of rh-MMP-2 to MT1-
E240A expressing cells restored VEGF-A mRNA levels to the level of MT1-WT 
expressing cells (dotted line, Figure 3.27B).  
 
Figure 3.27: MMP-2 is able to substitute for MT1-MMP catalytic activity in 
increasing VEGF-A mRNA levels 
MCF-7 cells were transfected with either MT1-WT (A) or MT1-E240A (B) and increasing concentrations of 
rh-MMP-2 were added for 24 hours, as indicated. VEGF-A relative expression levels were detected by 
TaqMan® Real-Time PCR and normalised to the mRNA levels of the house-keeping gene GAPDH. Data 
represent the mean expression of three (A) or four (B) independent experiments in fold change compared to 
MT1-WT transfected cells without rh-MMP-2 stimulation (dotted line) ± 95% confidence intervals. 
 
It was investigated further whether the MT1-MMP ICD is still required when MT1-E240A 
expressing cells were treated with rh-MMP-2. Therefore, double MT1-MMP mutants, 
containing the E240A point mutation as well as either a LLY573 => 571AAA573 mutation 
(MT1-E240A-571AAA573) or the complete deletion of the intracellular domain (MT1-
E240A-?ICD) were generated (Figure 3.28A). Addition of increasing concentrations of rh-
MMP-2 to the cells expressing the double mutants did not affect the level of VEGF-A 
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mRNA (Figure 3.28B, C). Figure 3.28D summarises the effect of exogenous rh-MMP-2 on 
VEGF-A expression in the different MT1-MMP mutants used.  
 
Figure 3.28: MMP-2 mediated increase of VEGF-A mRNA levels is dependent on the 
MT1-MMP intracellular domain 
(A) Schematic representation of the catalytic inactive intracellular domain mutants. S, signal sequence; Pro, 
prodomain; CAT, catalytic domain; HPX, hemopexin domain; stalk, amino acids P509 - S538; TMD, 
transmembrane domain; ICD, intracellular domain. (B,C) MCF-7 cells were transfected with the catalytic 
inactive intracellular domain mutants MT1-E240A-571AAA573 (B) or MT1-E240A-?ICD (C) and increasing 
concentrations of rh-MMP-2 were added for 24 hours, as indicated. VEGF-A relative expression levels were 
detected by Real-Time PCR and normalised to the mRNA levels of the house-keeping gene GAPDH. Data 
represent the mean expression of three independent experiments in fold change compared to MT1-WT 
transfected cells without rh-MMP-2 stimulation ± 95% confidence intervals. (D) Summary of the VEGF-A 
mRNA expression levels of MCF-7 cells transfected with either MT1-WT, MT1-E240A, MT1-E240A-
571AAA573 or MT1-E240A-?ICD.  
 
Results                                                                                                                                                             108 
Taken together, rh-MMP-2 stimulation increased VEGF-A mRNA levels in MT1-E240A 
expressing cells but did not affect VEGF-A expression levels in cells transfected with the 
catalytic inactive intracellular double mutants. Thus, the presence of an intact MT1-MMP 
intracellular domain is still required for MT1-MMP dependent VEGF-A expression. 
 
These results suggest that VEGF165 bioavailability may need to be increased by either 
MT1-MMP or MMP-2 catalytic activity in order to induce VEGF-A transcription in this 
system. However, the intact MT1-MMP intracellular domain sequence is still required for 
signal transduction.  
 
3.1.12 The MT1-MMP domains have different independent functions in 
the regulation of VEGF-A expression 
 
The data obtained suggest that the different MT1-MMP domains have distinct functions 
within the MT1-MMP induced signalling pathway (summarised in Figure 3.29A).  
MT1-MMP catalytic activity has been previously shown to be involved in the increase in 
VEGF-A expression (Figure 3.25B, Figure 3.4B) 73. The findings so far strongly suggest 
that the catalytic domain is required to cleave CTGF/VEGF165 complexes within the 
extracellular milieu in order to initiate the signalling pathway via VEGFR-2 (Figure 3.26 
and Figure 3.27). However, addition of exogenous rh-MMP-2 to MCF-7 cells has been 
shown to rescue VEGF-A expression in cells expressing inactive MT1-MMP, potentially 
by substituting for MT1-MMP catalytic function in cleaving CTGF/VEGF165 complexes 
and thus increasing the bioavailability of VEGF165. In contrast, the MT1-MMP hemopexin 
and transmembrane domains have been implicated in the interaction with VEGFR-2 
(Figure 3.20) as well as in regulating VEGFR-2 localisation (Figure 3.24), whereas the 
intracellular domain has been shown to interact with Src (Figure 3.12). However, the 
interpretation of the specific role of the transmembrane domain in VEGFR-2 interaction is 
difficult and is discussed in chapter 4.1.1.1. 
To test whether the functions identified for different MT1-MMP domains are independent, 
MCF-7 cells were co-transfected with the extracellular and intracellular deletion mutants 
(MT1-?ECD-FLAG and MT1-?ICD) and VEGF-A mRNA levels were assessed by 
TaqMan® Real-Time PCR. As previously shown, transfection of MCF-7 cells with either 
MT1-?ECD-FLAG or MT1-?ICD did not affect VEGF-A expression compared to empty 
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vector control transfected cells (Figure 3.25B and Figure 3.29B, dotted line; P < 0.05 
compared to MT1-WT transfected cells). However, when cells were co-transfected with 
both MT1-MMP mutants, VEGF-A expression was found to be increased but the detected 
mRNA level was not significantly affected compared to MT1-WT transfected cells (Figure 
3.29B, P = 0.29, Student t-test). 
 
 
Figure 3.29: The different roles of MT1-MMP domains 
(A) Schematic representation of the different roles of MT1-MMP in the regulation of VEGF-A expression. 
The role of the catalytic domain is shown in italic, since its function can be substituted by MMP-2 activity. 
The role of the transmembrane domain in the interaction with VEGFR-2 as well as its re-distribution in the 
cell is difficult to assess using the APP transmembrane domain mutant (shown in grey; discussed in chapter 
4.1.1.1). CAT, catalytic domain; HPX, hemopexin domain; TMD, transmembrane domain; ICD, intracellular 
domain. (B) MCF-7 cells were transfected with the extracellular deletion mutant (MT1-?ECD-FLAG), the 
intracellular deletion mutant (MT1-?ICD) or both (MT1-?ECD-FLAG + MT1-?ICD). VEGF-A relative 
expression levels were detected by TaqMan® Real-Time PCR and normalised to the mRNA levels of the 
house-keeping gene GAPDH. Data represent the mean expression of six independent experiments in fold 
change compared to pcDNA3.1 empty vector control transfected cells ± S.E.M. with P < 0.05 (*). 
 
These findings suggest that the MT1-MMP extracellular and intracellular domains are 
involved in different functions and that the presence of both is required for VEGF-A 
expression in the absence of another MP (e.g. MMP-2). Notably, the expression of both 
constructs from different cDNAs is sufficient to induce VEGF-A expression.  
A slight decrease in VEGF-A expression was observed in the MT1-?ECD-FLAG and 
MT1-?ICD co-transfected cells compared to the MT1-WT expressing control (Figure 
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3.29B). Both mutants expressed from two different expression vectors were co-transfected 
with FuGene into MCF-7 cells as described in Material and Methods (chapter 2.2.1.5). The 
difference in VEGF-A expression may be explained by (i) the different size and 
transfection efficiency of both constructs used or by (ii) the amount of cells that were co-
transfected by both, MT1-?ECD-FLAG and MT1-?ICD, compared to the proportion of 
cells that only express one of the deletion constructs.  
 
3.1.13 The role of the microtubular system in MT1-MMP – VEGFR-2 
complex formation 
 
In this thesis, MT1-MMP has been shown to co-localise with VEGFR-2 and pY416-Src in 
MCF-7 cells (Figure 3.17) and furthermore to modulate VEGFR-2 localisation (Figure 
3.24) as well as Src activation (Figure 3.9, Figure 3.10, Figure 3.14). VEGFR-2 and MT1-
MMP are known to traffic and recycle to the cell surface in a microtubular system-
dependent way 39,256, whereas Src activation and its transport to the plasma membrane has 
been demonstrated to be mediated by Actin filaments 253. As either the microtubules or the 
actin cytoskeleton are involved in VEGFR-2, Src and MT1-MMP trafficking, their 
respective role on the MT1-MMP – VEGFR-2 – pY416-Src complex was assessed. 
To test whether MT1-MMP co-localises with VEGFR-2 and the microtubule network, 
MCF-7 cells were transfected with MT1-WT and the localisation of MT1-MMP, VEGFR-
2 and tubulin was assessed by confocal microscopy. As shown in Figure 3.30A, 
intracellular vesicles containing both VEGFR-2 and MT1-MMP were found close to the 
microtubular network (arrows). Disruption of the microtubular system or the actin 
cytoskeleton by treatment of MT1-MMP and Src expressing MCF-7 cells with either 
Nocodazole or Cytochalasin D was found to reduce the amount of detected MT1-MMP 
and Src that co-immunoprecipitated with VEGFR-2 (Figure 3.30B).  
To test the effect of the actin and microtubular network disruption on MT1-MMP induced 
up-regulation of VEGF-A, MCF-7 cells were transfected with either pcDNA3.1 vector 
control or MT1-WT and cells were subsequently treated with Nocodazole, Cytochalasin D 
or DMSO control. VEGF-A mRNA levels were found to be decreased in cells with a 
disrupted microtubular system compared to MT1-WT expressing cells, but not in cells 
treated with Cytochalasin D (Figure 3.30C).  
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These findings suggest that actin and microtubules could be involved in the complex 
formation of VEGFR-2, MT1-MMP and Src, potentially by regulating the trafficking of 
these proteins. In contrast, only disruption of the microtubules but not of the actin 
cytoskeleton reduced MT1-MMP induced VEGF-A expression. 
 
 
Figure 3.30: MT1-MMP and VEGFR-2 positive vesicles co-localise with the 
microtubular system 
(A) MCF-7 cells were transiently transfected with MT1-WT and immunostained with an anti-VEGFR-2 
(AlexaFluor® 488 secondary), anti-tubulin (AlexaFluor® 546 secondary) and an anti-MT1-MMP antibody 
(N175/6; Cy5 secondary). Inset panel shows magnified portion of the merged image, as indicated (dashed 
square). The white scale bars present a distance of 25 μm. (B) MCF-7 cells were transfected with MT1-WT 
and Src and cell extracts were immunoprecipitated with an anti-VEGFR-2 antibody. Immunoprecipitates and 
Input controls were immunoblotted with an anti-MT1-MMP (LEM-2/15.8), anti-Src or an anti-ß-Actin 
antibody. (C) MCF-7 cells were transfected with pcDNA3.1 or MT1-WT and treated with Nocodazole or 
Cytochalasin D for 1 hour as indicated. VEGF-A mRNA levels were detected by TaqMan® Real-Time PCR. 
Relative expression levels of VEGF-A were normalised to the mRNA level of the house-keeping gene 
GAPDH. Data represent the mean expression of five independent experiments ± S.E.M. with P < 0.05 (*).  
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3.1.14 Summary: model of MT1-MMP induced increase of VEGF-A 
expression in MCF-7 cells 
 
Based on the data obtained so far, a model on MT1-MMP induced VEGF-A mRNA 
expression is proposed (summarised in Figure 3.31). 
MT1-MMP was found to form at least a ternary complex with Src and VEGFR-2, 
presumably at the cell surface of MCF-7 cells (Figure 3.17 - Figure 3.19). The interaction 
between MT1-MMP and Src was shown to be dependent on the MT1-MMP ICD (Figure 
3.11- Figure 3.13), whereas the hemopexin domain/hinge region mediates its interaction to 
VEGFR-2 (Figure 3.20). This complex was found to be required for the MT1-MMP 
induced up-regulation of VEGF-A transcription and expression of MT1-MMP furthermore 
induced the cell surface localisation of VEGFR-2 (Figure 3.24).  
 
 
Figure 3.31: Summary of the data obtained so far 
MT1-MMP expression in MCF-7 cells induces transcriptional up-regulation of VEGF-A expression. This 
effect was shown to be dependent on a VEGFR-2, Src, PI3 Kinase, Akt, mTOR and HIF-1? signalling 
pathway.  
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The signalling pathway leading to increased expression of VEGF-A mRNA is induced by 
VEGF165, which is potentially released through MP activity from the extracellular 
CTGF/VEGF165 complex (Figure 3.26 - Figure 3.28), and involves the activation of 
VEGFR-2, Src, PI3 Kinase, Akt, mTOR and HIF-1? (Figure 3.5A). 
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3.2 The role of MT1-MMP on VEGF-A expression in other human 
breast carcinoma cell lines 
 
The previous findings suggest an MT1-MMP mediated signalling pathway involving the 
activities of VEGFR-2, Src, PI3 Kinase, Akt and mTOR as well as the formation of an 
MT1-MMP – VEGFR-2 – Src complex in MCF-7 cells, leading to the up-regulation of 
VEGF-A expression (chapter 3.1). To test whether this newly identified autocrine VEGF-
A signalling loop is a conserved mechanism for regulating cell proliferation and survival, 
different breast cancer cell lines were analysed.  
The MT1-MMP mRNA and protein expression profile of MCF-7 and MDA-MB-453 cells 
with and without transfection of full-length MT1-MMP (MT1-WT) as well as MDA-MB-
231 and MDA-MB-468 cells is shown in Figure 3.32. As described by others 251, MCF-7 
and MDA-MB-453 cells were found to be deficient in MT1-MMP expression at the 
mRNA (Figure 3.32A) as well as at the protein level (Figure 3.32B), whereas MT1-MMP 
mRNA was readily detected in MDA-MB-231 and to a lesser extent in MDA-MB-468 
cells (Figure 3.32A). Over-expression of MT1-WT in MCF-7 and MDA-MB-453 cells 
increased the mRNA levels to those in MDA-MB-231 cells, indicating that the amount of 
transfected MT1-MMP in these cells is comparable to endogenous expression levels in a 
highly metastatic cell line (Figure 3.32A). Furthermore, MT1-MMP protein was expressed 
at similar levels in MCF-7 cells transfected with MT1-WT to endogenous levels in MDA-
MB-231 cells (Figure 3.32B).  
These data indicate, that the observations obtained in MT1-WT expressing MCF-7 cells as 
described in chapter 3.1 were close to endogenous levels of MT1-MMP expression 
observed in other cell lines and thus decrease the probability of being an artefact of 
unphysiological high protein over-expression.  
 
Based on these MT1-MMP expression results, a complementary approach was used where 
MT1-MMP was either over-expressed in MDA-MB-453 cells by transient expression or 
MT1-MMP expression was silenced by adenoviral expression of targeted anti-sense RNA, 
siRNA or lentiviral shRNA in MDA-MB-231 and MDA-MB-468 cells. 
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Figure 3.32: MT1-MMP expression in various breast cancer cell lines 
(A) The MT1-MMP mRNA expression levels of wild-type MCF-7 and MDA-MB-453 cells, transfected with 
or without MT1-WT, as well as of MDA-MB-231 and MDA-MB-468 cells was assessed by TaqMan® Real-
Time PCR. The relative expression levels of MT1-MMP were normalised to the mRNA levels of the house-
keeping gene GAPDH. Data represent the mean MT1-MMP expression in arbitrary units (AU) of six 
independent experiments ± S.E.M. (B) Protein lysates of MCF-7 (wild-type and MT1-WT transfected), 
MDA-MB-231, MDA-MB-453 and MDA-MB-468 cells were immunoblotted with an anti-MT1-MMP 
(LEM-2/15.8) antibody (at two different exposure times) or an anti-ß-Actin antibody. 
 
3.2.1 The role of MT1-MMP on VEGF-A expression in MDA-MB-453 
cells 
 
The MT1-MMP deficient MDA-MB-453 cells (Figure 3.32) were initially tested for 
VEGF-A mRNA levels following transient MT1-MMP expression.  
Similar to the results obtained in MCF-7 cells, MT1-MMP expressing MDA-MB-453 cells 
(Figure 3.33A) show an increase in VEGF-A mRNA expression compared to cells 
transfected with vector control (Figure 3.33B; P < 0.05, Student t-test), suggesting that the 
previously described pathway in MCF-7 cells (Figure 3.31) might be a ubiquitous 
mechanism in breast cancer cell lines to induce an autocrine VEGF-A signalling loop.  
The mRNA expression of MT2-MMP, MT3-MMP, MT4-MMP, MMP-2 as well as the key 
genes involved in the proposed signalling pathway was assessed in MT1-MMP and control 
vector expressing MDA-MB-453 cells (Figure 3.33C).  
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Figure 3.33: Expression profile of vector control and MT1-MMP transfected MDA-
MB-453 cells 
(A,B) MDA-MB-453 cells were transfected with MT1-WT or empty pcDNA3.1 vector control and the 
expression levels of MT1-MMP (A) and VEGF-A (B) were detected by TaqMan® Real-Time PCR. MT1-
MMP and VEGF-A relative expression levels were normalised to the mRNA levels of the house-keeping 
gene 18s. The data represent the mean expression in arbitrary units (AU) of three independent experiments ± 
S.E.M. (C) Gene expression profile of pcDNA3.1 and MT1-WT transfected MDA-MB-453 cells was 
assessed by TaqMan® Real-Time PCR. The relative expression levels of various target genes were 
normalised to the mRNA levels of the house-keeping gene 18s. Data represent the mean relative expression 
of three independent experiments in arbitrary units (AU).  
 
These data show that (i) transient expression of MT1-WT cDNA only affected expression 
levels of MT1-MMP and Caveolin-1 (discussed in chapter 3.2.4) significantly and (ii) 
CTGF and Src are both expressed at significantly higher levels than HARP and Fyn, 
similar to the expression profile obtained in MCF-7 cells (Figure 3.5B).  
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3.2.1.1 The role of MT1-MMP on VEGF-A expression in MDA-MB-231 and 
MDA-MB-468 cell lines 
 
To test the role of MT1-MMP on VEGF-A expression in MDA-MB-231 and MDA-MB-
468 cells, which endogenously express MT1-MMP (Figure 3.32), MT1-MMP expression 
was reduced using various approaches as listed in the following sections. 
 
3.2.1.2 Adenoviral anti-sense expression of MT1-, MT2-, MT3- and MT4-
MMP 
 
In order to target specifically the effect of MT1-MMP, adenoviruses expressing antisense 
RNA (asRNA) for MT1-MMP as well as for MT2-, MT3- and MT4-MMP as controls 
were generated. Adenoviral delivery of these single-stranded asRNAs provides a system to 
study the function of selective genes based on the high efficiency of adenoviral 
transduction. Therefore, sequences (Appendix B, Table 9.1) complementary to the mRNA 
strand of each MT-MMP gene were cloned into the adenoviral backbone as described in 
Material and Methods (chapter 2.2.2.11). 8 - 10 clones per MT-MMP were selected for 
subsequent characterisation. After titration and plaque-purification, the different clones 
were tested for knockdown efficiency and cross-reactivity within the MT-MMP subfamily.  
 
MDA-MB-231 cells were transduced with the different MT-MMP asRNA clones and the 
mRNA expression of MT1-, MT2-, MT3- and MT4-MMP was assessed by TaqMan® 
Real-Time PCR. As expected, every clone tested effectively silenced gene expression of 
the targeted MT-MMP as compared to MDA-MB-231 transduced with empty adenoviral 
vector control (Rad; Figure 3.34). 
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Figure 3.34: Adenoviral asRNA mediated knockdown of MT1-, MT2-, MT3- and 
MT4-MMP 
MDA-MB-231 cells were transduced with 70 pfu/cell of the indicated clones of MT1-, MT2-, MT3- and 
MT4-MMP asRNA expressing adenovirus. The mRNA expression level of MT1-, MT2-, MT3- and MT4-
MMP was assessed for each clone using TaqMan® Real-Time PCR. The expression levels were normalised 
to the expression level of the house-keeping gene 18s. Data represent the mean expression in arbitrary units 
(AU) of two independent experiments.  
 
The mRNA expression level of MT1-, MT2-, MT3- and MT4-MMP was next assayed by 
TaqMan® Real-Time PCR for each clone in order to test for cross-reactivity within the 
MT-MMP family. Therefore, MDA-MB-231 cells were transduced with 9 different clones 
expressing MT2-MMP or MT4-MMP asRNA as well as 10 clones expressing MT1-MMP 
or MT3-MMP asRNA and the mRNA expression level of MT1-, MT2-, MT3- and MT4-
MMP was detected for each clone. The relative expression of the MT-MMPs for each 
clone is normalised to the corresponding adenoviral empty vector control (Rad) and 
summarised in a heat-map (Figure 3.35). 
As shown in Figure 3.35, a broad knockdown of the other members of the MT-MMP 
subfamily was observed. Similar results were obtained using HeLa cells (data not shown).  
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Taken together, adenoviral asRNA delivery for MT-MMP silencing was shown to be 
unsuitable to study the specific role of MT1-MMP function on VEGF-A expression in 
MDA-MB-231 or MDA-MB-468 cells. 
 
 
Figure 3.35: Characterisation of adenoviral MT1-MMP asRNA specificity 
MDA-MB-231 cells were transduced with 70 pfu/cell of the indicated clones of MT1-, MT2-, MT3- and 
MT4-MMP asRNA expressing adenovirus (clones x.1 – x.10 with x = MT1 - MT4-MMP specific asRNA). 
The mRNA expression level of MT1-, MT2-, MT3- and MT4-MMP was assessed for each clone using 
TaqMan® Real-Time PCR. The expression levels were normalised to the expression level of the house-
keeping gene 18s. mRNA levels of each clone were normalised to the expression level of the empty 
adenoviral vector control (Rad). Data represent the mean expression in arbitrary units of two independent 
experiments.  
 
3.2.1.3 MT1-MMP knockdown by lentiviral shRNA 
 
As a further approach to effectively reduce MT1-MMP expression, a lentiviral short-
hairpin RNA (shRNA) system was used (MISSION® shRNA, Sigma-Aldrich). Lentiviral 
delivery of shRNA constructs provides long-term, stable gene silencing and clonal 
selection following puromycin treatment. Several different shRNA lentiviral particles, 
targeting different regions of the mRNA sequence, were used for each gene of interest 
(Appendix B, Table 9.2). 
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Initially, MDA-MB-231 cells were transduced with two different lentiviral MT1-MMP 
shRNA particles (shRNA3 and shRNA4), since the other shRNAs did not reduce MT1-
MMP expression significantly (data not shown), as well as the empty vector control 
containing the puromycin resistance cassette (pLKO) and a non-targeting shRNA control 
(nt). As shown in Figure 3.36, MT1-MMP expression was efficiently reduced by shRNA3 
and shRNA4 at the RNA (Figure 3.36A, P < 0.0001 compared to wild-type cells) as well 
as at the protein level (Figure 3.36B), albeit shRNA4 transduction did not decrease MT1-
MMP protein expression as significantly as shRNA3. MT1-MMP mRNA and protein 
expression was not affected in the pLKO or non-targeting (nt) control cells (compared to 
wild-type cells).  
 
Figure 3.36: MT1-MMP knockdown in MDA-MB-231 cells using lentiviral shRNA 
(A) MDA-MB-231 cells were transduced with 1 pfu/cell of Mission TRC lentiviral transduction particles. 48 
hours after transduction, RNA was isolated and MT1-MMP RNA expression levels were assessed by 
TaqMan® Real-Time PCR. Relative MT1-MMP expression levels were normalised to mRNA levels of the 
house-keeping gene GAPDH. Data represent the mean MT1-MMP expression in arbitrary units (AU) of six 
independent replicates ± S.E.M. with P < 0.0001 (***). plKO, empty lentiviral vector containing the 
puromycin resistance cassette; nt, non-targeting shRNA sequence; sh3, sh4, shRNA sequence 3 and 4 
targeting MT1-MMP. (B) MDA-MB-231 cells were transduced with 1 pfu/cell of Mission TRC lentiviral 
transduction particles. 48 hours after transduction, cell extracts were immunoblotted using an anti-MT1-
MMP (LEM-2/15.8) or an anti-ß-Actin antibody. (C) MDA-MB-231 cells were transduced with 1 pfu/cell of 
Mission TRC lentiviral transduction particles. 48 hours after transduction, RNA was isolated and VEGF-A 
RNA expression levels were assessed by TaqMan® Real-Time PCR. Relative VEGF-A expression levels 
were normalised to mRNA levels of the house-keeping gene GAPDH. Data represent the mean VEGF-A 
expression in arbitrary units (AU) of six independent replicates ± S.E.M. with P < 0.05 (*) and P < 0.0001 
(***). 
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The mRNA level of VEGF-A was increased in cells expressing MT1-MMP specific 
shRNA3 (Figure 3.36C, P < 0.0001 compared to wild-type cells) or shRNA4 (Figure 
3.36C, P < 0.05 compared to wild-type cells), showing the opposite effect of MT1-MMP 
in the regulation of VEGF-A expression in MDA-MB-231 cells compared to MCF-7 
(Figure 3.2) and MDA-MB-453 cells (Figure 3.33).  
Since MT1-MMP expression led to opposing results in MDA-MB-231 and MCF-7 or 
MDA-MB-453 cells and to confirm the reliability of the system used, the specificity of the 
shRNA knockdown was assessed. MT1-MMP targeting shRNA viral particles as well as 
the corresponding controls were transduced in MDA-MB-231 cells and the mRNA 
expression of MT1-, MT2-, MT3- and MT4-MMP as well as of key components of the 
previously described signalling pathway in MCF-7 cells was determined (Figure 3.31). The 
mRNA levels of 14 genes of interest normalised to the house-keeping gene GAPDH are 
summarised in a heat-map in Figure 3.37 (single analysis in Appendix C, Figure 10.1). 
 
 
Figure 3.37: Gene expression profile of MDA-MB-231 wild-type and MT1-MMP 
shRNA transduced cells 
MDA-MB-231 cells were transduced with 1 pfu/cell of non-targeting (nt) shRNA control or the MT1-MMP 
targeting shRNA sequences shRNA3 (sh3) or shRNA4 (sh4). The gene expression profile of wild-type and 
lentiviral transduced MDA-MB-231 cells was assessed by TaqMan® Real-Time PCR. The relative 
expression levels of various target genes were normalised to the mRNA levels of the house-keeping gene 
GAPDH. Data represent the mean expression of three independent experiments in arbitrary units (AU).  
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As previously shown, transduction of MDA-MB-231 cells with lentiviral MT1-MMP 
shRNA particles led to a significant reduction of MT1-MMP expression (P < 0.0001 
compared to MDA-MB-231 wild-type cells, Figure 3.37). However, similar results were 
obtained for MT3-MMP (P < 0.001), MT4-MMP (P < 0.0001), MMP-2 (P < 0.0001), 
VEGFR-2 (P < 0.0001), HARP (P < 0.0001), HIF-1? (P < 0.0001) and Caveolin-1 (P < 
0.0001) expression, while MT2-MMP (P < 0.0001) and VEGF-A (P < 0.0001) expression 
levels were found to be increased. 
These data indicate that transduction of the MT1-MMP targeting shRNA as well as 
induction of the non-targeting (nt) shRNA sequence (in 7 genes tested, Figure 10.1) affects 
the mRNA expression of other genes. 
 
Cells exhibit an innate defence mechanism directed against double-stranded (ds) RNA, 
such as virus infection. Introduction of short dsRNAs into mammalian cells causes a 
global, non-specific suppression of gene expression. These effects are known to be mainly 
mediated by activation of the dsRNA recognition proteins 2’,5’-oligoadeylate synthetase-1 
(OAS-1) or PKR (dsRNA-dependent protein kinase). Activation of either pathway leads to 
a general inhibition of protein synthesis and PKR activation induces a signalling pathway 
leading to the production of interferons (reviewed by 258). Interferons activate cellular 
signalling pathways and up-regulate the expression of interferon-stimulated genes, which 
mediate once again an inhibition of protein synthesis as well as an anti-proliferative and 
pro-apoptotic activity. These global effects are not apparent unless either global gene 
expression studies are performed beyond the analysis of the target gene expression, or the 
expression profile of interferon response genes is assessed.  
In order to test whether the shRNA system used is causing an inert non-specific defence 
response following transduction of dsRNA, the expression of the well-described ?-
interferon response genes OAS-1 as well as MX-1 and MX-2 was tested by TaqMan® 
Real-Time PCR. It is widely accepted that expression of OAS-1 corresponds to an 
increased risk of inducing off-target effects in the knockout system used 259.  
 
As shown in Figure 3.38, expression of ?-interferon response genes varied between the 
different cell lines tested. MCF-7 cells were found to be highly responsive to dsRNA 
transduction and the expression levels of the ?-interferon down-stream targets OAS-1, 
MX-1 and MX-2 were significantly increased in pLKO, non-targeting (nt) and VEGFR-2 
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shRNA transduced cells compared to MCF-7 wild-type cells (Figure 3.38C). Similar 
results, although to a lesser extent, were observed in the MDA-MB-468 cells (data not 
shown). In contrast, OAS-1 expression was not altered in MDA-MB-231 cells transduced 
with the pLKO or non-targeted (nt) control, but was slightly increased in these cells 
infected with the MT1-MMP targeted shRNA sample 4 (Figure 3.38A, B).  
 
 
Figure 3.38: Summary of off-target effects and ?-interferon response in MDA-MB-
231 and MCF-7 cells 
(A) Gene expression profile of MDA-MB-231 cells transduced with non-targeted (nt) shRNA or MT1-MMP 
specific shRNA3 and shRNA4 probes was assessed by TaqMan® Real-Time PCR. Gene expression-levels 
were normalised to GAPDH mRNA levels. Data represent the statistical significance of the mean expression 
of three independent experiments compared to wild-type MDA-MB-231 cells. ns, non-significant; nd, not 
detected. (B) pLKO, non-targeting (nt) shRNA, MT1-MMP specific shRNA3 and shRNA4 sequences were 
transduced into MDA-MB-231 cells. The relative expression of OAS-1 was detected by TaqMan® Real-
Time PCR and normalised to the mRNA levels of the house-keeping gene GAPDH. Data represent the mean 
expression of three independent experiments in arbitrary units (AU) ± S.E.M. with P < 0.05 (*). (C) pLKO, 
non-targeting (nt) shRNA and VEGFR-2 specific shRNA1 (R2 – shRNA1) sequences were transduced into 
MCF-7 cells. The relative expression of OAS-1, MX-1 and MX-2 was detected by TaqMan® Real-Time 
PCR and normalised to the mRNA levels of the house-keeping gene 18s. Data represent the mean expression 
of three independent experiments in arbitrary units (AU) ± S.E.M. with P < 0.05 (*), P < 0.001 (**) and P < 
0.0001 (***). 
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These findings demonstrate that the tested cell lines respond differently to infection with 
short dsRNA molecules. Interestingly, the activation of the inert defence mechanism by 
inducing ?-interferon pathways was found to correlate with the malignancy of the cell line 
with the least invasive and malignant MCF-7 cells to show the strongest response. 
Although MDA-MB-231 cells were not found to increase OAS-1 expression compared to 
the wild-type control, expression-profiling revealed that several genes were influenced 
significantly by MT1-MMP knockdown, including members of the MT-MMP sub-family 
as well as MMP-2 (Figure 3.37 and Figure 10.1). The differential expression of 15 target 
genes in MDA-MB-231 cells transduced with either non-targeting (nt) control, MT1-MMP 
shRNA3 or shRNA4 is summarised in Figure 3.38A, representing the statistical 
significance compared to MDA-MB-231 wild-type cells.  
Off-target effects observed, potentially by induction of interferons by dsRNAs, might be 
explained by the shRNA system used, which expresses shRNA under the control of a 
Polymerase III dependent U6 promoter. Recent findings suggest that a 5’-triphosphate 
modification, which is characteristic to all RNAs transcribed by Polymerase III promoters, 
is required for interferon induction 258,260,261. This interferon response was shown to be 
attenuated by removal of the 5’triphosphate. Recent siRNA technology mimics the 
endogenous miRNA system by transcribing shRNAs by Polymerase II and thus reduce the 
amount of off-target effects 262.  
 
Taken together, these results emphasise that a thorough characterisation of the gene 
expression silencing method used is necessary to draw coherent conclusions, especially 
when knockdown studies are used to determine gene function or the effect on the 
transcriptional regulation of downstream target genes. To address the role of MT1-MMP 
on VEGF-A expression in cells which endogenously express MT1-MMP, either a next-
generation shRNA system should be used to introduce a stable MT1-MMP knockdown or 
transient gene silencing by siRNA should be applied.  
 
3.2.1.4 MT1-MMP knockdown by siRNA 
 
In order to circumvent the previously described shRNA introduced off-target effects or 
interferon responses (Figure 3.37 and Figure 3.38), an siRNA based approach to transiently 
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silence MT1-MMP expression was next tested using the Dharmacon® AccellTM siRNA 
system, which is one of the latest generations of RNAi technology.  
Therefore, MDA-MB-231 cells were transfected with 0.25 ?M or 1 ?M of siRNA 
sequences targeting four different regions of the MT1-MMP mRNA sequence and the 
MT1-MMP and VEGF-A mRNA expression was detected by TaqMan®  Real-Time PCR.  
MT1-MMP mRNA levels were effectively reduced by all siRNA sequences used at both 
concentrations (Figure 3.39A. P < 0.0001 compared to wild-type (ctrl)), whereas the level 
of VEGF-A expression was slightly increased with all siRNAs used (Figure 3.39B, P < 
0.001 for siRNA 3 compared to wild-type (ctrl) cells).  
However, a full RNA and protein expression profile to test the specificity of the siRNA 
used remains to be assessed. 
 
Figure 3.39: VEGF-A expression in MDA-MB-231 cells transfected with MT1-MMP 
specific siRNA was slightly increased 
(A,B) MDA-MB-231 cells were transfected with three different siRNAs targeting different regions of the 
MT1-MMP mRNA sequence at 0.25 ?M or 1 ?M as indicated. The relative MT1-MMP (A) and VEGF-A 
(B) expression levels were analysed by TaqMan® Real-Time PCR and were normalised to the mRNA levels 
of the house-keeping gene GAPDH. Data represent the mean expression in arbitrary units (AU) of three 
independent experiments ± S.E.M. with P < 0.0001 (***) and P < 0.001 (**). scr, scrambled control 
sequence.  
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Despite the described limitations of the shRNA approach and the lack of a complete 
characterisation of the siRNA system, both techniques show independently an increase in 
VEGF-A expression in MT1-MMP silenced MDA-MB-231 cells (Figure 3.36C and Figure 
3.39B), suggesting a different mechanism of MT1-MMP dependent regulation of VEGF-A 
expression in these cells.  
 
3.2.1.5 VEGF-A expression does not depend on the MT1-MMP catalytic 
activity in MDA-MB-231 cells 
 
Since various knockdown systems in MDA-MB-231 cells made the interpretation of the 
role of MT1-MMP on VEGF-A expression difficult, an inhibitor-based approach was used 
in order to test the role of metalloproteinase (MP) function and in particular of MT1-MMP 
catalytic activity on VEGF-A expression.  
Cells were treated for 24 hours with rh-TIMP-1, rh-TIMP-2, the MP broad-spectrum 
inhibitor CT1746 at indicated concentrations as well as with the MT1-MMP specific 
catalytic activity-blocking antibody LEM-2/15.8. The mRNA expression of VEGF-A was 
subsequently determined by TaqMan® Real-Time PCR.  
 
 
Figure 3.40: MT1-MMP catalytic activity does not affect VEGF-A expression in 
MDA-MB-231 cells 
MDA-MB-231 cells were incubated for 24 hours with 1 ?M rh-TIMP-1, 1 ?M rh-TIMP-2, the broad-
spectrum MP inhibitor CT1746 at the indicated concentrations as well as with 10 ?g/ml of the anti-MT1-
MMP catalytic activity blocking antibody LEM-2/15.8. VEGF-A expression levels were determined by 
TaqMan® Real-Time PCR and were normalised to mRNA levels of the house-keeping gene GAPDH. Data 
represent the mean expression in fold change compared to MDA-MB-231 wild-type cells (dotted line) of 
three independent experiments ± S.E.M. 
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In contrast to MCF-7 cells (Figure 3.4B), neither of the inhibitors used were able to alter 
VEGF-A mRNA expression significantly compared to wild-type control (Figure 3.40, 
dotted line).  
This result suggests that VEGF-A expression is not affected by MT1-MMP catalytic 
activity in MDA-MB-231 cells. However, as shown in the gene expression profile of these 
cells (Figure 3.37, wild-type cells), MMP-2 mRNA expression was readily detected. 
Addition of exogenous rh-MMP-2 to MCF-7 cells expressing a catalytic inactive MT1-
MMP mutant has been shown to compensate for the lack of the catalytic activity in these 
cells (Figure 3.27B, Figure 3.28D). Inhibition of MT1-MMP catalytic activity using the 
catalytic function blocking antibody LEM-2/15.8 in MDA-MB-231 cells, which 
endogenously express MT1-MMP and MMP-2, might therefore have led to a MMP-2 
dependent rescue for loss of MT1-MMP activity. However, rh-TIMP-1, rh-TIMP-2 and 
CT1746 inhibit also MMP-2 activity, thus suggesting that VEGF-A expression does not 
depend on MT1-MMP or MP catalytic activity as observed in MCF-7 cells.  
 
3.2.2 MT1-MMP – VEGFR-2 complex formation in breast cancer cell 
lines 
 
MT1-MMP was found in a complex with VEGFR-2 and active Src (pY416-Src) in MCF-7 
cells and this complex was shown to be required for MT1-MMP induced VEGF-A 
expression (Figure 3.17 - Figure 3.19, Figure 3.25B). In contrast to MCF-7 and MDA-MB-
453 cells, MT1-MMP expression did not increase the level of VEGF-A mRNA in MDA-
MB-231 cells, suggesting a different mechanism of VEGF-A regulation depending on the 
cell line. In order to test whether the MT1-MMP – VEGFR-2 complex is conserved in 
different breast cancer cell lines, albeit potentially controlling the expression of different 
target genes, a co-immunoprecipitation assay using an anti-VEGFR-2 antibody was 
performed as previously described (Figure 3.17A).  
In addition to MT1-WT expressing MCF-7 cells, as previously described (Figure 3.17A), 
MT1-MMP was detected in MDA-MB-231 cells after immunoprecipitation with an anti-
VEGFR-2 antibody (Figure 3.41A). The expression levels of MT1-MMP in MDA-MB-
468 and especially in MDA-MB-453 were significantly lower than in the MDA-MB-231 
cells as demonstrated in the whole cell lysate (Figure 3.41B, Input), making the MT1-
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MMP detection after immunoprecipitation difficult. However, MT1-MMP could be 
detected at low levels in the MDA-MB-468 immunoprecipitates (Figure 3.41A). 
 
These results suggest that formation of the MT1-MMP – VEGFR-2 complex may be a 
conserved system across different breast cancer cell lines, although the down-stream 
targets and signalling pathways that are controlled by this complex may vary. 
 
 
Figure 3.41: MT1-MMP is in a complex with VEGFR-2 in MCF-7, MDA-MB-231 
and MDA-MB-468 cells 
MCF-7 wild-type cells, MT1-WT transfected MCF-7 cells, MDA-MB-231, MDA-MB-468 and MDA-MB-
453 cells were immunoprecipitated with an anti-VEGFR-2 antibody. Immunoprecipitates (A) and Input 
controls (B) were immunoblotted with an anti-MT1-MMP (LEM-2/15.8) or an anti-ß-Actin antibody. 
Asterisk indicates the IgG heavy chain.  
 
Taken together, the interpretation of the role of MT1-MMP on the regulation of VEGF-A 
transcription in MDA-MB-231 as well as MDA-MB-468 cells is difficult due to the 
possible side-effects of MT1-MMP gene silencing (chapters 3.2.1.2 - 3.2.1.4). However, 
VEGF-A mRNA levels were found to be decreased in two independent systems using 
MT1-MMP specific shRNA and siRNA in MDA-MB-231 cells (Figure 3.36C and Figure 
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3.39B), indicating a different mechanism of VEGF-A regulation in MDA-MB-231 as 
compared to MCF-7 and MDA-MB-453 cells.  
Previous findings using a Luciferase reporter gene under the control of a truncated 6 kb 
region of the VEGF-A promoter containing the hypoxia regulated element (HRE; Figure 
1.6) in MCF-7 cells, also led to a decrease in activation following MT1-MMP expression 
(C.H. Roghi, personal communication), suggesting that MT1-MMP dependent VEGF-A 
regulation requires additional distant regulatory elements that are not present in the 
artificial VEGF-A promoter. These could be differentially regulated or modified (e.g. 
aberrant DNA methylation) in different cell lines leading to an either positive or negative 
regulation of the VEGF-A promoter. 
These data indicate that VEGF-A regulation is dependent on the cell type, potentially due 
to a difference in regulatory elements distant to the 6 kb promoter region. In contrast, the 
complex-formation between MT1-MMP and VEGFR-2 was shown to be a more 
ubiquitous mechanism in various breast cancer cell lines tested.  
 
3.2.3 MT1-MMP, VEGFR-2 and pY416-Src are expressed in tumour 
cells of human mammary carcinomas 
 
As described before in this thesis, MT1-MMP was found to form a complex with VEGFR-
2 and Src, thus modulating the PI3 Kinase/Akt pathway and regulating VEGF-A 
expression in MCF-7 cells (chapter 3.1; Figure 3.31). The data obtained also revealed the 
presence of MT1-MMP – VEGFR-2 complexes in other human breast cancer cell lines 
(Figure 3.41), albeit the genes that are regulated by this complex may vary depending on 
the cell type.  
In order to correlate the data obtained in vitro with clinical specimens, sections of human 
breast carcinomas were obtained, embedded in paraffin and immunostained with an anti-
MT1-MMP (LEM-2/15.8) (Figure 3.42A, D), an anti-VEGFR-2 (Figure 3.42B, E) or an 
anti-pY416-Src antibody (Figure 3.42C, F) (in collaboration with Dr. Bence Sipos, 
Department of Pathology, Universitätsklinikum Schleswig-Holstein, Campus Kiel; current 
affiliation: Department of Pathology, University of Tübingen). Figure 3.42 shows a 
representative sample of human mammary carcinoma sections.  
As expected, VEGFR-2 was detected in the endothelial cells lining blood vessels (Figure 
3.42B, black arrows), indicating the correct specificity of the antibody used. Expression of 
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VEGFR-2 was also detected within the cytoplasma and at the plasma membrane of tumour 
cells (Figure 3.42B,E empty arrowheads) but not in the stromal compartment (black 
arrowheads). MT1-MMP was highly expressed within the tumour cells, in particular at the 
plasma membrane (Figure 3.42A,D, empty arrowheads). Consistent with previous data 263 
MT1-MMP was also found in the tumour stroma and in endothelial cells lining blood 
vessels in tumour sections that comprise of a more heterogeneous cell population (data not 
shown).  
A similar staining pattern was obtained following immunostaining with an anti-pY416-Src 
antibody. A clear pY416-Src signal was detected at the plasma membrane of the tumour 
cells (Figure 3.42C,F, empty arrowheads), whereas stromal cells remained negative (black 
arrowhead). 
 
Figure 3.42: MT1-MMP, VEGFR-2 and pY416-Src are expressed in human 
mammary carcinomas  
Representative sample of a paraffin-embedded section of human breast carcinoma was immunostained with 
an anti-MT1-MMP (LEM-2/15.8), an anti-VEGFR-2 or an anti-pY416-Src (Millipore) antibody. Black 
arrows indicate the staining of endothelial cells lining blood vessels, empty arrowheads show staining of 
tumour cells and black arrowheads indicate the stromal compartment. Lower panels (D-F) show magnified 
portions of each image, as indicated (dashed squares). Tissue specimens were counterstained with 50 % 
haemalaun. 100 ? magnification. 
 
These findings demonstrate that MT1-MMP, VEGFR-2 and pY416-Src are detected in 
tumour cells, in particular at or close to the plasma membrane, of human mammary 
carcinomas. To obtain a better understanding of the MT1-MMP – VEGFR-2 – Src 
complex in vivo, a comprehensive study using breast invasive ductal carcinoma tissue 
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microarrays (US Biomax, Inc., Heidelberg, GER) is currently being performed in 
collaboration with Dr. Bence Sipos. 
 
3.2.4 The potential role of MT1-MMP in Caveolin-1 regulation 
 
The plasma membrane is organised into various microdomains, including adhesive 
structures (substrate adhesions and cell-cell junctions), membrane invaginations (clathrin-
coated pits and caveolae) as well as lipid rafts, which organise the cellular distribution of 
cell surface receptors and membrane-associated proteins. Caveolae are organised by 
clustered transmembrane caveolins and regulate growth factor receptor signalling, raft-
dependent endocytosis and focal adhesion dynamics. As reported previously 264-267, wild-
type MCF-7 cells do not express detectable levels of caveolin-1 (Figure 3.43A), whereas 
caveolin-1 expression could be observed on the mRNA and protein level in MDA-MB-231 
cells (Figure 3.43B) 268. Interestingly, expression of MT1-MMP in MCF-7 and MDA-MB-
453 cells was consistently found to increase the level of caveolin-1 expression (Figure 
3.43A, Figure 3.5B, Figure 3.33C), whereas MT1-MMP gene silencing in MDA-MB-231 
cells using MT1-MMP specific shRNA decreased its detection at the mRNA and protein 
level (Figure 3.43B and Figure 10.1). 
Caveolin-1 is a substrate of Src kinase and its phosphorylated form (pY14-Cav-1) has been 
found to regulate interactions with integrins, the association with various signalling 
molecules and protein tyrosine phosphatases and was also described to act as a scaffolding 
complex, which enables intracellular signalling by facilitating the assembly of signalling 
complexes 269-272.  
Interestingly, both MT1-MMP and VEGFR-2 have been identified to localise within 
caveolae and to interact with caveolin-1 119,273. It has been recently shown that stimulation 
of bovine aortic endothelial cells (BAEC) with VEGF induces the dissociation of the 
VEGFR-2 – caveolin-1 complex, potentially following VEGF induced phosphorylation of 
the receptor 273. Subsequently, caveolin-1 is phosphorylated at its Y14 residue in a Src-
dependent way, facilitating its interaction with MT1-MMP 119. This MT1-MMP – pY14-
Cav-1 complex recruits Src, thereby inhibiting its activity. Notably, the association of 
MT1-MMP with pY14-Cav-1 was shown to be dependent on the MT1-MMP ICD, 
especially on its C574 and V582 residues.  
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Figure 3.43: Caveolin-1 expression is dependent on MT1-MMP in MCF-7 and MDA-
MB-231 cells 
(A) MCF-7 cells were transfected with pcDNA3.1 control or MT1-WT. Relative expression levels of 
caveolin-1 were detected by TaqMan® Real-Time PCR and were normalised to the mRNA levels of the 
house-keeping gene GAPDH. Data represent the mean expression in arbitrary units (AU) of six independent 
experiments ± S.E.M. with P < 0.05 (*). Lysates from MT1-WT and pcDNA3.1 expressing MCF-7 cells 
were immunoblotted with an anti-Caveolin-1 (Cav-1) or an anti-ß-Actin antibody. (B) MDA-MB-231 cells 
were transduced with 1 pfu/cell of pLKO empty lentiviral vector control or MT1-MMP targeting shRNA 
(MT1-sh3, MT1-sh4). Relative expression of caveolin-1 was detected by TaqMan® Real-Time PCR and was 
normalised to the mRNA levels of the house-keeping gene GAPDH. Data represent the mean expression in 
arbitrary units (AU) of six independent experiments ± S.E.M. with P < 0.0001 (***). Lysates from MDA-
MB-231 wild-type (WT) and lentiviral transduced cells were immunoblotted with an anti-Caveolin-1 (Cav-1) 
or an anti-ß-Actin antibody.  
 
Combining these findings with the regulation of caveolin-1 expression by MT1-MMP 
(Figure 3.43) as well as the MT1-MMP – VEGFR-2 – pY416-Src complex-formation that 
is described in this thesis (Figure 3.17 - Figure 3.19), suggests that caveolin-1 may play a 
role in the assembly of this signalling complex. However, this remains to be further 
investigated (discussed in chapter 4.1.3). 
 
3.2.5 Summary: MT1-MMP dependent VEGF-A regulation in other 
breast carcinoma cell lines and human mammary carcinomas 
 
In addition to the model system MCF-7 (described in chapter 3.1), two other breast cancer 
cell lines were tested for the MT1-MMP effect on the regulation of VEGF-A expression. 
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MT1-MMP overexpression in the MT1-MMP deficient MDA-MB-453 cells induced a 
significant up-regulation of VEGF-A expression, similar to the results obtained in MCF-7 
cells.  
As a complementary approach, MT1-MMP expression was silenced in MDA-MB-231 
cells using adenoviral asRNA, lentiviral shRNA or siRNA technology. The interpretation 
of the results are difficult due to non-specific off-target effects and a potential induction of 
?-interferon responses. However, two independent RNAi approaches, using shRNA and 
siRNA revealed an increased VEGF-A expression following MT1-MMP gene silencing, 
suggesting a different MT1-MMP dependent regulatory mechanism in MDA-MB-231 cells 
compared to MCF-7 and MDA-MB-453 cells. In contrast, the presence of the MT1-MMP 
– VEGFR-2 complex, as described in MCF-7 cells, was found in all cell lines tested and 
MT1-MMP, VEGFR-2 and pY416-Src expression was furthermore detected in vivo using 
human mammary carcinomas. These findings indicate that the formation of the MT1-MMP 
– VEGFR-2 complex might be a conserved mechanism in breast cancer cells, albeit 
controlling different down-stream target genes.  
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3.3 MT1-MMP intracellular domain release 
 
Recently a number of transmembrane proteins, including Notch-1, APP, SREBP2, LRP1 
and CD44 have been reported to undergo proteolytic processing in order to release their 
intracellular domains, which subsequently translocate as soluble transcription factors to the 
nucleus 59,143-146. Two major pathways have been reported in which transmembrane 
proteins were cleaved: (i) regulated intramembrane proteolysis (RIP), which is mainly 
dependent on the presenilin aspartyl proteinases (e.g. ?-Secretase), the rhomboid serine 
proteinases, the signal-peptide peptidase (SPP) or the site-2 proteinases (S2P), and (ii) 
regulated ubiquitin/proteasome dependent processing (RUP) 190 (chapter 1.4). However, 
the latter has been only described to take place in S. cerevisiae so far. 
There is emerging evidence that MT1-MMP undergoes various forms of autocatalytic and 
non-autocatalytic ectodomain shedding, which has been described to be a potential 
mechanism for regulating MT1-MMP activity 100,274 (chapter 1.3.4.4). Autocatalytic 
processing leads to the formation of the membrane-anchored 44 kDa form (G285 – V582) as 
well as the soluble released catalytic domain (18 kDa) 101,110, whereas non-autocatalytic 
processing of MT1-MMP results in a 50 – 52 kDa soluble fragment consistent with the 
entire extracellular domain 100,107,108,110. These fragments have been found in the 
supernatants of various cells, including breast carcinoma, lung fibroblasts, endothelial and 
fibrosarcoma cells (reviewed in 274). MT1-MMP shedding of the entire extracellular 
domain resulting in the secretion of the 50 – 52 kDa fragment into the medium leaves the 
transmembrane and intracellular domain remaining within the cell membrane. This raises 
the possibility that MT1-MMP ectodomain shedding is the initial step prior to processing 
that leads to the proteolytical release of the intracellular domain (chapter 1.4). 
 
The aim of this part of the thesis was to investigate whether the MT1-MMP intracellular 
domain, which is known to be involved in various cellular responses (chapter 1.3.5), is 
proteolytically released and has a potential function in regulating gene transcription.  
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3.3.1 The MT1-MMP intracellular domain is released in a Luciferase 
reporter gene assay 
 
The intramembrane proteolysis leading to the release of the intracellular domains of 
Notch-1, APP, SREBP2 and LRP1 in a ?-secretase or S2P dependent way was 
demonstrated by using a reporter gene assay (summarised in Figure 3.44A) 59,151,179,275,276. 
A similar methodical approach was adapted to test whether the MT1-MMP intracellular 
domain (ICD) is proteolytically released.  
Briefly, a construct encoding a full-length MT1-MMP with a GAL4 DNA-binding and a 
VP16 transactivation fusion domain (GAL4/VP16) inserted between the transmembrane 
and intracellular domain of MT1-MMP was used (GVMT1, Figure 3.44B). Previous 
attempts to fuse the GAL4/VP16 domain to the C-terminal end of the MT1-MMP ICD, as 
done for LRP1 and APP (Figure 3.44B), prevented trafficking of MT1-MMP to the cell 
surface (CH Roghi, personal communication). Proteolytic release of the carboxy-terminal 
part of MT1-MMP including the GAL4/VP16 fusion domain was subsequently detected by 
measuring the expression of a co-transfected Luciferase reporter gene under the control of 
a minimal GAL4-binding promoter (Figure 3.44B). Thereby, the Luciferase expression 
measured is proportional to the release of the MT1-MMP ICD. GAL4/VP16 fusion domain 
containing cDNAs of LRP1 and APP (GVLRP1 and GVAPP, Figure 3.44B), both of 
which undergo ?-secretase dependent RIP, were used as positive controls in this assay.  
Expression of the reporter gene construct pG5luc alone or MT1-MMP wild-type (MT1-
WT) was not found to induce Luciferase expression (Figure 3.44C-E). As expected, 
GVAPP expression in MCF-7 (Figure 3.44C) and HEK293 (Figure 3.44D) cells increased 
Luciferase activity (P < 0.0001 compared to pG5luc transfected control), whereas LRP1 
induced Luciferase expression was only detected to be significantly increased in MCF-7 
cells (Figure 3.44C, P < 0.05).  
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Figure 3.44: The MT1-MMP intracellular domain is proteolytically released as 
detetcted in a reporter gene assay 
(A) Schematic representation of presenilin-or S2P dependent RIP of Notch-1, APP and SREBP. Taken from 
144 (B) Schematic representation of wild-type MT1-MMP (MT1-WT) and MT1-MMP-GAL4/VP16 
(GVMT1) constructs as well as the LRP1-GAL4/VP16 (GVLRP1) and APP-GAL4/VP16 (GVAPP) 
constructs used as positive controls. The GAL4 DNA binding domain (amino acids 1-147) and the VP16 
transactivation domain of the Herpes simplex virus protein VP16 were fused between the transmembrane and 
intracellular domain of full-length MT1-MMP. ICD release was assessed by detection of the transcriptional 
activation of the co-transfected Luciferase reporter-gene under the control of a GAL4-binding minimal 
promoter. (C) MCF-7 cells or (D) HEK293 cells were co-transfected with the reporter gene plasmid pG5luc, 
control vector pCMV-?-Gal and either MT1-WT, GVMT1, GVLRP1 or GVAPP. The cells were lysed 24 
hours after transfection and Luciferase and ?-galactosidase activities were determined. Luciferase expression 
was normalised for transfection efficiency by dividing relative light unit values by those obtained for ?-
galactosidase expression. Data represent the mean Luciferase expression of three independent experiments 
measured in luminescence ± S.E.M. with P < 0.05 (*) and P < 0.0001 (***), Student t-test. (E) HEK293 cells 
were transfected with the reporter gene plasmid pG5luc, control vector pCMV-?-Gal and either MT1-WT, 
GVMT1 or GVLRP1 and stimulated in the absence or presence of 100 nM phorbol 12-myristate 13-acetate 
(PMA) for 24 hours. Luciferase reporter gene expression was corrected as described above. Data represent 
the mean Luciferase expression of three independent experiments measured in luminescence ± S.E.M. with P 
< 0.0001 (***), Student t-test. 
 
The expression level of the Luciferase reporter gene construct was increased in MCF-7 
cells overexpressing GVMT1 by ~23 fold compared to pG5luc transfected control (P < 
0.0001), 5.4 fold more than the positive control LRP1 (Figure 3.44C). A similar result was 
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obtained in GVMT1 expressing HEK293 cells (Figure 3.44D, P < 0.05 compared to 
pG5luc transfected control). Incubation of the cells with 100 nM phorbol 12-myristate 13-
acetate (PMA), which has been shown to induce ectodomain shedding of MT1-MMP 
100,108,277 and to increase intracellular domain release of LRP1 151 (Figure 3.44E), amplified 
the increase in Luciferase expression by ~147 fold in GVMT1 expressing cells compared 
to MT1-WT transfected control (Figure 3.44E, P < 0.0001). 
These findings indicate that the MT1-MMP ICD is released as shown in a reporter gene 
assay. Since the GAL4 DNA-binding sequence, which is still attached to the released 
MT1-MMP ICD following cleavage, has a nuclear translocation sequence (NLS) 278, this 
assay is not sufficient to demonstrate a nuclear translocalisation of the MT1-MMP ICD 
itself. 
 
3.3.2 Src and proteasome activities are required for the MT1-MMP 
intracellular domain release 
 
It was subsequently tested whether the activation of Luciferase activity by GVMT1, as 
previously observed (Figure 3.44, C-E), is dependent on proteinase activity. A comparison 
of transmembrane domain (TMD) sequences of proteins known to be processed in a 
presenilin dependent way to the TMD sequence of MT1-MMP, revealed a potential ?-
secretase cleavage site at the MT1-MMP AV559 motif (Figure 3.45A, empty arrowhead), 
whereas the intracellular K581 residue might provide a target for the proteasome/ubiquitin 
system involved in RUP.  
Various inhibitors of ?-secretase, the proteasome, Src and rhomboid proteinases were 
tested and the MT1-MMP ICD release was detected using the reporter gene assay as 
previously described. Inhibitors of site-2 proteinases (S2P) and signal-peptide peptidases 
(SPP) were disregarded in this initial screen since these proteinases were described to 
process type-II transmembrane proteins only (chapter 1.4.1).  
As observed before, GVMT1 expressing cells increased the expression of the reporter gene 
significantly compared to the MT1-WT expressing control (Figure 3.45B-D, Figure 
3.44C). Inhibition of Src by using PP2 and inhibition of the proteasome (Lactacystin, MG-
132, Epoxomicin, clasto-Lactacystin ?-lactone) led to a decrease in Luciferase expression 
as compared to the DMSO control (Figure 3.45C, D), whereas inhibition of ?-secretase (?-
secretase inhibitor IX (DAPT), XVII (31C), XXI (Compound E)) and Rhomboid 
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proteinases (DCI) did not alter the Luciferase activity induced by GVMT1 (Figure 3.45B, 
D). Luciferase activity was furthermore found to decrease in a dose-dependent way 
following treatment of GVMT1 expressing cells with increasing concentrations of PP2 or 
Lactacystin (Figure 3.45E).  
These findings indicate that the MT1-MMP ICD is not released in a ?-secretase dependent 
way but requires Src and proteasome activities as detected in a reporter gene assay.  
 
 
Figure 3.45: The MT1-MMP ICD is released in a Src and proteasome dependent 
mechanism  
(A) Comparison of the amino acid sequences of the presenilin cleavage sites within the LRP1, APP and 
Notch transmembrane domains with the MT1-MMP TMD sequence. The S3 cleavage site of Notch, the 
corresponding ?-secretase cleavage site in APP as well as a putative ?-secretase cleavage site in MT1-MMP 
or an ubiquitination site within the ICD are indicated by open arrowheads. The black arrowheads show the 
APP ?-secretase cleavage sites that lead to the production of A? 40 and A? 42. (B-E) MCF-7 cells were co-
transfected with the reporter gene plasmid pG5luc, control vector pCMV-?-Gal and either MT1-WT or 
GVMT1. Cells were incubated for 24 hours with either DAPT, 31C or Compound E (B), Lactacystin, MG-
132, Epoxomicin and clasto-Lactacystin ?-Lactone (C), DCI and PP2 (D) or various concentrations of PP2 
and Lactacystin, as indicated (E). Luciferase expression was normalised for transfection efficiency by 
dividing relative light unit values by those obtained for ?-galactosidase expression. Data represent the mean 
luminescence of three independent experiments measured in luminescence ± S.E.M. with P < 0.05 (*); P < 
0.001 (**); P < 0.0001 (***), Student t-test. ns, non-significant. 
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3.3.3 The MT1-MMP transmembrane and intracellular domains are 
both required for proteolytic cleavage 
 
RIP has been shown to take place within the bilipid layer of the plasma membrane 
targeting the transmembrane domains of various proteins including APP, Notch-1, 
SREBP2 and LRP1. In contrast, the release observed of the MT1-MMP ICD was shown to 
be dependent on the intracellularly active Src and Proteasome function (Figure 3.45C-E) 
and thus suggests that the MT1-MMP ICD is proteolytically targeted directly during this 
process. 
To investigate the requirement for the MT1-MMP transmembrane and intracellular 
domains in this proteolytic event independently, both domains were separately exchanged 
for the corresponding APP domains (Figure 3.46A, B). MCF-7 cells were transfected with 
MT1-WT, GVMT1 and GVMT1 containing either the APP transmembrane domain 
(Figure 3.46A, GVMT1-APP-TMD) or an APP intracellular domain (Figure 3.46B, 
GVMT1-APP-ICD). GVAPP expressing cells were assayed as a positive control.  
As previously observed, expression of GVMT1 induced Luciferase reporter gene 
expression significantly compared to MT1-WT transfected cells (P < 0.0001; Figure 
3.46C, Figure 3.44C - E, Figure 3.45). This effect was ablated after incubation with PP2 
and Lactacystin as shown before (Figure 3.45C – E, Figure 3.46C; P < 0.0001 and P < 
0.05, respectively, compared to DMSO control), but not following treatment with the ?-
secretase inhibitor Compound E (Figure 3.46C and Figure 3.45B). In contrast, Luciferase 
expression in GVAPP expressing cells was effectively reduced by Compound E treatment 
(P < 0.0001 compared to DMSO control) but not after Src and Proteasome inhibition 
(Figure 3.46C). Compound E treatment ablated reporter gene expression in GVMT1-APP-
TMD but not in GVMT1-APP-ICD transfected cells. This observation was expected since 
?-secretase inhibition attenuates presenilin dependent intramembrane cleavage of APP. 
Interestingly, both constructs, GVMT1-APP-TMD and GVMT1-APP-ICD were shown to 
induce less reporter gene expression following PP2 and Lactacystin treatments as 
compared to DMSO control (Figure 3.46C, P < 0.001 and P < 0.05, respectively), 
suggesting that both domains are necessary for the proteolytic release of the MT1-MMP 
ICD.  
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Figure 3.46: The MT1-MMP intracellular and transmembrane domains are both 
involved in the Src and Proteasome dependent proteolytic cleavage 
(A) The transmembrane domain of the GVMT1 construct was exchanged to that of APP (GVMT1-APP-
TMD) or (B) the MT1-MMP intracellular domain was replaced with the APP ICD (GVMT1-APP-ICD). (C) 
MCF-7 cells were co-transfected with the reporter gene plasmid pG5luc, the control vector pCMV-?-Gal and 
either MT1-WT, GVMT1, GVMT1-APP-ICD, GVMT1-APP-TMD or GVAPP as control. Cells were 
incubated with Compound E, PP2, Lactacystin or DMSO as control. Luciferase reporter gene expression was 
detected and normalised for transfection efficiency by dividing relative light unit values by those obtained for 
?-galactosidase expression. Data represent the mean Luciferase expression of three independent experiments 
measured in luminescence ± S.E.M. with P < 0.05 (*), P < 0.001 (**) and P < 0.0001 (***), Student t-test. 
 
3.3.4 The MT1-MMP intracellular domain is enriched in the nucleus 
 
The induction of reporter gene expression following GVMT1 expression previously 
described in this thesis (Figure 3.44 - Figure 3.46), raised the possibility that the MT1-
MMP ICD might translocte into the nucleus to affect gene expression as either a 
transcriptional regulator or co-factor. To test this hypothesis, MCF-7 cells were transfected 
with full-length MT1-MMP (MT1-WT) and the localisation of the MT1-MMP 
extracellular and intracellular domain was assessed by confocal microscopy using 
antibodies raised against the MT1-MMP ICD (ab28209) and MT1-MMP extracellular 
domain (ECD; N175/6).  
As shown in Figure 3.47A, antibodies detecting both domains co-localised within the 
cytoplasm and within the perinuclear region, potentially within the trans-Golgi network 
where MT1-MMP was previously observed 127. In contrast, staining was routinely 
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observed in the nuclear region using the anti-MT1-MMP ICD antibody but not for the 
ECD specific antibody (Figure 3.47A, iv). Staining on empty vector (pcDNA3.1) 
transfected control cells revealed that the nuclear staining detected by the anti-MT1-MMP 
ICD antibody was specific for MT1-MMP expression and does not detect non-specific 
backgound levels (Figure 3.47A, iii, arrows). 
To confirm these findings using a biochemical approach, cells were transfected with MT1-
WT and GVMT1 as control, since the GAL4/VP16 fusion domain is expected to 
translocate to the nucleus due to its intrinsic NLS, and cell extracts were separated into 
nuclear and cytoplasmic fractions followed by immunoblotting. Pro-MT1-MMP, active 
MT1-MMP as well as its ?44 kDa degradation product could be detected within the 
cytoplasmic fraction. However the ?3 kDa band expected for the MT1-MMP ICD was not 
found within the nuclear extract in both transfectants, even after blocking the nuclear 
export by Leptomycin B treatment (Figure 3.47B). Since the intracellular domain of 
GVMT1 transfected cells was also not found to be enriched in the nucleus, this result is 
most likely to be a consequence of a lack of sensitivity by either the antibody used or by 
the detection method itself.  
 
Intramembrane proteolysis has been shown to occur following ectodomain shedding of 
transmembrane proteins. This first proteolytic step was shown to be mainly mediated by 
metalloproteinase activity (chapter 1.4). Various publications have shown MT1-MMP to 
undergo ectodomain shedding, leading to the accumulation of ?15 kDa and ?50 – 52 kDa 
fragments within the medium 100,274,277. These fragments have been reported to be released 
due to an autocatalytic (Figure 3.47C (1)) or non-autocatalytic process (Figure 3.47C (2)). 
Non-autocatalytic processing has been recently shown to be a two-step mechanism, with 
an unknown protease involved in the first cleavage and an ADAM to mediate the 
generation of the 52 kDa fragment 112. 
In order to test whether ectodomain shedding is taking place in MCF-7 cells, cells were 
transfected with MT1-WT or pcDNA3.1 control and were stimulated with PMA for 24 
hours, where indicated, to induce the previously described ectodomain shedding of MT1-
MMP 100,108,277. Both, the ?15 kDa and ?50 – 52 kDa fragments were detected in the 
conditioned medium of MT1-WT expressing MCF-7 cells (Figure 3.47D), indicating that 
MT1-MMP ectodomain shedding occurs in MCF-7 cells. However, shedding was not 
found to be altered following PMA stimulation. 
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Figure 3.47: The MT1-MMP intracellular domain is released and is detected in the 
nucleus of MCF-7 cells by immunostaining 
(A) MCF-7 cells were transfected with either MT1-WT (i, ii, iv) or pcDNA3.1 empty vector control (iii) and 
the localisation of MT1-MMP was detected with an anti-MT1-MMP ICD specific antibody (ab28209, 
AlexaFluor® 488 secondary, i, iii) and an anti-MT1-MMP antibody raised against the ECD (N175/6, 
AlexaFluor® 546 secondary, ii). Inset panel shows magnified portion of the merged image, as indicated 
(dashed square). Arrows in iii indicate that the nuclear region is not stained unspecifically in pcDNA3.1 
transfected cells. (B) MCF-7 cells were transfected with MT1-WT, GVMT1 or pcDNA3.1 vector control and 
treated with Leptomycin B, where indicated. Nuclear and cytoplasmic fractions were isolated and 
immunoblotted with an anti-MT1-MMP ICD antibody (ab28209). (C) Schematic representation of MT1-
MMP ectodomain shedding due to autocatalytic (1) or non-autocatalytic (2) processing (adapted from 274). 
(D) MCF-7 cells were transfected with MT1-WT or pcDNA3.1 control and were treated with 100 nM PMA 
for 24 hours where indicated. The conditioned medium was collected, total protein was precipitated and 
immunoblotted with an anti-MT1-MMP ECD antibody (N175/6).  
 
In order to quantify the previously shown nuclear staining of the MT1-MMP ICD (Figure 
3.47A) and to test whether the nuclear localisation of the ICD observed correlates with the 
potential Src and Proteasome dependent ICD release, MT1-WT expressing MCF-7 cells 
were stained with an anti-MT1-MMP ICD or ECD antibody, as described before. Nuclear 
staining intensities were subsequently measured using the iCys™ laser scanning cytometer 
as described in chapter 2.2.4.3.3.  
Quantification of the nuclear staining intensities revealed that the fluorescence detected by 
the MT1-MMP extracellular domain antibody was similar between MT1-WT and 
pcDNA3.1 control transfected cells indicating that only background levels of fluorescence 
were detected within the nuclear region (Figure 3.48B). A similar detection level of anti-
MT1-MMP ECD antibody mediated fluorescence in the nucleus was obtained after 
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treatment of MT1-WT expressing cells with PP2, Lactacystin or PMA. In contrast, staining 
with the anti-MT1-MMP ICD antibody led to a significant increase in nuclear fluorescence 
in MT1-MMP expressing cells compared to pcDNA3.1 transfected controls (Figure 
3.48A). 
 
Figure 3.48 Nuclear localisation of the MT1-MMP intracellular domain is reduced by 
Src- and Proteasome inhibition 
(A,B) MCF-7 cells were transfected with either pcDNA3.1 vector control or MT1-WT and treated for 24 
hours with PP2, Lactacystin, PMA or DMSO as a control. MT1-MMP was detected with an anti-MT1-MMP 
intracellular domain antibody (ab28209, AlexaFluor® 488 secondary) or an anti-MT1-MMP extracellular 
domain specific antibody (N175/6, AlexaFluor® 488 secondary). Bar-graphs represent the quantification of 
nuclear staining intensities of both antibodies by scanning ~10,000 cells per biological triplicate using the 
CompuCyte iCys™ laser scanning cytometer ± 95% Confidence Intervals. The nuclear region was defined 
by counter-staining with DAPI as described in chapter 2.2.4.3.3. Dashed lines indicate the mean fluorescence 
intensity of pcDNA3.1 transfected cells. (C,D) MDA-MB-231 cells were transduced with 1 pfu/cell pLKO 
empty lentiviral vector control, non-targeting shRNA control (nt) or MT1-MMP targeting shRNA (MT1-sh3 
and MT1-sh4). MT1-MMP was detected with an anti-MT1-MMP intracellular domain antibody (ab28209, 
AlexaFluor 488® secondary) or an anti-MT1-MMP extracellular domain specific antibody (N175/6, 
AlexaFluor 488® secondary). Bar-plots represent the quantification of nuclear staining intensities of both 
antibodies by scanning ~10,000 cells per biological triplicate using the CompuCyte iCys system ± 95% 
Confidence Intervals. The nuclear region was defined by counter-staining with DAPI as described in chapter 
2.2.4.3.3. Dashed lines indicate the mean fluorescence intensity of MDA-MB-231 wild-type cells.  
 
Inhibition of Src and Proteasome activity using PP2 or Lactacystin respectively reduced 
the detected nuclear fluorescence significantly compared to the DMSO control (Figure 
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3.48A). Stimulation of cells with PMA augmented the level of nuclear MT1-MMP ICD 
detection, albeit not significantly (compared to DMSO treated control). These findings are 
consistent with the data obtained from the GAL4/VP16 reporter chimera (Figure 3.44 and 
Figure 3.45) and indicate that the MT1-MMP ICD localisation increases in the nucleus in a 
Src and proteasome dependent way. 
To confirm that the MT1-MMP ICD detection in MCF-7 cells is not a cell specific 
observation or a potential artefact of MT1-MMP overexpression, the nuclear localisation 
of the ICD was assessed in MDA-MB-231 cells, which endogenously express MT1-MMP 
(Figure 3.32). As a control, the expression of MT1-MMP was silenced using shRNA as 
described previously (chapter 3.2.1.3). Since MT1-MMP silencing is used only as a control 
for detecting the protease itself rather than investigating MT1-MMP down-stream effects, 
the previously described limitations of the shRNA approach due to off-target effects and a 
potential ?-interferon response, were considered negligible (Figure 3.37 and Figure 3.38).  
The detection of the MT1-MMP ICD and ECD within the nuclear region led to similar 
results in MDA-MB-231 cells as in MCF-7 cells. As shown in Figure 3.48C, the MT1-
MMP intracellular domain was detected in wild-type cells, pLKO and non-targeting (nt) 
shRNA controls but its fluorescent detection was significantly reduced in MT1-MMP 
shRNA3 expressing cells. In contrast, the nuclear MT1-MMP ICD detection level of 
shRNA4 transduced cells was not affected compared to wild-type MDA-MB-231 cells. 
These findings are in agreement with the weaker knockdown of MT1-MMP protein 
expression in shRNA4 expressing cells compared to shRNA3 as determined by 
immunoblotting (Figure 3.36B). The MT1-MMP extracellular domain staining was 
detected at low levels within the nuclear region and was not affected by MT1-MMP 
knockdown (Figure 3.48D). 
These data indicate that in two different breast cancer cell lines that are either deficient in 
MT1-MMP expression or express the protease at high levels, the intracellular domain 
staining but not the extracellular domain staining was detected within the nuclear region, 
suggesting that MT1-MMP ICD nuclear accumulation may be a general observation in 
breast cancer cells. 
 
It has been shown previously that the intracellular domain of MT1-MMP wild-type 
transfected MCF-7 cells could not be detected in the nucleus by immunoblotting (Figure 
3.47B), potentially due to the low amounts of MT1-MMP ICD enriched within the nuclear 
fraction or due to the lack of sensitivity of the antibody or detection method used. Blocking 
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the nuclear export by using Leptomycin B and thus enriching proteins within the nuclear 
region, was not sufficient to detect the MT1-MMP ICD (Figure 3.47B). Therefore, another 
approach using a soluble biotinylated MT1-MMP ICD penetratin peptide or a biotinylated 
control penetratin peptide was used in order to detect the MT1-MMP ICD in the nucleus 
using biochemical detection methods (Figure 3.49A). Thus, the Biotin tag facilitates MT1-
MMP ICD detection by using a different antibody.  
The penetratin peptide consists of a 16 amino acid sequence (RQIKIWFQNRRMKWKK) 
taken from the Drosophila melanogaster Antennapedia transcription factor which has the 
ability to penetrate cell membranes 279. MCF-7 cells were incubated for 3 hours with 25 
?M of the MT1-MMP ICD or control penetratin peptide and cells were subsequently 
trypsinised to remove the residual penetratin peptide from the cell surface, which had not 
translocated into the cytoplasm. The nuclear and cytoplasmic protein fractions were 
isolated, and the purity of nuclear protein isolation was confirmed by immunoblotting. The 
isolated nuclear fraction was found to be positive for the marker of the nuclear envelope 
Lamin B1 and negative for TGN46, a marker of the trans-Golgi network (TGN) (Figure 
3.49B). Both biotinylated peptides could be readily detected in the whole cell lysates 
(Input), whereas only the MT1-MMP ICD penetratin peptide was found within the 
cytoplasmic and nuclear fraction (Figure 3.49B).  
 
 
Figure 3.49: The MT1-MMP ICD is found in the nuclear fraction of MCF-7 cells 
(A) Schematic representation of the MT1-MMP penetratin peptide constructs used. (B) MCF-7 cells were 
incubated with 25 ?M MT1-MMP ICD or control biotinylated penetratin peptide for 3 hours. Proteins were 
isolated in nuclear and cytoplasmic fractions and both fractions as well as Input controls (whole cell lysate) 
were immunoblotted with an anti-Biotin, an anti-Lamin B1 or an anti-TGN46 antibody.  
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These findings suggest that the control peptide is most likely membrane associated as it is 
not detected within the cytoplasmic fraction but is present in the whole cell lysate (Input). 
In contrast, the MT1-MMP ICD could be detected within the nuclear fraction (Figure 
3.49B), indicating that the biotinylated soluble MT1-MMP ICD provides a promising tool 
to investigate nuclear localisation due to its highly sensitive Biotin-tag detection.  
 
3.3.5 The MT1-MMP intracellular domain is enriched in nuclei in vivo 
 
The MT1-MMP ICD was detected in the nucleus of MCF-7 and MDA-MB-231 cells by 
immunostaining and subsequent quantification (Figure 3.47A, Figure 3.48A, C). 
To test whether the MT1-MMP ICD is also enriched in the nuclear region in vivo, human 
mammary carcinoma tissue sections were obtained, embedded in paraffin and 
immunostained with an anti-MT1-MMP ICD antibody (ab28209) (in collaboration with 
Dr. Bence Sipos). Representative sections derived from two different mammary tumours 
are shown in Figure 3.50B and E. Notably, the MT1-MMP ICD was detected in the 
cytoplasma and nuclei of tumour cells (Figure 3.50C, F; black arrows). Immune cells, 
which infiltrated the tumour mass, also revealed a membrane-associated and nuclear MT1-
MMP ICD staining pattern (Figure 3.50A, D; empty arrowheads). In contrast, detection of 
MT1-MMP with the extracellular domain specific anti-MT1-MMP antibody revealed the 
absence of MT1-MMP ECD within the nuclear area (Figure 3.42). 
These preliminary immunohistochemical stainings of human mammary carcinoma samples 
demonstrate that the MT1-MMP ICD is also enriched in the nuclei of tumour cells in vivo, 
emphasising the relevance of the MT1-MMP ICD release in human breast carcinomas. A 
comprehensive study using breast invasive ductal carcinoma tissue microarrays (US 
Biomax, Inc., Heidelberg, GER) is currently being performed. 
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Figure 3.50: The MT1-MMP ICD is detected in the nuclei of human mammary 
carcinoma tissue sections 
Representative samples of paraffin-embedded sections derived from two human breast carcinomas were 
immunostained with an anti-MT1-MMP ICD (ab28209) antibody. Black arrows indicate the cytoplasmic and 
nuclear staining of tumour cells, whereas empty arrowheads show membrane-associated and nuclear staining 
pattern of infiltrating immune cells. Upper and lower panels (A and D, C and F) show magnified portions of 
each image (B and E), as indicated (dashed squares). Tissue specimens were counterstained with 50 % 
haemalaun. 100 ? magnification. 
 
3.3.6 Identification of MT1-MMP nuclear binding proteins 
 
The previoulsy demonstrated enrichment of the MT1-MMP ICD in MCF-7 cells using 
immunofluorescence quantification (Figure 3.48A) and the detection of a soluble 
biotinlylated MT1-MMP ICD within the nuclear fraction by immunoblotting (Figure 
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3.49B), raised the possibility that the MT1-MMP ICD may associate with nuclear proteins. 
In order to test whether the MT1-MMP ICD shown to be enriched in the nuclear fraction is 
interacting with nuclear proteins, MCF-7 cells were transfected with wild-type MT1-MMP 
(MT1-WT) or pcDNA3.1 control. Protein extracts were isolated from nuclear and 
cytoplasmic fractions as previously described (chapter 2.2.3.3). Separation of the nuclei 
from the cytoplasm and membrane fractions was verified by microscopy after each 
homogenisation step (Figure 3.51A) as well as by immunoblotting with an anti-Lamin B1 
or anti-TGN46 antibody, markers of the nuclear or trans-Golgi network, repectively 
(Figure 3.51B).  
 
 
Figure 3.51: Nuclear immunoprecipitation with MT1-MMP intracellular domain 
specific antibody 
(A) Images taken from different steps of mechanical homogenisation. (B) Western Blot analysis of nuclear 
and cytoplasmic fractions with an anti-Lamin B1 antibody as nuclear marker, an anti-TGN46 antibody as 
marker for the trans-Golgi network or an anti-MT1-MMP antibody (LEM-2/15.8). (C) Proteins of the nuclear 
fraction, derived from cells transfected with MT1-WT or pcDNA3.1 empty vector control, were 
immunoprecipitated with an anti-MT1-MMP ICD antibody (ab28209) and total protein was visualised by 
Coomassie blue staining. Red arrows indicate protein-bands that are present only in the MT1-WT transfected 
sample. 
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The nuclear fraction was subsequently immunoprecipitated with an anti-MT1-MMP ICD 
antibody (ab28209) and immunoprecipitates were run on a 4 – 20% gradient gel (Figure 
3.51C). Total protein staining using Coomassie blue revealed proteins in the MT1-MMP 
expressing sample which were absent in the pcDNA3.1 transfected control, as indicated by 
red arrows (Figure 3.51C). 
These findings indicate that proteins were immunoprecipiated with the anti-MT1-MMP 
ICD antibody in the nuclear fraction. Mass spectrometry will be performed in order to 
identify the proteins that were found in a complex with the MT1-MMP ICD.  
 
3.3.7 The MT1-MMP intracellular domain is ubiquitinated 
 
Although the MT1-MMP ICD was found in the nucleus using a tagged penetratin peptide 
(Figure 3.49B) it was not detected in MT1-WT transfected cells using biochemical 
detection methods (Figure 3.47B). Therefore, a different approach was applied to test for 
MT1-MMP ICD enrichment in the nuclear fraction of MCF-7 cells by using a double-
tagged MT1-MMP mutant (MT1-MYC-FLAG, Figure 3.52A) in order to (i) use an 
alternative method to the penetratin peptide and (ii) to test whether the lack of sensitivity 
of the anti-MT1-MMP ICD antibody (ab28209) by immunoblotting is the reason that the 
MT1-MMP ICD was not detected in the nuclear fraction of wild-type transfected cells 
(Figure 3.47B). 
Cells were transfected with the truncated double-tagged MT1-MMP mutant (MT1-MYC-
FLAG), which has a Myc tag fused to its intracellular domain and a Flag tag attached to its 
extracellular domain (Figure 3.52A), and the nuclear fraction was isolated. 
Immunoblotting with an anti-Myc antibody directed against the intracellular tag, revealed 
that in contrast to the expected ?5 – 6 kDa fragment, a higher band at approximately ?16 
kDa was observed in the MT1-MYC-FLAG transfected cells compared to pcDNA3.1 
transfected control (Figure 3.52B).  
The difference in the molecular weight of ?8 - 10 kDa as well as the previous findings 
indicating that the MT1-MMP ICD release occurs in a proteasome dependent way (Figure 
3.45) raised the possibility that the MT1-MMP ICD could be post-translationally modified 
by ubiquitination. The MT1-MMP intracellular domain has a unique intracellular K581 
residue, which might be a potential ubiquitination site (Figure 3.45A, arrowhead). In order 
to test this hypothesis, MCF-7 cells were transfected with MT1-WT, an HA-tagged 
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Ubiquitin or an HA-tagged K11,27,29,48,63R Ubiquitin mutant, which prevents the 
formation of poly-ubiquitin chains occurring during ubiquitination. Immunoprecipitation 
of whole cell lysates with an anti-MT1-MMP ICD antibody and immunoblotting with an 
anti-HA antibody revealed that MT1-MMP and Ubiquitin interact. A characteristic smear 
of ubiquitin detection was observed in MT1-WT and Ubiquitin expressing cells, as well as 
a single band in cells expressing MT1-MMP and the Ubiquitin mutant at a molecular 
weight corresponding to full-length ubiquitinated MT1-MMP (?70 kDa, Figure 3.52C).  
 
Figure 3.52: The MT1-MMP intracellular domain is ubiquitinated 
(A) Schematic representation of the MT1-MMP and Ubiquitin constructs used. HA, hemagglutinin epitope 
(YPYDVPDYA) tag; Bio, Biotin tag. (B) MCF-7 cells were transfected with pcDNA3.1 control or the MT1-
MYC-FLAG construct and nuclear proteins were isolated. The nuclear fraction was immunoblotted with an 
anti-Myc antibody. Asterisk indicates a non-specific signal. (C) MCF-7 cells were transfected with 
pcDNA3.1 control, MT1-WT, HA-tagged Ubiquitin, or the HA-tagged Ubiquitin K11,27,29,48,63R mutant, 
as indicated. Cell extracts were immunoprecipitated with an anti-MT1-MMP ICD specific antibody 
(ab28209) and immunoblotted with an anti-HA antibody. (D) MCF-7 cells were co-transfected with 
pcDNA3.1 control, MT1-MYC-FLAG and HA-tagged Ubiquitin, as indicated. Nuclear proteins were 
isolated, immunoprecipitated with an anti-HA antibody and immunoblotted using an anti-Myc antibody. 
Asterisk indicates a non-specific signal. 
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Another band at ?50 kDa was observed in both samples, raising the possibility of an 
ubiquitinated ?44 kDa MT1-MMP autocatalytic degradation fragment (Figure 3.52C).  
To test whether MT1-MMP ICD ubiquitination is also detected in the nuclear fraction, thus 
explaining the ?16 kDa fragment detected in the nuclear extract of MCF-7 cells expressing 
the MT1-MYC-FLAG construct (Figure 3.52B), MCF-7 cells were co-transfected with 
either pcDNA3.1 control or MT1-MYC-FLAG as well as the HA-tagged Ubiquitin. Cell 
extracts were immunoprecipitated with an anti-HA antibody and immunoprecipitates were 
immunoblotted with an anti-Myc antibody. As shown in Figure 3.52D, a ?16 kDa band 
was detected in cells co-expressing MT1-MYC-FLAG and HA-ubiquitin, thus indicating 
that the MT1-MMP ICD may be ubiquitinated within the nuclear fraction of MCF-7 cells. 
These data show that MT1-MMP may be ubiquitinated, as detected in whole cell lysates 
and in nuclear extracts. However, the precise mechanism and form of ubiquitination cannot 
be determined from this experiment. Mono-ubiquitination as well as poly-ubiquitination at 
K63 regulates various processes including endosomal sorting, trafficking, DNA repair, 
activation of kinases, inflammatory responses as well as regulation of nuclear import 
280,281. Poly-ubiquitination at K48 targets proteins for proteasomal degradation only 282,283. 
Single lysine mutations within the Ubiquitin sequence need to be generated in order to 
address the question of MT1-MMP ubiquitination in more detail. 
 
3.3.8 The MT1-MMP intracellular Lysine581 is important for nuclear 
localisation of the MT1-MMP intracellular domain 
 
Ubiquitination was usually associated with targeting proteins for proteasomal degradation. 
However, in recent publications new functions of protein ubiquitination have emerged, 
including the regulation of cell cycle progression, stress response, signal transduction, 
DNA repair, apoptosis and transcriptional regulation (reviewed in 280). The proteasome 
does not degrade proteins into their constitutive amino acids, but generates short peptides 
of approximately 20 amino acids, a similar size to the MT1-MMP ICD. Interestingly, 
ubiquitination can also play a role in regulating nuclear import by proteasomal processing 
of transcription factor zymogens or by causing nuclear translocation of proteins lacking a 
nuclear localisation sequence (NLS) 280,284-286. As the MT1-MMP ICD may be 
ubiquitinated at its intracellular lysine K581 (Figure 3.52), ubiquitination could provide an 
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interesting mechanism for nuclear import of the MT1-MMP ICD as it lacks an NLS 
consensus sequence. 
To test whether K581 affects nuclear localisation of the MT1-MMP ICD, a double-tagged 
truncated MT1-MMP lysine mutant (MT1-MYC-FLAG-K581A) was generated (Figure 
3.53B). MCF-7 cells were transfected with MT1-MYC-FLAG (Figure 3.53A), MT1-
MYC-FLAG-K581A (Figure 3.53B) or MT1-?ECD-FLAG (Figure 3.53C), permeabilised 
and the localisation of the external Flag and the internal Myc tag was assessed by confocal 
microscopy. The nuclei were visualised by counter-staining with DAPI. The external Flag 
tag could be detected within the cytoplasm for all cDNAs transfected, especially within 
perinuclear vesicles, possibly the Golgi, and at or close to the plasma membrane (Figure 
3.53). The intracellular Myc tag was detected within the nuclear region of MT1-MYC-
FLAG expressing MCF-7 cells (Figure 3.53A), consistent with immunofluorescence data 
obtained from full-length MT1-MMP transfected cells (Figure 3.47A, Figure 3.48A). 
 
 
 
Figure 3.53: Nuclear localisation of MT1-MMP intracellular domain depends on 
intracellular Lysine581 
MCF-7 cells were transfected with the double-tagged MT1-MYC-FLAG (A), the MT1-MYC-FLAG-K581A 
(B) or the MT1-?ECD-FLAG (C) construct and the localisation of the internal Myc and the external Flag tag 
was assessed with an anti-Myc (9B11) or an anti-FLAG (M2) antibody by confocal microscopy. Nuclei were 
counter-stained with DAPI.  
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Interestingly, Myc expression in the lysine mutant (MT1-MYC-FLAG-K581A) was 
redistributed and significantly reduced within the nuclear region (Figure 3.53B). 
Expression of the non Myc-tagged control (MT1-?ECD-Flag) led to the non-specific 
detection of AlexaFluor® 488 induced background staining (Figure 3.53 C).  
These findings show that the MT1-MMP K581 residue plays a potential role in the MT1-
MMP ICD localisation in the nucleus.  
In order to confirm this observation and to quantify nuclear localisation of the MT1-MMP 
ICD, the MT1-MYC-FLAG double tagged construct as well as the corresponding K581 
mutant were expressed in MCF-7 cells and the nuclear localisation of the internal Myc and 
the external Flag tag was analysed by iCys™ laser scanning cytometer quantification as 
previously described using an anti-Myc and an anti-Flag antibody (chapter 2.2.4.3.3).  
 
Figure 3.54: Quantification of nuclear staining in MT1-MMP double-tagged cDNA 
transfected cells 
MCF-7 cells were transfected with pcDNA3.1 (detection level presented as dotted lines), the double tagged 
MT1-MYC-FLAG construct as well as the lysine mutant MT1-MYC-FLAG-K581A. Cells were stained with 
an anti-Myc antibody (9B11; AlexaFluor® 488 secondary, A) or an anti-FLAG antibody (M2; AlexaFluor® 
488 secondary, B) and nuclear staining was assessed using the iCys™ laser scanning cytometer. Data 
represent the quantification of nuclear staining intensities ± 95% confidence intervals. 10,000 cells were 
counted per three biological replicates.  
 
As shown in Figure 3.54A, expression of the MT1-MYC-FLAG construct increased the 
detection of the Myc-tagged MT1-MMP ICD in the nucleus significantly compared to 
pcDNA3.1 control, similar to full-length MT1-MMP (Figure 3.48A). In contrast, mutation 
of the K581 residue did not affect the Myc detection level compared to pcDNA3.1 control, 
suggesting that the MT1-MMP intracellular K581 plays a role in nuclear localisation. The 
MT1-MMP extracellular domain antibody staining was detected at similar low levels in the 
nucleus of pcDNA3.1, MT1-MYC-FLAG and MT1-MYC-FLAG-K581A transfected cells 
(Figure 3.54B). 
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Latent forms of transcription factors that are expressed as transmembrane proteins have 
been described to undergo several steps of processing by either RIP or RUP (chapter 1.4). 
The common sequence of action includes ectodomain shedding mediated mainly by a 
metalloproteinase and subsequent proteolysis by either transmembrane proteinases or the 
intracellular functioning proteasome (chapters 1.4) 148,180,183,287. It has been shown that 
MT1-MMP is processed, leading to the release of either a ~16 kDa or a ~50 – 52 kDa 
fragment into the medium 100,108,277, which might be followed by the MT1-MMP ICD 
release (Figure 3.47D). Since the MT1-MMP intracellular lysine (K581) has been shown to 
play a role in nuclear localisation (Figure 3.53, Figure 3.54A), the role of K581 on MT1-
MMP processing within the transmembrane and intracellular domain was tested. 
Therefore, MCF-7 cells were transfected with the double-tagged MT1-MYC-FLAG, the 
corresponding lysine mutant (MT1-MYC-FLAG-K581A) or the pcDNA3.1 vector control. 
Whole cell extracts were immunoblotted with two different anti-Myc antibodies and an 
anti-Flag antibody confirming similar expression levels between the mutants used (Figure 
3.55).  
 
Figure 3.55: MT1-MMP ectodomain shedding is reduced following Lysine581 
mutation 
MCF-7 cells were transfected with pcDNA3.1 vector control, MT1-MYC-FLAG or MT1-MYC-FLAG-
K581A and the proteins of the conditioned medium as well as whole cell extracts were analysed by 
immunoblotting with two different anti-Myc antibodies (9B11, 4A6) and an anti-FLAG antibody (M2).  
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The corresponding conditioned medium was collected, cleared from remaining cells and 
the total soluble protein was concentrated as described (chapter 2.2.3.4). Immunoblotting 
with an anti-Flag antibody revealed that a signal was detected in cells expressing both 
mutants corresponding to the size of the Flag-tagged extracellular stalk region (Figure 
3.55). Interestingly, the amount of MT1-MMP soluble cleavage fragments detected was 
reduced in cells expressing the lysine mutant (MT1-MYC-FLAG-K581A). 
These findings suggest that the MT1-MMP K581 residue plays a role in MT1-MMP 
processing, either within the transmembrane or intracellular domain, leading to the release 
of the extracellular domain.  
 
3.3.9 The soluble MT1-MMP intracellular domain penetratin peptide 
co-immunoprecipitates with RNA-Polymerase II in a ChIP assay 
 
The data obtained previously indicate a proteolytic release of the MT1-MMP ICD (Figure 
3.44 - Figure 3.46), its enrichment in the nucleus (Figure 3.47 - Figure 3.50) as well as its 
interaction with nuclear proteins (Figure 3.51). However, these potential binding-partners 
of the MT1-MMP ICD in the nucleus remain to be identified.  
To test whether the MT1-MMP ICD may play a role in regulating gene transcription, a 
chromatin immunoprecipitation (ChIP) assay was performed. The requirement for a highly 
sensitive and ChIP grade compatible antibody in this assay led to the usage of a tagged 
MT1-MMP ICD construct rather than using the MT1-MMP ICD specific antibody in wild-
type MT1-MMP transfected cells. Also due to the small size of the MT1-MMP ICD, 
epitopes could be masked by binding other proteins.  
Therefore, MCF-7 cells were incubated with 25 ?M control or MT1-MMP ICD penetratin 
peptide and protein – protein as well as protein – DNA complexes were cross-linked by 
paraformaldeyde treatment. Following disruption of the chromatin into ~200 – 1000 bp 
fragments, lysates were immunoprecipitated with an anti-Biotin or an anti-RNA-
Polymerase II (Pol II) antibody and genomic DNA (gDNA) was isolated (summarised in 
Figure 3.56A).  
As no potential target gene was known to be regulated by the MT1-MMP ICD directly 
using the proposed mechanism of ICD release, the previously described regulatory effect 
of MT1-MMP on VEGF-A transcription (chapter 3.1) 73 was tested. The potential presence 
of the VEGF-A promoter region in the MT1-MMP immunoprecipitate was assessed by 
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SYBR® Green based Real-Time PCR, using primer corresponding to the promoter region 
of VEGF-A (Appendix A, Table 8.1). As a positive control gDNA isolated from Pol II 
immunoprecipitated samples was amplified with XBP-1 (X Box-binding protein 1) primer, 
targeting the promoter region of this transcription-factor previsouly described in MCF-7 
cells to recruit Pol II 288.  
 
 
Figure 3.56: The MT1-MMP intracellular domain penetratin peptide does not bind to 
the VEGF-A promoter sequence 
(A) Experimental set-up of the chromatin immunoprecipitation (ChIP) assay. MCF-7 cells were treated with 
25 ?M biotinylated penetratin peptides for 3 hours, washed and protein-protein as well as DNA-protein 
interactions were cross-linked with 1% PFA. Cells were lysed and gDNA was sheared into 200 – 1000 bp 
fragments by sonication. Cell extracts were immunoprecipitated with 3 ?g anti-RNA-Polymerase II or anti-
Biotin antibody and subjected to either immunoblotting or gDNA isolation with subsequent SYBR® Real-
Time PCR analysis. (B) Wild-type MCF-7 cells as well as cells incubated with 25 ?M of either control or 
MT1-MMP ICD penetratin peptide for 3 hours were chromatin immunoprecipitated as described. Samples 
were fixed, sonicated and immunoprecipitated with an anti-Biotin antibody (penetratin peptide samples) or 
with an anti-Polymerase II antibody (wild-type MCF-7) as a control. gDNA of immunoprecipitates was 
isolated and the VEGF-A (penetratin peptide samples) or XBP-1 promoter region (wild-type MCF-7) was 
amplified by SYBR® Green Real-Time PCR. As a negative control up-stream regions of VEGF-A and XBP-
1 were amplified. Data represent the mean relative expression of the promoter region of two independent 
experiments ± S.E.M. in fold change compared to the up-stream regions of VEGF-A or XBP-1 respectively. 
(C) MCF-7 cells were transfected with MT1-WT and treated for 24 hours with DMSO, PP2 or Lactacystin 
where indicated. VEGF-A relative expression levels were detected by TaqMan® Real-Time PCR and were 
normalised to the house-keeping gene GAPDH. Data represent the mean expression of two independent 
experiments ± S.E.M. with P < 0.001 (**). 
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As expected, the XBP-1 promotor region was found to co-immunoprecipitate with Pol II 
and was detected by Real-Time PCR (Figure 3.56B, WT sample). Its expression was found 
to be ?740 fold enhanced over the corresponding XBP-1 up-stream control level, a 
sequence which is not associated with Pol II due to its distance to the promoter. In contrast, 
no amplification of the VEGF-A promoter region was observed in the control or MT1-
MMP ICD penetratin peptide treated samples (Figure 3.56B), suggesting that VEGF-A is 
not regulated by the MT1-MMP ICD directly. These findings are consistent with previous 
results indicating an MT1-MMP induced signalling pathway leading to VEGF-A mRNA 
expression (chapter 3.1, Figure 3.31). 
In addition to Src activity the involvement of proteasome function has been implicated in 
the MT1-MMP ICD release (Figure 3.45C). To confirm that MT1-MMP ICD is not 
regulating VEGF-A expression as part of a transcription-initiation complex, the VEGF-A 
mRNA expression levels of PP2 and Lactacystin treated MT1-WT transfected cells were 
determined by Real-Time PCR. As previoulsy found, the increase of VEGF-A mRNA 
level in MT1-MMP expressing cells treated with the Src inhibitor PP2 was significantly 
less than the increase observed in MT1-WT transfected cells treated with DMSO (P < 
0.001, Figure 3.5A, Figure 3.56C). However, inhibition of proteasome activity by 
Lacatcystin did not affect the increase of VEGF-A mRNA expression compared to DMSO 
treated control, suggesting that MT1-MMP dependent VEGF-A regulation is indeed 
independent of the MT1-MMP ICD release. 
 
To investigate whether the MT1-MMP ICD could be functionally involved in gene 
transcription, albeit the lack of known target genes, a potential complex of the MT1-MMP 
ICD with Pol II was tested by ChIP following immunoblotting. MCF-7 cells were 
incubated with MT1-MMP ICD or control penetratin peptide as previously described and 
cell extracts were co-immunoprecipitated with an anti-Pol II antibody. Immunoprecipitates 
and whole cell lysates (Input) were subsequently analysed by immunoblotting with an anti-
Biotin antibody.  
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Figure 3.57: The MT1-MMP intracellular domain penetratin peptide co-
immunoprecipitates with Polymerase II 
MCF-7 cells were incubated with 25 ?M of MT1-MMP ICD or control penetratin peptide for 3 hours and 
protein – protein as well as protein – chromatin complexes were fixed as decribed above (Figure 3.56A). 
Sonicated chromatin fragments were immunoprecipitated with an anti-Pol II antibody. Input and 
imunoprecipitates were immunobloted with an anti-Biotin antibody. 
 
Both peptides were found at similar expression levels in the whole cell lysate (Input), 
indicating comparable biotinylated peptide penetration in both samples prior to ChIP 
(Figure 3.57). However, in contrast to the control peptide only MT1-MMP ICD containing 
penetratin peptide could be clearly detected after ChIP with Pol II (Figure 3.57).  
These data are (i) consistent with previous findings showing MT1-MMP ICD to be 
enriched in the nuclear fraction and (ii) indicate that MT1-MMP co-immunoprecipitates 
with RNA-Polymerase II, suggesting a potential role of the MT1-MMP ICD in 
transcriptional regulation. 
 
The molecular mass detected for the MT1-MMP ICD (?6 kDa) after ChIP with Pol II 
(Figure 3.57) indicates that it was not ubiquitinated. The current understanding of the 
MT1-MMP ICD release implies that MT1-MMP ubiquitination at its K581 residue is 
required for a proteaome dependent ICD release and its subsequent translocation to the 
nucleus. As the MT1-MMP ICD penetratin peptide is a soluble membrane-penetrating 
peptide, it might enter the nucleus by a different ubiquitin/proteasome independent way.  
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3.3.10 Summary: MT1-MMP intracellular domain release 
 
The current understanding of the MT1-MMP intracellular domain release is summarised in 
Figure 3.58.  
Data obtained in this thesis indicate that the MT1-MMP ICD is released in a Src and 
Proteasome-dependent way as detected in a reporter gene assay. The intracellular domain 
was found to be ubiquitinated at its K581 residue, thus potentially inducing the proteolytic 
release by the proteasome. Ubiquitination also raises an interesting possibility of a 
mechanism for nuclear translocation of the MT1-MMP ICD, which lacks an intrinsic NLS. 
The role of Src, which is activated and transported in an MT1-MMP dependent way 
(chapter 3.1), is not completely understood in this system. Src-dependent phosphorylation, 
as reported previously 249, might play a role in initiating the MT1-MMP ICD 
ubiquitination. Immunofluorescence data further supported the notion that ubiquitination is 
required for nuclear localisation of the MT1-MMP ICD since the MT1-MMP K581 mutant 
showed a decreased nuclear localisation of the ICD. Using tagged MT1-MMP ICD 
constructs, the intracellular domain was further detected in the nuclei of MCF-7 cells and 
was found to co-immunoprecipitate with RNA-Polymerase II. These findings indicate a 
potential role of the MT1-MMP ICD in a transcription-initiation complex. 
ChIP-Seq experiments need to be performed in order to identify target genes that are 
regulated by the MT1-MMP ICD directly. 
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Figure 3.58: Summary and working hypothesis for the MT1-MMP ICD release based 
on data obtained so far 
The data obtained so far indicate that MT1-MMP and Src may co-traffic to the cell surface, thus activating 
Src activity. The MT1-MMP ICD is subsequently released in a Src- and Proteasome dependent mechanism, 
potentially induced by ubiquitination of the MT1-MMP K581 residue. Ubiquitination may be a consequence 
of MT1-MMP autocatalytic degradation resulting in the 44 kDa membrane-tethered form. The K581 residue 
was shown to be required for MT1-MMP ICD nuclear localisation, thus raising the possibility that 
ubiquitination is needed for nuclear translocation. The MT1-MMP ICD was further found to co-
immunoprecipitate with RNA-Polymerase II, suggesting a role for the MT1-MMP ICD in transcriptional 
regulation.  
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4 Discussion 
 
MT1-MMP has been implicated in the modulation of gene expression including the 
regulation of VEGF-A 73, DKK-3 139 and Smad1 138 (chapter 1.3.6), although the molecular 
mechanisms remain to be investigated.  
Thus, the aim of this thesis was (i) to investigate how MT1-MMP induces signalling 
pathways, (ii) to characterise MT1-MMP induced signalling pathways leading to the 
transcriptional regulation of target genes and in particular to dissect the molecular 
mechanism underlying the MT1-MMP induced up-regulation of VEGF-A expression and 
(iii) to get a better understanding of MT1-MMP mediated transcriptional regulation and its 
non-catalytic functions.  
 
In this thesis, two novel and independent MT1-MMP induced signalling pathways have 
been described in breast carcinoma cell lines that regulate gene transcription either 
indirectly (discussed in chapter 4.1) or directly (discussed in chapter 4.2). Both signalling 
pathways are induced by non-proteolytic functions of MT1-MMP, thus broadening the 
functional spectrum of the proteinase and emphasising the multiple roles of MT1-MMP in 
tumour initiation, angiogenesis and metastasis (chapter 1.3.3).  
 
4.1 Indirect MT1-MMP induced signalling 
 
In the first sections of this thesis (chapters 3.1 and 3.2) the molecular mechanism of the 
MT1-MMP induced up-regulation of VEGF-A expression has been dissected and a novel 
MT1-MMP – VEGFR-2 – Src dependent pathway has been identified in breast carcinoma 
cell lines.  
In MCF-7 cells, which were used as a model system, MT1-MMP was found to (i) increase 
the levels of VEGF-A mRNA and protein via a VEGFR-2, Src, PI3K, Akt, mTOR and 
HIF-1? dependent pathway, (ii) enhance the phosphorylation of Src, Akt and mTOR, (iii) 
form a tri-molecular complex with VEGFR-2 and pY416-Src that is required for VEGF-A 
transcription, (iv) regulate VEGFR-2 cell surface localisation and to (v) play a potential 
role in the VEGF-A – VEGFR-2 autocrine signalling axis.  
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Based on these observations an MT1-MMP induced signalling pathway is proposed 
(Figure 4.2A). The implications of the afore mentioned key findings will be summarised 
and discussed in the following chapters. 
 
4.1.1 MT1-MMP induces the PI3 Kinase – Akt pathway 
 
Initially, the role of MT1-MMP in up-regulating VEGF-A transcription, as described 
previously 73, was confirmed in the MCF-7 cells used as a model system (chapter 3.1). 
MCF-7 cells express neither MT1-MMP nor MMP-2 251 and are therefore an ideal model 
to study the effect of these proteinases individually as well as to introduce various mutants 
in order to study the role of the different MT1-MMP domains. By using transient 
expression or adenoviral delivery of MT1-MMP cDNAs, VEGF-A expression data were 
obtained immediately following MT1-MMP expression, resembling molecular changes in 
the early stages of tumour growth and metastasis. MT1-MMP expression in MCF-7 cells 
increased VEGF-A mRNA (Figure 3.2 and Figure 3.3) and protein levels, as well as 
protein secreted into the extracellular milieu (Figure 3.4), independently of the MT1-MMP 
expression system used.  
 
Although MT1-MMP has been implicated in the regulation of gene transcription, only one 
MT1-MMP mediated signalling pathway has been described so far. Gingras et al. reported 
previously an MT1-MMP dependent increase in ERK activation followed by subsequent 
induction of transcription through serum response elements (SRE), which induced cell 
migration in COS-7 cells 61. Similar to the requirements for MT1-MMP induced increase 
in VEGF-A expression 73, the ERK pathway was shown to be dependent on the MT1-
MMP catalytic activity, as well as on its intracellular domain, and in particular on the 
YCQR576 motif. By using an inhibitor based screening method targeting a variety of key 
signalling proteins (summarised in Table 3.1), the MT1-MMP dependent expression of 
VEGF-A was found to be independent of ERK signalling but required Src, consistent with 
previous findings 73, as well as PI3 Kinase, Akt, mTOR and HIF-1? activity (Figure 3.5A).  
Notably, expression of MT1-MMP was routinely observed to increase the phosphorylation 
level of Src at Y416, mTOR at S2448 and Akt at T308 and S473, whereas total Src, mTOR and 
Akt protein expression levels were not affected (Figure 3.6 - Figure 3.10). Akt was found 
to be phosphorylated downstream of VEGFR-2 and Src activation, as determined by an 
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inhibitor-based assay followed by immunoblotting (Figure 3.6). Breast carcinoma cell lines 
have been shown before to exhibit constitutively elevated PI3K activity following VEGF-
A stimulation 236, supporting the role of a PI3K/Akt pathway as described in this thesis. 
Interestingly, inhibition of Akt activity using the Akt inhibitors SH-5 or Tricibine led to the 
down-regulation of MT1-MMP protein expression, whereas the level of the loading control 
?-Actin or total Akt was not affected. These findings suggest that Akt activity may be 
needed in order to maintain MT1-MMP expression, potentially acting as a positive 
feedback loop.  
 
Nyalendo et al. have reported previously that MT1-MMP is phosphorylated in a Src 
dependent manner at its unique intracellular tyrosine residue Y573, leading to tumour and 
endothelial cell migration 249. In this study MT1-MMP expression led to the 
phosphorylation of Src at Y416, downstream of VEGFR-2 activity (Figure 3.9B). Mutation 
of the MT1-MMP Y573 residue was however found to ablate MT1-MMP induced Src 
phosphorylation suggesting that this tyrosine residue may play a role in the activation of 
Src. Accordingly, mutation of Y573 was found to ablate the MT1-MMP induced up-
regulation of VEGF-A at the mRNA level, potentially due to the lack of Src activation 
(Figure 3.25B). 
 
The previously described MT1-MMP induced activation of the ERK signalling pathway 
led to transcription of target genes under the control of serum-response elements 61. 
Inhibition of HIF-1? was found in the inhibitor-screening assay to reduce the level of 
VEGF-A mRNA in MT1-MMP expressing MCF-7 cells. HIF-1? is a well-described 
transcription factor that translocates to the nucleus following activation of the PI3 Kinase, 
Akt and mTOR pathway 218. It is widely acknowledged that this pathway is activated by 
various growth factors and angiogenic mitogens, including VEGF-A 218. Structural 
analyses of the VEGF-A genomic sequence revealed HIF-1 binding motifs within the 
promoter region (Figure 1.6), thus strongly supporting the notion that MT1-MMP 
dependent up-regulation of VEGF-A depends on the HIF-1 transcription factor. 
 
By binding to glycosylated proteins, the extracellular matrix stores and masks many latent 
cytokines. Thus, degradation of components of the extracellular milieu by different 
proteinases affects various cellular responses. CTGF has been shown to be processed by 
MT1-MMP, MMP-1, -2, -3, -7 and -13 54,257, thus releasing biologically active VEGF165 
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from CTGF/VEGF165 complexes. MMP dependent cleavage leads to the generation of the 
NH2- and COOH-terminal CTGF degradation products, whereas biological activity of 
VEGF165 is restored 
257. 
Ablation of MT1-MMP activity by mutating the extracellular E240 residue or treatment 
with the synthetic broad-spectrum MP inhibitor CT1746 as well as rh-TIMP-2 reduced the 
MT1-MMP induced up-regulation of VEGF-A (Figure 3.4B). Interestingly, when cells 
expressing the catalytically inactive MT1-MMP mutant were treated with increasing 
concentrations of rh-MMP-2, VEGF-A expression was restored (Figure 3.27B and Figure 
3.28D). Furthermore, increasing concentrations of MT1-MMP transfected into MCF-7 
cells resulted in an accumulation of CTGF cleavage products (Figure 3.26C). These 
findings strongly suggest that MMP dependent release of VEGF165 from CTGF/VEGF165 
complexes induces VEGFR-2 signalling via the proposed mechanism shown in Figure 
4.2A. However, further evidence for the involvement of this complex remains to be 
obtained. One way to answer that question could be by using an in vitro approach with 
recombinant CTGF/VEGF165 complexes that are processed by MT1-MMP catalytic 
activity in solution. Following inhibition of MT1-MMP activity (using synthetic or 
recombinant endogenous MMP inhibitors) the in vitro processed CTGF/VEGF165 
complexes would be added to cells expressing catalytically inactive MT1-MMP and 
VEGF-A mRNA expression levels would be detected. Although this experiment would 
address the role of the CTGF/VEGF165 complexes, it would generate various questions and 
biases due to its experimental setup. 
It has been reported previously that TIMP-2 expression in murine mammary tumours 
conferred an anti-angiogenic tumour phenotype by down-regulating VEGF-A expression 
289. Accordingly, synthetic broad-spectrum inhibitors also down-regulated VEGF-A 
expression in vivo using a T cell lymphoma model 290. These findings were believed to 
occur due to inhibition of MT1-MMP catalytic activity. However, both synthetic broad-
spectrum MP inhibitors and TIMP-2 are inhibiting MT1-MMP as well as MMP-2 function, 
emphasising the role of MMP function in the transcriptional regulation of VEGF-A, 
potentially by liberating VEGF165 from CTGF. 
 
The role of MT1-MMP in the up-regulation of VEGF-A mRNA expression was also 
confirmed in another breast carcinoma cell line, MDA-MB-453 (Figure 3.33). MT1-MMP 
gene silencing in the MT1-MMP expressing MDA-MB-231 cells was performed using 
adenoviral asRNA, lentiviral shRNA or siRNA. These RNAi-based approaches led to off-
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target effects or interferon responses, which have already been described and discussed in 
more detail in the chapters 3.2.1.2 - 3.2.1.4. Notwithstanding these limitations, MT1-MMP 
gene silencing using two independent RNAi techniques (lentiviral shRNA and siRNA) led 
to the up-regulation of VEGF-A expression at the mRNA and protein level (Figure 3.36C 
and Figure 3.39B). These observations are opposing the results obtained in MDA-MB-453 
and MCF-7 cells, which showed an increase of VEGF-A mRNA expression levels in MT1-
MMP expressing cells (Figure 3.2B, D, Figure 3.3B,C, Figure 3.33B). Consistent with the 
findings in MDA-MB-231 cells, expression of a reporter gene construct comprising of a 
Luciferase gene under the control of a 6 kb VEGF-A promoter in MT1-MMP expressing 
MCF-7 cells led to a decrease in reporter gene expression (CH Roghi, personal 
communication). These findings may be explained by the lack of additional regulatory 
sequences in the artificial promoter. Also, a cell-type specific variation in DNA 
modification including DNA methylation, might affect the transcriptional activity of the 
VEGF-A promoter region.  
In this study MCF-7 cells were chosen as a model system to (i) study the role of the 
different MT1-MMP domains separately and (ii) to particular mimic early events in 
tumour growth and metastasis following MT1-MMP expression. Since the highly 
metastatic MDA-MB-231 cells express MT1-MMP constitutively at high levels, the MT1-
MMP effect on VEGF-A expression may be temporarily restricted and/or attenuated by 
negative feedback loops. 
 
4.1.1.1 Formation of an MT1-MMP – VEGFR-2 – Src tri-molecular 
complex in breast carcinoma cells 
 
Using immunofluorescence and immunoprecipitation assays, a complex comprising of 
MT1-MMP, VEGFR-2 and Src was found in MCF-7 cells (Figure 3.17).  
The interaction between MT1-MMP and VEGFR-2 was shown to be dependent on the 
MT1-MMP hemopexin and transmembrane domains (Figure 3.19 and Figure 3.20). The 
MT1-MMP hemopexin domain is known to confer substrate specificity and to be involved 
in the binding to substrates or interacting proteins, including its binding to native type I 
collagen and its role in the activation of pro-MMP-2 (chapter 1.3.4.3) 114,291. In contrast to 
the co-immunoprecipitation of various MT1-MMP transfectants with VEGFR-2, the lack 
of the transmembrane domain using recombinant proteins in an ELISA assay did not affect 
Discussion                                                                                                                                                       166 
the interaction between MT1-MMP ECD and VEGFR-2 (Figure 3.20C). The mutant used 
to study the function of the transmembrane domain comprised of the full-length MT1-
MMP with an APP transmembrane domain (MT1-TMD-APP, Figure 3.25A). The different 
results obtained from the experiments using the TMD mutant and the recombinant protein 
lacking the TMD, may be explained by differences in folding of the mutant that interfered 
with the hemopexin-dependent binding to VEGFR-2 or by different trafficking patterns 
and subcellular localisation. 
VEGFR-2 is a member of the immunoglobulin (Ig) superfamily. Interestingly, MT1-MMP 
has been shown previously to interact with another Ig family member, ICAM-1, in an in 
vitro binding assay using purified full-length MT1-MMP and to co-localise in HEK293 
and human aortic endothelial cells overexpressing ICAM-1 292. However, the MT1-MMP 
domain involved in the interaction with ICAM-1 has not been further characterised. 
Combining these findings and the identification of the MT1-MMP – VEGFR-2 complex 
described in this thesis, suggest that binding of MT1-MMP to Ig family members may be a 
conserved mechanism. Since the Ig family comprises of various cytokine and growth 
factor receptors, receptor tyrosine kinases/phosphatases, adhesion molecules as well as co-
receptors, this potential interaction may provide an interesting mechanism to modulate 
cellular signalling. 
 
In contrast to MT1-MMP binding to VEGFR-2 via its hemopexin/transmembrane domain, 
MT1-MMP was shown to interact with Src via its intracellular domain as shown by using a 
mammalian-two hybrid assay in different cell lines (Figure 3.11C and Figure 3.12). The 
MT1-MMP – Src interaction was confirmed by co-immunoprecipitation in MCF-7 cell 
lysates, however the interaction was not ablated by using the MT1-MMP ICD deletion 
mutant, suggesting the involvement of a third party protein (Figure 3.13B). Src is a known 
down-stream effector of VEGFR-2 signalling, although mainly described in endothelial 
cells (reviewed in 226), and was found to co-immunoprecipitate with VEGFR-2 in MCF-7 
cells (Figure 3.17B). These findings suggest that the direct binding of the MT1-MMP 
intracellular domain to Src as observed using the mammalian-two hybrid model, may be 
spacio-temporarily restricted or only occur in a sub-fraction of total MT1-MMP protein. 
Caveolin-1 is another protein that is known to associate with VEGFR-2, Src and MT1-
MMP and might provide an additional interesting possibility as a bridging protein 
(discussed in chapter 4.1.3.). 
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4.1.2 MT1-MMP regulates VEGFR-2 localisation 
 
In endothelial cells, VEGFR-2 was found to mainly localise in intracellular vesicles, 
whereas only a small sub-fraction of active receptor is localised at the cell surface 256. 
VEGFR-2 cell surface localisation was increased following stimulation with exogenous 
VEGF-A. Similar results were obtained in wild-type MCF-7 cells (Figure 3.24C). Notably, 
in cells expressing MT1-MMP, VEGFR-2 cell surface localisation was significantly 
increased compared to empty vector transfected cells (Figure 3.24A). This MT1-MMP 
dependent re-distribution of VEGFR-2 was found to be dependent on the MT1-MMP 
extracellular and transmembrane domain, as detected by flow cytometry (Figure 3.24C). 
Expression of the extracellular domain deletion mutant led to a similar vesicular staining 
pattern compared to MCF-7 wild-type cells (Figure 3.24B).  
These observations raise the possibility that MT1-MMP may be co-trafficked and co-
endocytosed with VEGFR-2 as a mechanism to regulate the signalling capacity of the 
MT1-MMP – VEGFR-2 – Src complex. Furthermore, MT1-MMP and VEGFR-2 positive 
intracellular vesicles were found to co-localise with the microtubular network in MCF-7 
cells (Figure 3.30), as reported previously for VEGFR-2 in endothelial cells 256. 
Consistently, the microtubular cytoskeleton was shown to be important for trafficking and 
internalisation of MT1-MMP 293.  
 
After reaching the plasma membrane, MT1-MMP was shown to be internalised in Rab4 
positive recycling endosomes and Rab11 positive pericentrosomal recycling endosomes 
(chapter 1.3.4.5). It is believed that the TMD of MT1-MMP is required for the 
microtubular vesicular trafficking of MT1-MMP, although the TMD is not interacting 
directly with the microtubuli 40. On the other hand, deletion of the MT1-MMP hemopexin 
domain or the ICD did not affect internalisation after membrane association. The potential 
requirement for the TMD (discussed in chapter 4.1.1.1) in the MT1-MMP induced up-
regulation of VEGF-A as well as in MT1-MMP dependent cell surface localisation of 
VEGFR-2 as described in this thesis, may be explained by the role of the TMD in 
microtubular trafficking of MT1-MMP. However, the potential intracellular co-trafficking 
as well as the co-internalisation of MT1-MMP and VEGFR-2 as a mechanism to attenuate 
intracellular signalling remains to be investigated in more detail. 
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4.1.3 MT1-MMP: modulator of autocrine VEGF-A signalling 
 
The transcriptional up-regulation of VEGF-A expression by MT1-MMP has many 
ramifications for tumour growth, angiogenesis and cell migration. VEGF-A expression has 
been implicated in cell survival and induces breast carcinoma progression mainly via a PI3 
kinase pathway as well as inducing angiogenesis as a pro-angiogenic mitogen 236,294,295. On 
the other hand MT1-MMP fulfils dual roles: (i) MT1-MMP expression leads to various 
cellular responses including cell motility, invasion and proliferation regulated through 
MT1-MMP catalytic activity (summarised in Figure 1.2) and (ii) VEGF-A expression is 
elevated by MT1-MMP in a process independent of its catalytic activity, thus increasing 
the functional repertoire of MT1-MMP (chapter 1.3.3). 
The data obtained in this thesis suggest an MT1-MMP induced pathway dependent on the 
formation of the tri-molecular MT1-MMP – VEGFR-2 – Src complex that is necessary for 
VEGF-A expression (Figure 4.2A). However, the precise regulation of complex 
assembling or the molecular mechanism of the described MT1-MMP dependent 
phosphorylation of Src as well as the MT1-MMP dependent cell surface localisation of 
VEGFR-2 require further dissection.  
Surprisingly, MT1-MMP expression has been shown to induce caveolin-1 expression in 
the caveolin-1-deficient MCF-7 and MDA-MB-453 cells, whereas MT1-MMP specific 
gene silencing reduced the level of caveolin-1 mRNA and protein (Figure 3.43 and Figure 
3.33C). Caveolin-1 is known to associate with MT1-MMP, Src and VEGFR-2 and its 
expression was shown to be modulated by angiogenic factors 296. Caveolin-1 is a key 
component of caveolae and acts as a scaffold for the assembling of various signalling 
proteins, including VEGFR-2, PDGFR and Src family kinases (SFKs) 273,297,298. 
Based on the findings obtained in this thesis and consistent with recent publications (as 
outlined below), a potential multi-step mechanism leading to the assembling of signalling 
proteins dependent on MT1-MMP is proposed (the various steps are summarised in Figure 
4.1): 
(i) MT1-MMP potentially co-traffics with Src in RhoB positive endosomes. Src was 
described to be activated during its transport from the perinuclear region to the cell surface 
in RhoB positive vesicles 253. Here, Src and MT1-MMP were found to co-localise in RhoB 
containing endosomes (Figure 3.16) and MT1-MMP Y573 was shown to modulate Src 
activation, potentially by interacting with Src and modulating its compartmentalisation. 
MT1-MMP is directed to the leading edge of the cell at distinct microdomains of the 
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plasma membrane, including lamellipodia, focal adhesions and caveolae (chapter 1.3.4.5). 
(ii) VEGFR-2 is enriched in caveolae. VEGFR-2 is predominantly localised to caveolin-
enriched membrane microdomains, which have been shown to be important for the 
induction of downstream signalling events induced by VEGF-A and to interact directly 
with caveolin-1 273. The mRNA and protein expression levels of caveolin-1 were found to 
be increased by MT1-MMP (Figure 3.43 and Figure 3.33C).  
(iii) VEGF-A ligand binding. VEGF-A binding to VEGFR-2 induces dissociation of 
caveolin-1 from VEGFR-2 273 and Caveolin-1 is subsequently phosphorylated by Src 
273,299.  
(iv) phospho-Caveolin-1 (pCav-1) binds to MT1-MMP followed by recruitment of Src 
119
. 
Src activity is subsequently attenuated by Csk (C-terminal Src kinase). 
(v) MT1-MMP complex-formation with VEGFR-2. MT1-MMP was shown to interact 
with VEGFR-2, although the hierarchical and temporal process of sequential protein 
interaction needs to be further investigated.  
 
 
Figure 4.1: Potential mechanism of trafficking, protein activation and interaction 
leading to the assembling of the MT1-MMP – VEGFR-2 – Src complex. 
A mechanism of MT1-MMP – VEGFR-2 – Src assembly is proposed. Details are described in the text. 
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This proposed pathway could be negatively regulated by Src de-phosphorylation, which 
was shown to occur after Src recruitment to MT1-MMP – phospho-caveolin-1 complexes, 
potentially due to phospho-caveolin-1 association with Csk (Figure 4.1 iv) 300. 
Furthermore, the MT1-MMP – VEGFR-2 complex may be co-internalised as a mechanism 
to attenuate signalling, potentially in a microtubule dependent mechanism.  
The signalling could be enhanced by positive feedback loops including the autocrine 
VEGF-A expression described (chapter 3.1, Figure 3.31) as well as the reported induction 
of MT1-MMP expression following VEGF-A stimulation in endothelial cells 301. 
Although the involvement of caveolin-1 as a bridging protein raises an interesting 
hypothesis, the precise mechanism as well as the hierarchical sequence of action remains 
to be further investigated. 
 
4.1.4 MT1-MMP dependent signalling – implications for tumourigenesis 
 
Recent findings increased the notion that angiogenesis and in particular the signalling 
capacities of VEGF-A and its receptors play pivotal roles in pathophysiological conditions 
making them a promising target in cancer therapy. Accordingly various therapeutic 
approaches targeting VEGF signalling have been tested in clinical trials. Amongst those, 
the monoclonal anti-VEGF-A antibody bevacizumab (Avastin) given in combination with 
5-fluorouracil (FU)-based chemotherapy, showed the most promising results 203. Although 
treatment of patients with bevacizumab increased the survival, the disease proceeded 
eventually. There is emerging evidence that other pro-angiogenic mitogens compensate for 
the loss of VEGF-A function. In particular, VEGF-C and -D were shown to bind to 
VEGFR-2 after being processed and induce VEGFR-2 mediated signalling (Figure 1.7).  
MMPs and in particular MT1-MMP are well-known proteinases that are highly expressed 
in malignant tissue and their role in pathophysiological conditions is widely 
acknowledged. The various functions and induced down-stream effects mediated by 
MMPs make it difficult to target the proteinases specifically. Indeed, inhibition of MMP 
function in clinical trials has been disappointing as treatments failed to increase patient 
survival or to produce adverse effects 302. These findings were explained by the lack of 
specificity of the broad-spectrum inhibitors available, their use in late stage disease as well 
as the use as a single therapy instead of a combinational approach. The new focus in MMP 
targeting therapy is the design of agents that do not bind to the conserved sequence of the 
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catalytic pocket, but target substrate binding motifs or selective down-stream effectors. 
Dissecting the molecular mechanisms of regulation by distinct MMPs in angiogenesis will 
provide a basis for the design of new MMP inhibitors. 
 
In the first sections of this thesis, a novel signalling pathway dependent on MT1-MMP, 
VEGFR-2 and Src was described in breast cancer cell lines. This tri-molecular complex 
mediated signalling was shown to induce VEGF-A expression in MCF-7 and MDA-MB-
453 cells, but not in the MT1-MMP endogenously expressing MDA-MB-231 cells. Since 
the MT1-MMP – VEGFR-2 – Src complex was found in all cell lines tested, it might be a 
conserved mechanism to induce intracellular signalling pathways in breast cancer cell 
lines, albeit regulating different target genes depending on the cell type. Additional target 
genes that are regulated by this complex in different cell lines remain to be identified.  
In order to correlate these in vitro findings with clinical data, a meta-analysis of existing 
mRNA gene expression data of breast cancer tissues derived from tumours of either (i) 
different stages (stage I-IV dependent on tumour size, lymph node involvement, 
metastases), (ii) different grades (grade 1 – 3 dependent on nuclear polymorphism, tubule 
formation and mitotic count), (iii) different estrogen receptor (ER) status or (iv) different 
histological classification (apocrine, basal and luminal) was performed by using the 
Oncomine™ database. Studies that revealed a differential expression of MT1-MMP, 
VEGF-A or VEGFR-2 are summarised in Appendix D. VEGFR-2 was not found to be 
differentially expressed in either type of analysis, although a slight increase in mRNA 
expression was observed in ER negative tumours as detected in 3 studies (P < 0.05). 
Differential expression of MT1-MMP was not consistent in tumours of different grading, 
but was found to be increased in ER negative (2 studies P < 0.0001) and to a lesser extent 
in luminal tumours (P < 0.05). The mRNA expression of VEGF-A was significantly 
enriched in ER negative (P < 0.0001) and luminal tumours (P < 0.0001). These findings 
confirm VEGF-A detection to be a prognostic marker in breast carcinomas corresponding 
to a poor outcome. VEGFR-2 expression levels were not found to be significantly affected 
by different types of analyses. This observation strengthen the current understanding of the 
proposed MT1-MMP dependent pathway, that the MT1-MMP – VEGFR-2 – Src 
signalling complex may be regulated by cellular localisation rather than by transcriptional 
control. The model cell lines used in this study originate from different breast cancer types. 
Whereas MCF-7 cells are derived from luminal and ER positive tumours, MDA-MB-231 
cells are ER negative and basal. VEGF-A and MT1-MMP expression detected in these cell 
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lines correspond to the expression data obtained in the meta-analysis of the cell origin. The 
data furthermore emphasise that the expression of MT1-MMP and VEGF-A correlate in 
human physiology.  
Although mRNA microarray studies provide an important tool for correlating in vitro 
findings with clinical data, it is necessary to acknowledge that the mRNA used is derived 
from an heterogeneous tumour cell population consisting of tumour cells, stromal and 
infiltrating immune cells. In order to address this heterogeneity within the tumour mass, a 
study using human mammary carcinoma tissue sections was performed (in collaboration 
with Dr. Bence Sipos). Preliminary data revealed that MT1-MMP, VEGFR-2 and pY416-
Src are expressed in the cytoplasma and at or close to the plasma membrane of tumour 
cells (Figure 3.42). To get a deeper understanding of the expression of MT1-MMP, 
VEGFR-2 and pY416-Src depending on different histological sub-categories (e.g. grading, 
staging), a comprehensive study using breast invasive ductal carcinoma tissue microarrays 
is currently performed (in collaboration with Dr. Bence Sipos).  
As the MT1-MMP effect on VEGF-A regulation was solely performed on breast cancer 
cell lines, it will be interesting to test whether this pathway or the MT1-MMP – VEGFR-2 
– Src complex is a common mechanism in different carcinoma cell lines or in stromal and 
endothelial cells. As MT1-MMP plays a key role in angiogenesis and is constitutively 
expressed in endothelial cells (ECs), this pathway may provide a mechanism to enhance 
the angiogenic response as well as cell proliferation in ECs.  
 
Taken together, the data obtained in this thesis enhance the understanding of the 
mechanism underlying the MT1-MMP transcriptional regulation of VEGF-A. These 
observations strengthen the role of MT1-MMP in tumourigenic angiogenesis and provide a 
link between MT1-MMP and an autocrine VEGF-A activation loop. It is essential to get a 
deeper functional understanding of the different roles of MT1-MMP in tumourigenesis, in 
particular based on clinical samples, in order to target specific signalling pathways for 
therapeutics. 
 
4.2 Direct MT1-MMP dependent signalling 
 
In the third part of this thesis (chapter 3.3), a novel mechanism of MT1-MMP processing 
leading to the release of its intracellular domain was described. The results obtained 
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indicate for the first time that the MT1-MMP intracellular domain (ICD) (i) is released in a 
Src-and Proteasome-dependent way, (ii) is ubiquitinated at its intracellular K581 residue, 
(iii) is detected in the nucleus using a soluble tagged MT1-MMP ICD penetratin peptide, a 
MYC-FLAG double-tagged truncated MT1-MMP construct and in human mammary 
carcinoma sections and (iv) co-immunoprecipitates with RNA-Polymerase II, suggesting a 
role in transcriptional activation. 
 
4.2.1 MT1-MMP intracellular domain release 
 
An increasing number of transcriptional regulators have been shown to be synthesised as 
latent transmembrane precursors that have to undergo proteolytic processing in order to be 
activated (chapter 1.4). Intramembrane proteolysis is mainly mediated by presenilin-
dependent ?-secretase, site-2 proteinases (S2P), signal peptide peptidases (SPP) or 
rhomboid proteinases. Recently, a novel mechanism of intracellular domain release was 
observed in S. cerevisiae depending on the ubiquitin-proteasome system (chapter 1.4).  
The proteins undergoing intramembrane processing share several characteristics. They are 
mainly type-I transmembrane proteins (except proteins that are processed by S2P or SPP) 
oriented with their NH2-termini towards the extracellular milieu and their COOH-termini 
in the cytosol. Another shared feature is the sequential proteolytic processing at various 
extracellular and intramembranous sites that eventually leads to the release of their 
intracellular domains from the plasma membrane 148,179,180,183,287. In each case, the 
extracellular domain is removed in a primary cleavage event, resulting in the truncation of 
the extracellular segment to less than 30 amino acids. This initial cleavage is a prerequisite 
for intramembrane cleavage and occurs mainly in a metalloproteinase dependent step 161,182 
except for the ?-secretase dependent APP cleavage 173. Similar to Notch1 and LRP1, MT1-
MMP undergoes activation by furin in a late secretory compartment cleaving the Arg-Arg-
Lys-Arg motif between the catalytic domain and pro-peptide 21,88-90 as well as undergoing a 
metalloproteinase (e.g. ADAM) dependent extracellular domain cleavage step, resulting in 
the release of a soluble ~50 kDa fragment, which corresponds to the entire extracellular 
domain (chapter 1.3.4.4) 112. These similarities raised the possibility of MT1-MMP 
undergoing either regulated intramembrane proteolysis (RIP) or regulated 
ubiquitin/proteasome dependent processing (RUP).  
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Adapting the methodology that was used for the identification of Notch1 144,184, APP 179 
and LRP1 151 RIP, the MT1-MMP intracellular domain was shown to be released and to 
induce transcription in a reporter gene assay. A variety of inhibitors targeting proteinases 
known to be involved in RIP or RUP were tested for their capacity to induce MT1-MMP 
processing (Figure 3.45). Since Site-2 proteinases (S2P) and signal peptide peptidases 
(SPP) were only shown to be required for cleaving type-II transmembrane proteins, agents 
inhibiting these proteinases were omitted in this screening. In contrast to other proteins 
undergoing RIP, MT1-MMP ICD release was not dependent on ?-secretase or rhomboid 
proteinases but required Src and Proteasome activity (Figure 3.45). This Src and 
Proteasome mediated MT1-MMP ICD release was found to depend on the MT1-MMP 
intracellular and transmembrane domains (Figure 3.46). In the reporter gene assay, MT1-
MMP mutants were used where the ICD or transmembrane domain (TMD) were 
exchanged by those of the APP protein. The reduction of reporter gene activity following 
Src or Proteasome inhibition in cells expressing either mutant suggests that both MT1-
MMP domains are required for the proteolytic release of the ICD. These observations are 
consistent with the direct interaction observed between MT1-MMP ICD and Src (Figure 
3.12) and suggest a potential difference in folding of the protein due to the APP TMD, that 
potentially attenuates the interaction with Src or the activity of the proteasome. 
There is limited knowledge about the mechanism of ubiquitin/proteasome dependent 
release of membrane-bound transcription factor precursors. So far, this processing has only 
been reported for the yeast homologs of NF-?B, SPT23 and MGA2 (chapter 1.4.2) 190. 
During this process, the membrane-bound precursors interact with the RSP5 ubiquitin 
ligase (an E3 enzyme), are subsequently ubiquitinated and the intracellular part is released 
via proteasome-dependent proteolysis (Figure 1.5). Notably, only the 90 kDa ubiquitinated 
intracellular part is spared from proteasomal degradation and released into the cytoplasm 
190. The possibility of an ubiquitin/proteasome dependent release of the MT1-MMP ICD is 
further discussed in chapter 4.2.2.  
As the Gal4/VP16 tagged MT1-MMP construct used for the reporter gene assay contained 
an intrinsic nuclear localisation sequence (NLS) 278, further independent approaches were 
used to study the nuclear localisation of MT1-MMP. Immunocytochemical detection 
methods using MT1-MMP expressing MCF-7 cells revealed the presence of the MT1-
MMP ICD in the nucleus (Figure 3.47 and Figure 3.48). However, the intracellular domain 
could not be detected in the nuclear fraction by immunoblotting (Figure 3.47B). This 
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observation may be explained either by the small amount of MT1-MMP protein enriched 
within the nuclear fraction and thus being below the critical threshold of antibody-
detection, as observed for the Notch1 ICD 184, or by the insufficient sensitivity of the 
antibody used. The first analyses of Notch1 ICD release were performed using constructs 
encoding the transmembrane and the intracellular domain to mimic endogenous 
transmembrane processing or by using a soluble ICD mutant in order to increase the 
sensitivity by using biochemical detection methods 144. These constructs as well as cDNAs 
used in other RIP studies were C-terminal modified by Myc or EGFP tags in order to 
facilitate detection 144,148,168,184. 
Accordingly, different tagged MT1-MMP constructs were generated and used in further 
MT1-MMP ICD localisation studies. The intracellular domain of the truncated MYC-
FLAG tagged MT1-MMP construct (MT1-MYC-FLAG) as well as the MT1-MMP ICD 
containing biotinylated soluble penetratin peptide were detected in the nuclei of MCF-7 
cells by immunostaining and immunoblotting (Figure 3.49, Figure 3.52 - Figure 3.54). The 
presence of the MT1-MMP ICD in tumour cell nuclei was further confirmed in human 
mammary carcinoma tissue sections, indicating that the MT1-MMP ICD is also localised 
in the nucleus in vivo (Figure 3.50). This observation emphasise the role of the MT1-MMP 
ICD release and its presence in tumour cell nuclei during tumourigenesis.  
Earlier studies addressing the subcellular localisation of MT1-MMP in hepatocellular 
carcinoma led to the detection of mature MT1-MMP at the plasma membrane, the 
cytoplasm and also within nuclei 303. Presence of nuclear MT1-MMP was associated with 
poor survival and larger tumours in patients with hepatocellular carcinoma 303. Another 
study described full-length MT1-MMP accumulation in the centrosomal compartment by 
binding to the integral centrosomal protein pericentrin in the human glioma cell lines U251 
as well as MCF-7 cells 304. In contrast to these two publications, immunostaining using 
antibodies specifically raised against the ectodomain of MT1-MMP did not show nuclear 
localisation in either the literature before, nor in human mammary tissue sections (Figure 
3.42). In this thesis only the MT1-MMP ICD was found in the nuclear fractions of MCF-7 
and MDA-MB-231 cells as well as in human mammary carcinoma tissue sections (Figure 
3.48 and Figure 3.50). 
Recently, MMP-3 has also been found to localise in the nucleus 305,306. Interestingly, a 
nuclear interaction between MMP-3 and either TRENDIC (transcription enhancer 
dominant in chondrocytes) or heterochromatin protein gamma has been found on the 
CTGF promoter, enhancing its expression 306.  
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Co-immunoprecipitation with an anti-MT1-MMP ICD specific antibody in the nuclear 
fraction of MT1-MMP expressing MCF-7 cells revealed several proteins that were absent 
in the control sample, suggesting that MT1-MMP interacts with nuclear proteins (Figure 
3.51). The MT1-MMP nuclear localisation as well as its interaction with nuclear proteins 
was confirmed by chromatin immunoprecipitation (ChIP). Due to the lack of known target 
genes that are directly regulated by the MT1-MMP ICD, protein – chromatin lysates were 
immunoblotted following ChIP revealing an interaction between the MT1-MMP ICD and 
RNA-Polymerase II (Figure 3.57). Thus, raising the possibility that the MT1-MMP ICD is 
involved in transcriptional regulation. However, potential target genes that are regulated by 
the MT1-MMP ICD directly remain to be identified. A ChIP sequencing approach using 
Illumina® Solexa® technology is currently being prepared.  
 
It has been established that the initial proteolytic events during RIP are triggered upon 
ligand binding to the receptors, leading to shedding of the ectodomain. The molecular 
mechanism regulating MT1-MMP ectodomain shedding as well as the regulation of its 
intracellular domain release is not completely understood. Preliminary studies revealed that 
the MT1-MMP ~44 kDa form is ubiquitinated (chapter 4.2.2), thus indicating that MT1-
MMP undergoes autocatalytic processing that is required for the subsequent release of its 
intracellular domain. However, ectodomain shedding was also observed in cells expressing 
the MYC-FLAG- tagged truncated MT1-MMP construct that lacks the catalytic domain. It 
has been shown before that incomplete ectodomain shedding leaving ~30 amino acids of 
the extracellular part of proteins undergoing RIP is sufficient to induce intracellular 
domain release, suggesting that the initial step of ectodomain shedding may not be 
required for the ICD release in cells expressing the extracellular truncated MT1-MMP 
construct.  
 
4.2.2 MT1-MMP ubiquitination: a potential mechanism for nuclear 
translocation 
 
There is emerging evidence that, in addition to targeting proteins for proteasomal 
degradation, ubiquitination regulates many cellular aspects. The consequences of this post-
translational modification depend on whether the ubiquitin is attached to the protein as a 
monomer or as polyubiquitin chains. Generally, a protein that has been modified by a 
chain of ubiquitins (polyubiquitination) is targeted for degradation by the 26S proteasome 
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283, while conjugation of a single ubiquitin to one lysine (monoubiquitination) or to several 
lysines (multiubiquitination) does not lead to degradation but is a key regulatory 
mechanism for various cellular responses including histone regulation, endocytosis, Golgi 
reassembly, DNA repair, nuclear/cytosolic transport and gene transcription (reviewed in 
280). It has been recently shown that the nuclear – cytoplasmic transport and therefore the 
activity of the transcription factors including p53 284, PTEN 285 and FOXO 286 depends on 
monoubiquitination. Thus, ubiquitination provides an intriguing route for proteins that are 
lacking an intrinsic NLS to translocate to the nucleus. In contrast to other transmembrane 
proteins undergoing RIP including Notch1, LRP1 and SREBP, the MT1-MMP ICD does 
not exhibit an intrinsic NLS. Amongst the well-characterised proteins processed by RIP the 
NLS-lacking APP intracellular domain translocates to the nucleus by interacting with the 
nuclear adaptor protein Fe65 179. 
In this study, MT1-MMP was found to be ubiquitinated as detected by co-
immunoprecipitation in total cell lysates of MT1-MMP expressing cells as well as in the 
nuclear fraction of cells expressing the MYC-FLAG truncated MT1-MMP construct 
(Figure 3.52). The presence of a ~16 kDa signal in the nuclear fraction corresponded to the 
molecular weight of a mono-ubiquinitated MT1-MMP ICD. This observation suggest that 
the post-translational modification is required for nuclear localisation, thus substituting for 
a conserved NLS. The MT1-MMP ICD contains a single lysine residue as a potential 
ubiquitination site (K581, Figure 1.3 and Figure 3.45A). Mutation of that residue to alanine 
led to a decreased nuclear localisation of the MT1-MMP ICD as detected and quantified by 
immunofluorescence (Figure 3.53 and Figure 3.54) and furthermore decreased the amount 
of soluble extracellular cleavage fragments that were released into the medium (Figure 
3.55).  
So far, a proteasomal release of transcriptional activators from transmembrane precursors 
has been demonstrated only for the NF-?B homologs in yeast. However, activation of 
human NF-?B was also shown to be dependent on ubiquitination. Latent NF-?B is bound 
to I?B proteins that are phosphorylated by I?B kinases (IKK) and are subsequently 
ubiquitinated. Then, E3 ligases bind to the phosphorylated form of I?B through their C-
terminal part allowing the conjugation of ubiquitin to N-terminal lysine residues. The 
ubiquitinated I?B is selectively degraded by the proteasome, whereas NF-?B is spared 
from degradation and released from the inhibitory binding partner 281. This activation of 
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NF-?B provides a mechanism for selective proteasomal degradation and subsequent 
activation of transcription factors in humans. 
Phosphorylation of proteins is believed to be an initial step for ubiquitination in order to 
regulate protein activity, stability and specific localisation. MT1-MMP has been shown 
previously to be phosphorylated at its Y473 residue in a Src dependent way 249. It is 
tempting to hypothesise that this phosphorylation step may induce MT1-MMP ICD 
ubiquitination and thus explaining the requirement for Src in the MT1-MMP ICD release. 
 
 
Figure 4.2: MT1-MMP induced signalling pathways in breast cancer cell lines as 
described in this thesis 
MT1-MMP was found to induce at least two independent intracellular signalling pathways leading to 
transcriptional regulation in beast cancer cell lines. Both signalling pathways are dependent on the MT1-
MMP mediated activation of Src, which may occur during the transport of MT1-MMP and Src to the plasma 
membrane in RhoB positive endosomes. (A) VEGFR-2 activation leads to transcription of VEGF-A by 
activating Src, PI3 Kinase, Akt, mTOR and HIF-1?. Initial data suggest that this pathway is presumably 
initiated by VEGF165 following metalloproteinase mediated proteolytic cleavage of CTGF/VEGF165 
complexes. (B) The MT1-MMP intracellular domain is released in a Src and Proteasome dependent way. 
Various methodical approaches confirm the presence of the MT1-MMP ICD in the nucleus of MCF-7 and 
MDA-MB-231 cells. The nuclear localisation depends on the K581 residue, which was shown to be 
ubiquitinated in whole cell lysates and within the nucleus. The MT1-MMP ICD co-immunoprecipitates with 
RNA-Polymerase II, suggesting a role of MT1-MMP ICD in a transcription initiation complex. Ub, 
ubiquitin.
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5. Summary 
 
Membrane-type-1 matrix metalloproteinase (MT1-MMP, MMP-14) is a zinc-dependent 
type-I transmembrane proteinase, which is known to play a key role in pericellular 
proteolysis, cell invasion and angiogenesis. Overexpression or conditional expression of 
MT1-MMP enhances tumour growth in in vivo mouse models and elevated MT1-MMP 
levels in human cancer cells correlate with a poor prognosis. Tumourigenic angiogenesis 
and growth has been reported to be at least partly driven by the MT1-MMP-mediated 
transcriptional activation of the angiogenic factor vascular endothelial growth factor A 
(VEGF-A), which is dependent on the catalytic and intracellular domain (ICD) of MT1-
MMP. There is increasing evidence that in addition to the catalytic activity of MT1-MMP, 
it is involved in the transcriptional regulation of various target genes. However, the 
molecular mechanism underlying this regulation has not been investigated in detail so far. 
 
In this thesis two novel and independent MT1-MMP mediated signalling pathways have 
been identified. 
Initially, MT1-MMP dependent regulation of VEGF-A transcription was shown to involve 
the activity of VEGF receptor 2 (VEGFR-2) as well as key kinases including Src, PI3 
kinase, mTOR and Akt. Accordingly, the phosphorylation levels of Src, Akt and mTOR 
were significantly enhanced by MT1-MMP expression in vitro and co-localisation between 
MT1-MMP and these phospho-forms was observed. Using deletion and substitution 
mutants of the ICD and catalytic domain, new motifs regulating VEGF-A expression were 
defined. Co-immunoprecipitation and immunofluorescent analyses revealed a complex of 
MT1-MMP, VEGFR-2 and active Src, which was primarily located at the cell surface of 
MCF-7 cells. This expression pattern was also confirmed by immunostaining of human 
mammary carcinoma sections. The interaction between MT1-MMP and Src was shown to 
be dependent on the MT1-MMP ICD, whereas its interaction with VEGFR-2 is dependent 
on the hemopexin and transmembrane domains. VEGFR-2 signalling and its localisation at 
the cell surface were further shown to be highly dependent on the MT1-MMP hemopexin 
and transmembrane domains.  
These findings suggest the involvement of a VEGFR-2 induced PI3K/Akt pathway in 
MT1-MMP dependent transcriptional regulation of VEGF-A and further emphasise the 
non-proteolytic functions of MT1-MMP during tumourigenic angiogenesis. 
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Another MT1-MMP dependent signalling pathway was identified, which involves the Src- 
and Proteasome mediated proteolytic cleavage of MT1-MMP. This processing led to the 
release of the ICD and transcriptional activation in a reporter gene assay. Accordingly, 
immunostaining and immunoblotting revealed the MT1-MMP ICD within the nucleus of 
MCF-7 cells transfected with either full-length MT1-MMP or tagged MT1-MMP 
constructs, in MDA-MB-231 cells and in sections of human mammary carcinomas. A 
soluble tagged intracellular domain penetratin peptide was found to enrich in nuclear 
fractions of MCF-7 cells and to co-immunoprecipitate with RNA-Polymerase II in a 
potential transcription initiation complex. Interestingly, MT1-MMP was found to be 
ubiquitinated at its intracellular K581 and mutation of this residue ablated nuclear detection 
of the MT1-MMP ICD, suggesting a potential role for MT1-MMP ubiquitination in 
proteasomal ICD release and nuclear translocalisation.  
 
Taken together, two novel MT1-MMP dependent pathways were identified. These findings 
(i) show that MT1-MMP induces a PI3 Kinase/Akt dependent pathway leading to the 
transcriptional up-regulation of VEGF-A, (ii) demonstrate an MT1-MMP – VEGFR-2 – 
Src tri-molecular complex in breast cancer cells, (iii) reveal the requirement for MT1-
MMP, in particular its hemopexin domain, in the sub-cellular localisation of VEGFR-2 and 
(iv) demonstrate for the first time that MT1-MMP is ubiquitinated and undergoes 
proteolytic processing leading to the release of the MT1-MMP ICD, which was found to 
co-immunoprecipitate with Polymerase II in the nuclei of MCF-7 cells. These observations 
strengthen the role of MT1-MMP as a key protein in tumour growth, angiogenesis and cell 
motility and further emphasise the function of its intracellular domain as well as the 
emerging field of non-catalytic functions of MT1-MMP. 
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6. Zusammenfassung 
 
Membrane-type-1 matrix metalloproteinase (MT1-MMP, MMP-14) ist ein Zink-
abhängiges Typ-I Transmembranprotein, das eine wichtige Rolle in der perizellulären 
Degradation, der Zellmigration und -invasion sowie der tumorigenen Angiogenese spielt. 
Endogene Expression bzw. Überexpression von MT1-MMP erhöht die Malignität der 
Zellen sowie das Wachstum und die Größe von Tumoren. MT1-MMP nimmt eine 
Schlüsselrolle in der malignen Progression durch die Induktion der Tumorangiogenese ein, 
die zumindest zum Teil auf die MT1-MMP vermittelte Expression des pro-
angiogenetischen Faktors Vascular Endothelial Growth Factor A (VEGF-A) 
zurückzuführen ist. Es konnte gezeigt werden, dass diese MT1-MMP abhängige 
transkriptionelle Regulation sowohl von der extrazellulären katalytischen Domäne als auch 
von der intrazellulären Domäne (IZD) des Enzyms abhängt. Neben der Regulation der 
VEGF-A Expression verstärken sich Hinweise, dass MT1-MMP auch die Transkription 
von weiteren Zielgenen kontrolliert und dass es in nicht-katalytisch vermittelten zellulären 
Prozessen involviert ist. Der molekulare Mechanismus der transkriptionellen Regulation 
durch MT1-MMP wurde bislang jedoch nur unzureichend aufgeklärt. 
 
Im Verlauf dieser Doktorarbeit wurden zwei neue, voneinander unabhängige MT1-MMP 
vermittelte Signaltransduktionswege identifiziert. 
Zunächst wurde gezeigt, dass die beschriebene MT1-MMP abhängige Hochregulierung der 
VEGF-A Expression von der Aktivität von VEGF Receptor-2 (VEGFR-2) sowie den 
Schlüsselkinasen Src, PI3 Kinase, mTOR und Akt abhängig ist. Die in diesem Signalweg 
beteiligten Kinasen zeigten zudem einen signifikanten Anstieg ihres 
Phosphorylierungsgrades in Abhängigkeit der MT1-MMP Expression in in vitro 
Zellkultursystemen. Mit Hilfe immunologischer Detektionsverfahren wurde MT1-MMP 
zudem in einem Komplex mit den aktiven Phosphorylierungsformen von Src und Akt 
gefunden. Durch den Einsatz von Substitutions- und Deletionsmutationen wurden 
zusätzlich neue Motive der MT1-MMP Aminosäurensequenz identifiziert, die die 
transkriptionelle Expression von VEGF-A kontrollieren. Zudem wurde die Formation 
eines Komplexes bestehend aus MT1-MMP, VEGFR-2 und Src an der Zelloberfläche von 
MCF-7 Zellen beobachtet, welcher für die Genexpression von VEGF-A notwendig ist. Die 
IZD von MT1-MMP wurde als MT1-MMP - Src Interaktionsdomäne identifiziert. Die 
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extrazelluläre Hemopexin- und die Transmembrandomäne hingegen vermitteln bzw. 
regulieren sowohl die Interaktion zwischen MT1-MMP und VEGFR-2 als auch die 
Lokalisierung von VEGFR-2. Die nähere Charakterisierung dieses MT1-MMP abhängigen 
Signalweges, der zur Expression von VEGF-A führt, legt einen VEGFR-2 induzierten 
Transduktionsweg mit anschließender Aktivierung von PI3 Kinase, Akt und mTOR nahe 
und unterstreicht die nicht-katalytische Rolle von MT1-MMP im Zuge der 
Tumorangiogenese. 
In dieser Arbeit wurde ein weiterer MT1-MMP abhängiger Signalweg identifiziert und 
charakterisiert, der durch eine Src- und Proteasom-vermittelte proteolytische Spaltung von 
MT1-MMP induziert wird. Diese Prozessierung führt zur Abspaltung der IZD und zur 
transkriptionellen Aktivierung in einem Reportergen System. Dementsprechend wurde die 
MT1-MMP IZD mittels immunologischer Ansätze in Zellkernen von (i) MCF-7 Zellen, (ii) 
MDA-MB-231 Zellen und (iii) humanen Mammakarzinomen detektiert. Ein Biotin-
markiertes MT1-MMP IZD Peptid wurde in der nukleären Fraktion von MCF-7 Zellen 
nachgewiesen und ko-immunopräzipitierte mit RNA Polymerase II, was auf einen 
potentiellen Transkriptions-Initiations Komplex hinweist. Interessanterweise konnte 
nachgewiesen werden, dass die MT1-MMP IZD ubiquitiniert (K581) wird und dass eine 
Mutation dieser Aminosäure die nukleäre Lokalisierung der MT1-MMP IZD signifikant 
reduziert. Die post-translationale Ubiquitinierung bietet eine interessante Erklärung für 
sowohl die Proteasom-abhängige Abspaltung als auch die nukleäre Translokalisierung der 
MT1-MMP IZD.  
 
Zusammenfassend wurden im Zuge dieser Arbeit zwei MT1-MMP abhängige 
Signaltransduktionswege identifiziert. Die hier zusammengefassten Daten zeigen, dass (i) 
VEGF-A Expression durch eine MT1-MMP vermittelte Aktivierung des PI3 Kinase/Akt 
Signalwegs induziert wird, (ii) MT1-MMP einen trimolekularen Komplex mit VEGFR-2 
und Src an der Zelloberfläche bildet, (iii) MT1-MMP die zelluläre Lokalisierung und 
Kompartimentalisierung von VEGFR-2 steuert, (iv) die MT1-MMP IZD post-translational 
ubiquitiniert wird und dass (v) die MT1-MMP IZD abgespalten wird und im Nukleus von 
MCF-7 Zellen mit RNA-Polymerase II ko-immunopräzipitiert. Die hier dargestellten 
Ergebnisse heben die Rolle von MT1-MMP, insbesondere der intrazellulären Domäne, in 
der Tumorigenese hervor und fügen dem bereits umfassenden tumorigenen 
Funktionsspektrum von MT1-MMP neue nicht-katalytische Aktivitäten in der Biologie 
transformierter Zellen hinzu. 
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8 Appendix A 
 
Primer sequences and TaqMan® probes 
 
Name  Sequence (5’ => 3’) 
 
VEGFpromotors CCTCAGTTCCCTGGCAACATCTG 
VEGFpromoteras GAAGAATTTGGCACCAAGTTTGT 
GAPDHpromoters TACTAGCGGTTTTACGGGCG 
GAPDHpromoteras TCGAACAGGAGGAGCAGAGAGCGA 
XBP-1s  ATACTTGGCAGCCTGTGACC 
XBP-1as GGTCCACAAAGCAGGAAAAA 
CHR521s  CGGCTCGGCCCAATCACCGGTCATGGACTACAAGGACGACG 
   ATGACAAGGCCCCATCGGGAGGCCGGCCGGAT  
BGHas  TCCTCATTTTATTAGGAAAG 
115.K/As  CGTTCCCTGCTGGACGCGGTCGAGCAAAAGCTAATA  
115.K/Aas  TATTAGCTTTTGCTCGACCGCGTCCAGCAGGGAACG 
115.Stps  TCCCTGCTGGACAAGGTCTAGCAAAAGCTAATATCA 
115.Stpas  TGATATTAGCTTTTGCTAGACCTTGTCCAGCAGGGA 
CHR508  CCAGTGTGGTGGGATCCCCATGGGCAGCAACAAGAGCAAG 
CHR509   TACCTGCGGCCGCTCTAGACTATAGGTTCTCCCCGGGCTGG 
pACTs1200   GACGATTTCGATCTGGACATGTTGGGGGAC 
pACTas1446  TGTATCTTATCATGTCTGCTC  
VEGF-As  CCTGGTGGACATCTTCCAGGAGTA 
VEGF-Aas  CTCACCGCCTCGGCTTGTCACA 
MT1-MMPs1335 ATCAACACTGCCTACGAGAG 
MT1-MMPas1744 CCCTCAGGGCTGACTTGG 
Table 8.1: Oligonucleotides 
 
 
Name  Assay number 
 
MT1-MMP  Hs_00237119_m1 
MT2-MMP  Hs00233997_m1 
MT3-MMP  Hs01095537_m1 
MT4-MMP  Hs01108847_m1 
VEGF-A  Hs_00173626_m1 
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18s   Hs_9999901_s1 
Src   Hs_00178494_m1 
Fyn   Hs_00176628_m1 
Caveolin-1  Hs_00971716_m1 
VEGFR-1  Hs_01052936_m1 
VEGFR-2  Hs_00176676_m1 
CTGF   Hs_00170014_m1 
HARP   Hs_00383235_m1 
MMP-2  Hs_00234422_m1 
GAPDH  Hs_99999905_m1 
 
Table 8.2: TaqMan® probes 
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9 Appendix B 
 
 
List of asRNA and shRNA sequences used in this thesis. 
 
 
Target gene  Sequence 
 
MT1-MMP  TGGCCGAGGGGTCACTGGAATGCTCGAGCCCCAGGGCATGGCCCAGC 
TCGTGCACAGCCACCAGGAAGATGTCATTTCCATTCAGATCCTCATTC 
CTGACAGTCCAAGGCTCGGCAGAGTCAAAGTGGGTGTCTCCTCCAAT 
GTTGGGGCCTGGGAAGTAGGCATGGGCCAGGAAGCCGCCCTCACCAT 
CGAAGGGCGTGCTGTCGCCATGGAAGCCCTCGGCAAAGAAGATCAT
GATGTCGGCCTGCTTCTCATGGCCCTCACGGATGTAGGCATAGGGCA 
CACCTCGCGGAAGCGCAGTGGTGTGGCACTCTCCCACACGCGGAACG
CCTTGCGAATGGCCTCGTATGTGGCATACTCGCCCACCTTGGGGGTGT
AATTCTGGATGCAGAAAGTGATTTCATTATGTTGCCATTTGAGACCCT
GGATGGCGTAGCGCTTCCTTCGAACATTGGCCTTGATCTCAGCCCCA
AACTTGTCTGGAACACCACATCGGGGGCGCCT 
MT2-MMP  ATTGGGGTTGCTGGAGTGCTCCAGCCCCAGCGCGTGGCCCAGCTCAT 
GCACTGCCACCAGGAAGAGGTTGTTTCCATGCAGGTCAGTGCTGGAG
AAGGTCCAGGGCTCATCTGCGTCAAAATGGGTGTCCCCGCCTAGGCC
GGGGCCAGGGAAATAGGCGTGGGCCAGAAAGCCACCGGTGCCATCA
AACGGCGAGCTGTCGCCGTGGAAGCCAGAGGCAAAGAGTACCATGA
TGTCGGCCTCCTTCTGTCGCCGCAGCCGGATGTCCTCATAGGGCACCT
CCTGGAAGACCAGGGGCGTGGCCTGCTCCCACACGCGGAAGGCCCTG
CGCACCGCCTCCATCGAGTGGTACCAGCCCAACTTCTCCGTGTAGTTC
TGGATGCTAAAGGTCAGATGGTGGTTGTTCCACTTCCTCCCGGTG 
MT3-MMP  CACTTCCAAGGGTTATCAAGTCATGAGGGTAACCAGGTTGAAGAGTT 
GTATCCTTGAACACCCAATATTTGTTACCTTTAAAGAACACAAAATTC
CCGTCGCTATTTTCATAAACTGCATCGATACTAGGAGGCAAGCCCCG
CCAGAAGTAAGTAATTTGCATTGGGTATCCATCCATCACCCTGTTGTT
TCTCACTCGCCAAAACCACTGGTCCTTGAAAACAAACATCTCACGAC
GAAGAATAGCTAGAGTGTTAAAGTTCCCATCACAGATGTTGGGTTTG
GCTCCGGGATAGGAGGGTCTGCCGGTTGGAGGCCGAGGAGGTTTTGG
CCTGTCATTTTTCCTTGGGTCAGCCGGAGGAATAGAGCGGTGTGGGG
GC 
MT4-MMP  CGCCATCCAGCACTTTCCAGTACTCCTGGCCACGGAAGAAGTAGGAG 
GCACCGTCGGACCAGCGCATGGCGTCGTCCAGCGTGCTGGGGACACC 
CCTCCACAGGGGGCTCTGGGCGGGGTAGCCGGGGTCCATGTGCCTCG
TGTGGTCATCGTAGCGCCAGTACAGCTGGTCCTTAAAGAAATAAGTC
CTGTCATTGTGGGCCCA 
 
 
Table 9.1: List of asRNA sequences 
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Target gene Name  Number  Oligo sequence 
 
MT1-MMP shRNA1  TRCN0000050853  CCGGGCTGAGATCAAGGCCAATGTTCTC 
GAGAACATTGGCCTTGATCTCAGCTTTTG 
  shRNA2  TRCN0000050854  CCGGCGGCCTTCTGTTCCTGATAAACTC 
GAGTTTATCAGGAACAGAAGGCCGTTTTG 
  shRNA3  TRCN0000050855  CCGGCGATGAAGTCTTCACTTACTTCTC 
GAGAAGTAAGTGAAGACTTCATCGTTTTG 
  shRNA4  TRCN0000050857  CCGGGCTACAGCAATATGGCTACCTCTC 
GAGAGGTAGCCATATTGCTGTAGCTTTTG 
  shRNA5  TRCN0000050856  CCGGGTGGATGGACACGGAGGATTTCT 
CGAGAAATTCTCCCTGTCCATCCACTTTTG 
VEGFR-1 shRNA1  TRCN0000000631  CCGGCCCGTCTCTATACCAACCAAACTC 
GAGTTTGGTTGGTATAGAGACGGGTTTTT 
  shRNA2  TRCN0000000632  CCGGCCCGAATCTATCTTTGACAAACTC 
GAGTTTGTCAAAGATAGATTCGGGTTTTT 
  shRNA3  TRCN0000000633  CCGGCGCCGGAAGTTGTATGGTTAACTC 
GAGTTAACCATACAACTTCCGGCGTTTTT 
  shRNA4  TRCN0000000634  CCGGGAGAGACTTAAACTGGGCAAACT 
CGAGTTTGCCCAGTTTAAGTCTCTCTTTTT 
  shRNA5  TRCN0000000635  CCGGCTTGACACTTTGATCCCTGATCTC 
GAGATCAGGGATCAAAGTGTCAAGTTTTT 
VEGFR-2 shRNA1  TRCN0000001685  CCGGGCGGCACGAAATATCCTCTTACTC 
GAGTAAGAGGATATTTCGTGCCGCTTTTT 
  shRNA2  TRCN0000001686  CCGGAGGCTAATACAACTCTTCAAACTC 
GAGTTTGAAGAGTTGTATTAGCCTTTTTT 
  shRNA3  TRCN0000001687  CCGGGTGCTGTTTCTGACTCCTAATCTC 
GAGATTAGGAGTCAGAAACAGCACTTTTT 
  shRNA4  TRCN0000001688  CCGGCTTTACTATTCCCAGCTACATCTC 
GAGATGTAGCTGGGAATAGTAAAGTTTTT 
  shRNA5  TRCN0000001689  CCGGGTGGTCTCTCTGGTTGTGTATCTC 
GAGATACACAACCAGAGAGACCACTTTTT 
 
Table 9.2: List of MISSION® shRNA sequences  
The target sequence is shown in bold letters. 
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Figure 10.1: Gene expression profile of MDA-MB-231 transduced with MT1-MMP 
targeting shRNA  
Single analysis of data shown in Figure 3.37. 
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Meta-analysis of MT1-MMP, VEGFR-2 and VEGF-A mRNA expression profile in 
microarray studies derived from the Oncomine™ database comparing breast carcinoma 
tissues derived from (i) tumours of different stages, (ii) tumours of different grading, (iii) 
tumours exhibiting different estrogen receptor (ER) status or (iv) basal or luminal tumours. 
Data represent the name and details of the studies revealing data sets that are differentially 
expressed. 
 
Analysis of MT1-MMP expression  
 
Study   Class1  Class2  Class3   P-value 
Link   (number) (number) (number)  t-test 
 
Ginestier_Breast  1(4)  2(12)  3(39)   0.004 
Ivshina_Breast  1(68)  2(126)  3(55)   0.025 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4922 
Miller_Breast  1(67)  2(128)  3(54)   0.029 
Sotiriou_Breast_3 1(67)  2(46)  3(59)   0.031 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2990 
Bittner_Breast  1(30)  2(107)  3(141)   0.077 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109 
Finak_Breast  1(3)  2(23)  3(27)   0.126 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9014 
Farmer_Breast  1(22)  2(16)  3(8)   0.134 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1561 
Sorlie_Breast  1(9)  2(33)  3(33)   0.149 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3193 
Ma_Breast_3  1(3)  2(39)  3(18)   0.251 
Sotiriou_Breast_2 1(16)  2(37)  3(45)   0.278 
http://www.pnas.org/cgi/content/full/1732912100/DC1 
Hess_Breast  1(2)  2(54)  3(77)   0.33 
http://bioinformatics.mdanderson.org/pubdata.html 
Kreike_Breast  1(10)  2(12)  3(28)   0.41 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4913 
vantVeer_Breast  1(12)  2(27)  3(78)   0.901 
http://www.rii.com/publications/2002/vantveer.html 
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Table 11.1: MT1-MMP expression in breast carcinomas derived from differently 
graded tumours 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
 
 
Figure 11.1: MT1-MMP expression in breast carcinomas derived from differently 
graded tumours 
Data represent the box-plots of 13 different studies as listed in Table 11.1 showing category 1 (blue), 
category 2 (red) and category 3 (green) graded breast carcinomas.  
 
Study   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Hess_breast  N0(40)  N1(62), N2(14), N3(17)   0.056 
http://bioinformatics.mdanderson.org/pubdata.html 
Sorlie_Breast_2  N0(25)  N1(35), N2(19)    0.083 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE4382 
Sorlie_Breast  N0(23)  N1(34), N2(19)    0.103 
http://genome-www5.stanford.edu/cgi-bin/SMD/publication/viewPublication.pl?pub_no=95 
Yu_Breast  N0(37)  N1(12), N2(46)    0.119 
http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE2294 
Sotiriou_Breast_2 N0(46)  N1(52)     0.972 
http://www.pnas.org/cgi/content/full/1732912100/DC1 
 
Table 11.2: MT1-MMP expression in breast carcinomas derived from differently 
staged tumours 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
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Figure 11.2: MT1-MMP expression in breast carcinomas derived from differently 
staged tumours 
Data represent the box-plots of 5 different studies as listed in Table 11.2 showing stage 1 (blue) or stage 2 
(red) classified breast carcinomas.  
 
 
Name   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Hess_Breast  ER-(51)  ER+(82)     8.4E-04 
http://bioinformatics.mdanderson.org/pubdata.html 
Ginestier_Breast  ER-(28)  ER+(27)     8.5E-04 
Sotiriou_Breast  ER-(34)  ER+(85)     0.003 
Sotiriou_Breast_2 ER-(33)  ER+(65)     0.006 
http://www.pnas.org/cgi/content/full/1732912100/DC1  
Minn_Breast_2  ER-(42)  ER+(57)     0.01 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE2603 
Table 11.3: MT1-MMP expression in breast carcinomas derived from tumours with 
different ER status 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
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Figure 11.3: MT1-MMP expression in breast carcinomas derived from tumours with 
different ER status 
Data represent the box-plots of 5 different studies as listed in Table 11.3 showing ER- (blue) or ER+ (red) 
classified breast carcinomas.  
 
Name   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Farmer_Breast  Apocrine(6) luminal(27)    0.023 
   Basal(16) 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1561 
 
Table 11.4: MT1-MMP expression in breast carcinomas derived from tumours of 
different histology 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
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Figure 11.4: MT1-MMP expression in breast carcinomas derived from tumours of 
different histology 
Data represent the box-plots one study as listed in Table 11.4 showing apocrine (blue, left), basal (blue, right) 
or luminal (red) classified breast carcinomas.  
 
Analysis of VEGF-A expression 
 
Study   Class1  Class2  Class3   P-value 
Link   (number) (number) (number)  t-test 
 
vantVeer_Breast  1(12)  2(27)  3(78)   3.8E-05 
http://www.rii.com/publications/2002/vantveer.html 
Ishvina_Breast  1(68)  2(126)  3(55)   8.2E-05 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4922 
Miller_Breast  1(67)  2(128)  3(54)   9.3E-05 
Bittner_breast  1(30)  2(107)  3(141)   1.2E-04 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109 
Sotiriou_Breast_3 1(67)  2(46)  3(59)   0.001 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2990 
Hess_Breast  1(2)  2(54)  3(77)   0.003 
http://bioinformatics.mdanderson.org/pubdata.html 
Ginestier_breast  1(4)  2(12)  3(39)   0.003 
Farmer_Breast  1(22)  2(16)  3(8)   0.003 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1561 
Finak_Breast  1(3)  2(23)  3(27)   0.04 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9014 
Sorlie_Breast  1(9)  2(33)  3(33)   0.046 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3193 
Sotiriou_Breast_2 1(16)  2(37)  3(45)   0.164 
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http://www.pnas.org/cgi/content/full/1732912100/DC1 
Ma_Breast_3  1(3)  2(39)  3(18)   0.247 
Kreike_Breast  1(10)  2(12)  3(28)   0.357 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4913 
 
Table 11.5: VEGF-A expression in breast carcinomas derived from differently graded 
tumours 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
 
 
Figure 11.5: VEGF-A expression in breast carcinomas derived from differently 
graded tumours 
Data represent the box-plots of 13 different studies as listed in Table 11.5 showing category 1 (blue), 
category 2 (red) and category 3 (green) graded breast carcinomas.  
 
Study   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Hess_breast  N0(40)  N1(62), N2(14), N3(17)   0.184 
http://bioinformatics.mdanderson.org/pubdata.html 
Sotiriou_Breast_2 N0(46)  N1(52)     0.343 
http://www.pnas.org/cgi/content/full/1732912100/DC1 
Sorlie_Breast  N0(23)  N1(34), N2(19)    0.582 
http://genome-www5.stanford.edu/cgi-bin/SMD/publication/viewPublication.pl?pub_no=95 
Yu_Breast_3  N0(37)  N1(12), N2(46)    0.674 
http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE2294 
Sorlie_Breast_2  N0(25)  N1(35), N2(19)    0.699 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE4382 
 
Table 11.6: VEGF-A expression in breast carcinomas derived from differently staged 
tumours 
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Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
 
 
Figure 11.6: VEGF-A expression in breast carcinomas derived from differently 
staged tumours 
Data represent the box-plots of 4 different studies as listed in Table 11.6 showing stage 1 (blue) or stage 2 
(red) classified breast carcinomas.  
 
Name   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Desmedt_Breast    ER-(64)  ER+(134)    1.1E-07 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE7390 
Wang_breast  ER-(77)  ER+(209)    6.6E-07 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE2034 
Hess_Breast  ER-(51)  ER+(82)     7.3E-07 
http://bioinformatics.mdanderson.org/pubdata.html 
Yu_Breast  ER-(39)  ER+(57)     1.4E-05 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE2294 
Bittner_breast  ER-  ER+     3.5E-05 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109 
 
Table 11.7: MT1-MMP expression in breast carcinomas derived from tumours with 
different ER status 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
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Figure 11.7: VEGF-A expression in breast carcinomas derived from tumours with 
different ER status 
Data represent the box-plots of 5 different studies as listed in Table 11.7 showing ER- (blue) or ER+ (red) classified 
breast carcinomas.  
 
Name   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Farmer_Breast  Apocrine (6) luminal (27)    1.2E-05 
   Basal (16) 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1561 
 
Table 11.8: VEGF-A expression in breast carcinomas derived from tumours of 
different histology 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
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Figure 11.8: VEGF-A expression in breast carcinomas derived from tumours of 
different histology 
Data represent the box-plots of the study as listed in Table 11.8 showing apocrine (blue, left), basal (blue, 
right) or luminal (red) classified breast carcinomas.  
 
Analysis of VEGFR-2 expression 
 
Study   Class1  Class2  Class3   P-value 
Link   (number) (number) (number)  t-test 
 
Sotiriou_Breast_2 1(16)  2(37)  3(45)   0.038 
http://www.pnas.org/cgi/content/full/1732912100/DC1 
Ginestier_Breast  1(4)  2(12)  3(39)   0.124 
Miller_Breast  1(67)  2(128)  3(54)   0.19 
Ishvina_Breast  1(68)  2(126)  3(55)   0.227 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4922 
Sotiriou_Breast_3 1(67)  2(46)  3(59)   0.366 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2990 
Sorlie_Breast  1(9)  2(33)  3(33)   0.374 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3193 
Finak_Breast  1(3)  2(23)  3(27)   0.555 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9014 
Farmer_Breast  1(22)  2(16)  3(8)   0.668 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1561 
Hess_Breast  1(2)  2(54)  3(77)   0.684 
http://bioinformatics.mdanderson.org/pubdata.html 
Bittner_Breast  1(30)  2(107)  3(141)   0.701 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109 
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vantVeer_Breast  1(12)  2(27)  3(78)   0.919 
http://www.rii.com/publications/2002/vantveer.html 
Ma_Breast_3  1(3)  2(39)  3(18)   0.951 
Kreike_Breast  1(10)  2(12)  3(28)   0.968 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4913 
 
Table 11.9: VEGFR-2 expression in breast carcinomas derived from differently 
graded tumours 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
 
 
Figure 11.9: VEGFR-2 expression in breast carcinomas derived from differently 
graded tumours 
Data represent the box-plots of 13 different studies as listed in Table 11.9 showing category 1 (blue), 
category 2 (red) and category 3 (green) graded breast carcinomas.  
 
Name   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Sotiriou_Breast_2 N0(46)  N1(52)     0.078 
http://www.pnas.org/cgi/content/full/1732912100/DC1 
Yu_Breast  N0(37)  N1(12), N2(46)    0.086 
http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE2294 
Sorlie_Breast_2  N0(25)  N1(35), N2(19)    0.126 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE4382 
Sorlie_Breast  N0(23)  N1(34), N2(19)    0.233 
http://genome-www5.stanford.edu/cgi-bin/SMD/publication/viewPublication.pl?pub_no=95 
Hess_breast  N0(40)  N1(62), N2(14), N3(17)   0.056 
http://bioinformatics.mdanderson.org/pubdata.html 
 
Table 11.10: VEGFR-2 expression in breast carcinomas derived from differently 
staged tumours 
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Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
 
 
Figure 11.10: VEGFR-2 expression in breast carcinomas derived from differently 
staged tumours 
Data represent the box-plots of 5 different studies as listed in Table 11.10 showing stage 1 (blue) or stage 2 
(red) classified breast carcinomas.  
 
Name   Class1  Class2     P-value 
Link   (number) (number)    t-test 
 
Hess_Breast  ER-(51)  ER+(82)     0.002 
http://bioinformatics.mdanderson.org/pubdata.html 
Wang_breast  ER-(77)  ER+(209)    0.024 
http://www.ncbi.nlm.nih.gov/geo/query.acc.cgi?acc=GSE2034 
Sotiriou_Breast_3 ER-(34)  ER+(85)     0.026 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2990 
Sotiriou_Breast  ER-(33)  ER+(65)     0.095 
 
Table 11.11: VEGFR-2 expression in breast carcinomas derived from tumours with 
different ER status 
Data represent studies in which MT1-MMP was found to be expressed differentially. The name of the study, 
the n-numbers of each category and the corresponding link are indicated. Significance was calculated using 
the Student t-test. Bold P-values indicate P < 0.05. 
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Figure 11.11: VEGFR-2 expression in breast carcinomas derived from tumours with 
different ER status 
Data represent the box-plots of 4 different studies as listed in Table 11.11 showing ER- (blue) or ER+ (red) 
classified breast carcinomas.  
 
 
No studies with differential VEGFR-2 expression was found in the category of different 
histological classifications. 
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